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Abstract  
 
We are living in what has been termed the “post antibiotics era’ where the emergence of 
multidrug-resistant pathogen strains is rapidly growing and where the introduction of  
and the development of novel antimicrobial agents, which are effective against these 
pathogens has declined significantly. As a result, we urgently need 
effective alternatives to the use of antibiotics. The overall aim of the study was to add 
further our knowledge of some of these alternatives to antibiotics, concentrating on 
maggot therapy, apitherapy and to a lesser extent mycotherapy.  
    The nature of the exceptionally high non-peroxide antibacterial activity of 
Leptospermum scoparium Manuka honey was further investigated. It was shown that 
this activity is unlikely to be due to accumulated residual hydrogen peroxide and the 
microflora of bees and honey probably act as a source of any non–hydrogen peroxide 
inhibitory components. Tregothnan English Manuka did not show any exceptionally 
high non-peroxide antibacterial activity compared to New Zealand Manuka.   
Studies on the mechanisms of the antibacterial activity of high medical grade New 
Zealand Manuka (UMF 20+,25+) against methicillin-resistant Staphylococcus 
aureus (MRSA) and  (SEM) and TEM studies on the morphological effects on (MRSA) 
and Escherichia coli were conducted. It was observed that Gram-positive and Gram-
negative cells were not uniformly affected by Manuka honey, Gram-positive bacteria 
were more sensitive and had less MICs and MBCs values.  Time killing assays 
confirmed the bactericidal effect of Manuka. 16S rRNA sequencing technique 
confirmed that that C. botulinum spores are not likely to be detectable in tested medical 
grade New Zealand Manuka honey samples. Leptospermum scoparium essential oil 
showed a marked inhibitory activity against Gram-positive bacteria, including  MRSA, 
M. phlei and B. subtilis;significant antifungal activity against Trichophyton terrestre 
was also observed. 
The in vitro antibacterial activity of tamarind (Tamarindus indica) was evaluated and 
compared with 25+ Manuka honey. Data obtained from the agar diffusion, MICs, 
MBCs values and time to kill study show that tamarind exhibits a stronger antimicrobial 
effect against the six tested bacteria and C. albicans than do high medical grade manuka 
honeys. It is suggested that an autoclaved, sterilized, commercially available tamarind 
paste should be clinically evaluated for the treatment of wounds and indolent ulcers 
which are infected with bacteria, notably MRSA. 
V 
 
    In relation to maggot therapy, evidence is provided to support the anti-
Mycobacterium activity of Calliphora quadrimaculata maggot gases; unfortunately, 
attempts to isolate these gases were unsuccessful. For first time, in vitro evidence ( such 
as antifungal and yeast (S. cerevisiae (BY4742) GFP ingestion ability),  was provided to 
support the use of Lucilia sericata maggot to control fungi involved in  superficial  
fungal infections, i.e. fungal burn wound infections  and dermatomycoses. A study was 
made to determine if Mycoplasmas can be detected in the hemolymph of maggots of 
Calliphora quadrimaculata and Lucilia sericata maggots by using Mycoplasma, EZ-
PCR Mycoplasma Test Kit. Mycoplasmas were not detected in any of the maggot 
samples tested. These observations suggest that Calliphora quadrimaculata and Lucilia 
sericata larvae are unlikely to act as transmission vectors for Mycoplasmas. 
   Another antibiotic-alternative called mycotherapy (an approach which as yet has not 
be reinstated in medicine) was also studied. The results presented here show that 
mycelium of all Penicillium cultures, isolated from foods, and inhibited both MSSA and 
MRSA. SNAP* MRL Beta-Lactam Kit has been used to test for penicillin and TLC for 
patulin showed that penicillin was found in culture filtrates obtained from all of the 
individual fungi, while patulin was produced by only two samples. Clearly then, a pure 
culture of a Penicillium, known to produce penicillin and not patulin or other toxicant 
(like the two IMI strains used here) could be safely used to treat wound infections in 
hospitals at the present time. 
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1. Introduction  
 
From the mid-1940s until relatively recently we have been fortunate to be living 
through what has been termed “the Golden Age of Antibiotics”. During this period all 
of the major infections caused by bacteria and fungi have been defeated by the use of 
antibiotics, a period which has also seen dramatic improvements in surgical procedures 
which have revolutionised medicine and saved countless lives (Wainwright, 1990). 
Unfortunately this golden age is now at end due to the development of antibiotic 
resistance amongst pathogens. Such resistance was noticed immediately after the 
introduction of penicillin and has grown worse over the last half of this century or so to 
the point where some hospitals have only one antibiotic, vancomycin, available for the 
treatment of bacterial infections and resistance to this, “last hope” antibiotic, has been 
reported. The development of antibiotic resistance is particularly problematic in the case 
of MRSA (Methicillin Resistant Staphylococcus aureus), which is endemic in most 
hospitals worldwide (Boyce et al., 2005). 
     The problem of antibiotic resistance can be mitigated to some extent by better 
prescribing practises and the banning of the use of these compounds in agriculture. 
However, the reality is that antibiotic resistance will continue to remain a major 
problem in future medicine. The obvious way around this problem is to develop new 
antibiotics which pathogens have not previously seen and therefore have not had time to 
develop resistance (Mulvey and Simor (2009). Unfortunately the economics and 
exceptionally high regulatory hurdles presented to pharmaceutical companies wishing to 
develop new antibiotics are so adverse that no new antibiotics are likely to be produced 
until the situation becomes so grave that international bodies, such as the UN, demand 
that new antibiotic compounds be developed for world-wide use. As a result of this 
quandary clinicians around the world are seeking alternatives to antibiotics for use in 
the treatment of bacterial and fungal infections. It might be imagined that high-tech 
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solutions, such as the use of molecular vaccines or gene therapy might have been 
developed to overcome the problem of antibiotic resistance. In reality, although vast 
amounts of research monies have been devoted to such sophisticated approaches they 
are not currently medically useful and clinicians are having to resort to a number of 
more basic and less sophisticated approaches to pathogen control, especially in relation 
to the treatment of surface wound infections. Such longstanding, or indolent infections, 
present a major problem when caused by antibiotic resistant bacteria and may, notably 
in older patients suffering from diabetes, cause longstanding, painful and long-term 
suppurating wounds, which if untreated may lead to limb amputation (Boyce et 
al.,2005). The relatively unsophisticated approaches which are now being reintroduced 
into medicine were in use before the advent of antibiotics and were shown to be useful 
in medicine, and in some case proved to be highly successful. When antibiotics 
appeared however, such approaches were naturally seen to be old-fashioned and 
otherwise undesirable and most became historical oddities which had no place in 
modern, ”scientific medicine”. Such old-fashioned approaches which are currently 
being re-evaluated, or are currently being used, in medicine include: Bacteriophage 
Therapy, Apitherapy (Honey Therapy), Maggot Debridement Therapy and 
Mycotherapy. 
1.1 A brief history of antibiotics  
 
Although microbial antagonism, i.e. the ability of one microorganism to limit the 
growth, or kill, another, was observed many times during the late Victorian period, the 
discovery of the first true antibiotic dates to 1928 when Alexander Fleming observed 
the antibacterial effect of a Penicillium mould against Staphylococcus aureus 
(Wainwright, 2008). Despite this discovery, penicillin was not made available as the 
first true antibiotic until the mid-1940s (Projan and Shlaes, 2004). The true 
chemotherapeutic era had already begun when protonsil (early synthetic sulphonamide 
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drug) was discovered in 1932 (Domagk, 1957) and then introduced into medical use in 
1935. Sulphonamides were successfully used to cure meningitis, streptococcal 
infections and infections of the urinary tract, but   were less active in the treatment of 
the Staphylococcal infections (Brumfitt and Hamilton-Miller, 1988). During the 1940s 
many researchers started to focus on the search for antibiotics produced by soil 
organisms. One of these researchers was Selman Waksman who, with Albert Schatz, 
reported the isolation of the first aminoglycoside antibiotics streptomycin (from 
Streptomyces griseus) in 1943. Streptomycin was the first antibiotic to be effective 
against tuberculosis (TB) and despite producing side effects, including kidney damage 
and deafness, streptomycin is still being used to treat this disease (McKenna, 1998). 
Chloramphenicol  was subsequently used to treat typhus and subsequently  typhoid 
fever (McKenna, 1998), but  its use  started to decline in 1960 due to its ability to 
induce aplastic  anaemia, bone marrow suppression and the gray syndrome (Feder, 
1986). Based on the detailed examination of the antibacterial substances isolated from a 
strain of Cephalosporium acremonium by Giuseppe Brotzu in the mid 1940s, Florey 
and his co-workers in Oxford discovered the cephalosporin family of β-lactams which 
were very active against a wide spectrum of bacterial infections with a very low toxicity 
(McKenna, 1998; Brown, 1987). Comprehensive investigations during the mid 1950's 
then led to the recognition and isolation of penicillin 'nucleus' (6-aminopenicillanic 
acid) (6-APA), a penicillin precursor produced during the fermentation of 
P.chrysogenum. The isolation of (6-APA) paved the way for a large-scale production 
and marketing of  semi-synthetic penicillins during the 1960s, including  ampicillin, 
methicillin, flucloxacillin, amoxycillin, ticarcillin and carbenicillin, followed later by 
mezlocillin, azlocillin, piperacillin and mecillinam (Brown, 1987; Brumfitt and 
Hamilton-Miller, 1988). Chlortetracycline was the first member of the tetracycline 
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group to be isolated by Benjamin M. Duggar in 1947; oxytetracycline then soon 
followed (McKenna, 1998; Chopra and Roberts, 2001).  
   Tetracyclines are the second most commonly used antibiotics after the penicillins due 
their activity against a long list of infections and because they are relatively cheap to 
produce (McKenna, 1998). The 1970s, which witnessed an increase in the resistance 
among Gram-negative bacilli, saw the introduction of amikacin, a semisynthetic 
derivative of kanamycin.(Brumfitt and Hamilton-Miller, 1988; Begg and Barclay, 1995)  
   In 1962 Lesher and his co-workers recognized nalidixic acid, a by-product of 
chloroquine production (Barlow, 1963), which became the first quinolone antibiotic to 
be developed. The first-generation quinolones were active against aerobic Gram-
negative bacillary infections, especially those found in the human urinary tract. This 
limited activity against aerobic Gram-negative bacteria was enhanced (1000-fold) in the 
1980s when the second-generation fluoroquinolones were introduced (Dembry et al., 
1999). 
1.2 Commonly occurring sites of antibiotics action 
Selective toxicity is considered as the main basis of all antimicrobial chemotherapy, in 
short the pathogen must be killed but not the human host. (Finch, 2003).The 
peptidoglycan layer of Gram-positive bacteria is one such selective target, others 
include compounds which are selective against other bacterial cell macromolecules and 
which can interfere with protein synthesis, DNA replication and transcription and folic 
acid metabolism (Figure 1.1) (Lambert, 2005). For example, β-lactams and 
glycopeptides, such as vancomycin, exert an antibacterial effect by inhibiting formation 
of the bacterial cell wall peptidoglycan layers. Macrolides, aminoglycosides, 
chloramphenicol, and tetracyclines interfere with protein synthesis, sulfonamides inhibit 
DNA synthesis by interfering with the pathway for folic acid synthesis, and 
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fluoroquinolones target components which are essential for DNA synthesis (Tenover, 
2006). 
 
 
Figure 1.1: Sites of action and potential mechanisms of bacterial resistance to antimicrobial 
agents (Mulvey and Simor, 2009) Copied under licence from the Canadian Medical Association 
and Access Copyright. Further reproduction prohibited. 
 
 
1.3 The antibiotic resistance problem. 
The resistance of pathogenic bacteria to a wide range of antibiotics is a major public 
health concern in the 21st century. Resistance of a microorganism to an antibiotic 
means that a microorganism formerly susceptible to the action of the antibiotic is no 
longer inhibited by the agent by using normal dosage rates (Finch, 2003). 
    The unprecedented successes of early antibiotic therapies allowed William H. 
Stewart, at the time US Surgeon General, to deliver a speech to Congress, in the late 
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1960s, which shows the general sentiment in the medical community at the time, he said  
“It’s time to close the book on infectious diseases, declare the war against pestilence 
won, and shift national resources to such chronic problems as cancer and heart disease" 
(Spellberg et al., 2008).  This, despite the fact that resistance was detected almost 
immediately following the introduction of any new antibiotic. For example, penicillin-
resistant Staphylococci began to be reported only three years following its introduction 
as antimicrobial agent into clinical practice and in the subsequent two decades, more 
than 80% of Staphylococcal isolates from both community and hospitals were found to 
be resistant to penicillin.  
    Methicillin, semisynthetic penicillinase resistant penicillins, were introduced in 1961 
to treat staphylococcal infections caused by penicillin-resistant strains; methicillin-
resistant isolates were however, soon seen after its introduction (Lowy, 2003). 
1.4 The genetics basis of antibiotic resistance 
1.4.1 Intrinsic resistance  
Antibiotic resistance may either be intrinsic or acquired. Intrinsic resistance is due to the 
innate chromosomal (genetic) makeup of the bacterial strain in question, which can 
explain the resistance of some bacteria to a certain class of antibiotics by their 
physiology, biochemistry or morphology that originate by virtue of their inherent 
genetic makeup (Mulvey and Simor, 2009); this type of resistance is not horizontally 
transferable (Mathur and Singh, 2005). Generally, Gram-positive bacteria are more 
sensitive to antibiotics than are Gram-negative bacteria which have more complex cell 
wall and non- specific permeability barriers in their outer membrane; these prevent the 
access of antibiotic molecules to their active site (Hammond and Lambert, 1978) 
(Mulvey and Simor, 2009). Pseudomonas aeruginosa has a high degree of intrinsic 
resistance and was already resistant to many antibiotics even before they were 
introduced (Finch, 2003). 
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1.4.2 Acquired resistance  
Antibiotic resistance may also be acquired. This occurs when the organism’s genetic 
composition is changed by either a spontaneous mutation in the bacterial DNA genes, or 
by the acquisition of new genetic material, causing the bacteria to develop new 
mechanisms of resistance (Finch, 2003; Mathur and Singh, 2005; Mazel and Davies, 
1999). 
1.4.2.1 Mutational resistance 
  Mutations usually occur when a single or a few more  base pairs of the DNA are 
deleted, substituted, or added, thereby causing substitution of a single or few more 
amino acids in an essential peptide. Mutational resistance can significantly affect the 
genes coding for the antibiotic target and may reduce its affinity for the antibiotics 
(Finch, 2003). The rate of mutations in bacteria is not particularly high, perhaps 
occurring at a frequency of one gene mutation per 10
7–1010 bacteria, but the large 
numbers involved in bacterial populations increase the chance of the development of 
resistance in initially susceptible bacteria (Mulvey and Simor, 2009). Single mutants 
can cause a high degree of resistance. After a single exposure to streptomycin or 
erythromycin, for example, up to a thousand-fold resistant increase over the parent 
strain has been reported (Hammond and Lambert, 1978). High level streptomycin 
resistant Mycobacterium tuberculosis (Mazel and Davies, 1999) and Enterococcus 
faecalis are  a common example of acquired resistance caused by a mutation affecting 
the specific streptomycin–binding protein of the 30S subunit of the bacterial ribosome 
(Finch, 2003). 
1.4.2.2 Transferable resistance  
Concern is particularly focussed on the rapid emergence and development of resistance 
that results from the acquisition of exogenous genetic material from (resistant) species. 
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In 1959 transferable resistance was first observed, when resistance genes native to 
Shigella were transferred by plasmids to E. coli (Hawkey, 1998). Three mechanisms of 
the horizontal gene transfer (HGT) have been identified :( i) natural transformation, this 
phenomenon is assigned as the acquisition and incorporation of free"naked" DNA from 
the extracellular medium (Mathur and Singh, 2005). In bacteria such as Str. 
pneamoniae, H. influenza, Helicobacter, Neisseria and Moraxella spp, transformation 
of resistance factors is a significant mechanism which causes extensive genetic variation 
(Finch, 2003), (ii)  transduction, is a transfer of  DNA in a process mediated by 
bacteriophages (viruses that infect bacteria) which may also participate in the 
transformation of  some resistance genes, this being commonly seen in Staphylococci 
(Hawkey, 1998): (iii) conjugation, this involves transfer of DNA from one bacterial cell 
to another and is  found to occur in most bacterial genera  (Mathur and Singh, 2005). 
Conjugation plays a vital role in the transfer of resistance across genus and species lines 
of clinically important bacteria using plasmids and transposons. Plasmids are extra-
chromosomal, autonomous, DNA molecules that replicate separately from the bacterial 
genome and may contain some antibiotic resistance genes (Mulvey and Simor, 2009; 
Levy, 1997). Conjugative plasmids, which are capable of self-transmission to other 
bacterial hosts, are common in Gram-negative enteric bacilli and are relativity large; 
non-conjugative plasmids are common in Gram-positive cocci. In order to increase the 
probability of their distributing to progeny during cell division, small plasmids are 
usually present at more than 30 copies per cell, while the large plasmids are usually 
present at one or two copies per cell, and their replication is closely linked to replication 
of the bacteria chromosome. Conjugative transfer of plasmids has been observed, 
however, between distant bacterial groups and even between bacteria and eukaryotic 
cells such as yeasts (Finch, 2003). Transposons are mobile DNA units, which are 
generally smaller than plasmids. Beside antibiotic resistance genes, transposons carry 
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genes required for their transposition, replication and jumping to other regions of the  
bacterial chromosome or bacterial plasmids (Mulvey and Simor, 2009). Conjugative 
transposons are circular segments of double-stranded DNA, ranging in size from 18 to 
over 150 kbp (Salyers and Amabile-Cuevas, 1997), and usually consist of a functional 
central region flanked by long terminal repeats. Insertion sequences that encode 
transposases and resolvases are found in the complex transposons which are responsible 
for their own transposition. Conjugative transposons can transfer 
independently of plasmid intermediate between chromosomes in different bacterial 
strains. For example, conjugative transposon Tn416 mediates the spreading of the tetM 
gene from Gram-positive cocci to various bacteria such as Clostridium and Neisseria 
(Finch, 2003). Some transposons and plasmids possess genetic elements which help 
them to acquire new genes; termed integrons which contain a range of gene clusters that 
often contain multiple determinants of antibiotic resistance (Gold and Moellering, 
1996). 
1.5 Mechanisms of antibiotic resistance in bacteria 
In order to be effective against given bacteria, antibiotics must meet the following: 1) a 
vital target susceptible to a low concentration of the antibiotic must exist in the bacteria 
and 2); the antibiotic should directly contact to and bind to its intended bacterial target 
site in sufficient quantity (Finch, 2003). Whether antibiotic resistance is intrinsic or 
acquired, bacteria use their genetic determinants of resistance to encode different 
resistance mechanisms to neutralise the action of antibiotics, these resistance 
mechanisms can be classified into the following three basic types (Figure 1.1) : (i) 
enzymatic inactivation by either destruction or chemical modification of the antibiotics; 
(ii) prevention of antibiotic access to the target site (iii) alteration of the antibiotic target 
site (Schwarz and Chaslus-Dancla, 2001; Mulvey and Simor, 2009). 
Chapter One: Introduction  
11 
 
  Enzymatic inactivation of antibiotics is accomplished when acetyl, adenyl or 
phosphoric groups are enzymatically transferred to specific sites of the antibiotics 
(Schwarz and Chaslus-Dancla, 2001), this kind of inactivation is the main mechanism 
of resistance to beta-lactams. β-lactamases enzymatically cleave the β-lactam ring of 
penicillins, cephalosporins and carbapenems which  leads consequently  to the loss of 
their antibacterial activity. More than 200 different types of β-lactamase have been 
described (Hawkey, 1998) that may be categorized by their different substrates and 
activities. The production of β–lactamases commonly mediates penicillin resistance in 
S. aureus and N. gonorrheae and ampicillin-resistance in H. influenzae (Mulvey and 
Simor, 2009), whereas the production of chloramphenicol acetyltransferase enzyme 
mediates chloramphenicol resistance in both Gram-positive and Gram-negative species 
(Finch, 2003). 
For an antibiotic to bind with a bacterial target effectively, an antibiotic must reach a 
threshold concentration within the bacterium. Therefore, yet another strategy has 
evolved to neutralize antibiotic activity which prevents an antibiotic from accessing its 
target site, this can be achieved by either reducing the uptake or increasing  the removal 
of the antibiotics (Croft et al., 2007). Efflux pumps, actively pump out antibiotics from 
the bacterial cytoplasm before they start their action and mediate resistance to the 
tetracyclines, chloramphenicol and the fluoroquinolones (Levy and Marshall, 2004; 
Alanis, 2005). In Gram-negative bacteria, the outer membrane of the cell wall can act as 
a permeability barrier for certain antibiotics. Some essential compounds and antibiotics 
diffuse into Gram-negative bacteria cell cytoplasm through a cellular membrane protein 
know as a porin. Porin mutations, which reduce its expression, cause a structural 
alteration which may prevent or reduce access of antibiotics to their cytoplasmic target 
active site. This mechanism can be best exemplified by the resistance  of Pseudomonas 
aeruginosa and other Gram-negative bacteria to β-lactams and aminoglycosides 
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(Mulvey and Simor, 2009), Pseudomonas aeruginosa switch the charge of their cell 
wall lipopolysaccharides (LPS) to impede the antibiotics with highly positive charges, 
like aminoglycosides, from passing the cell wall outer membrane (Schwarz and 
Chaslus-Dancla, 2001).  
 Alterations of the antibiotic target site, e.g. by methylation, may make the target active 
site inaccessible to antibiotics (Schwarz and Chaslus-Dancla, 2001), consequently, this 
leads to a loss of any antibacterial effect. For example, alterations in the structural 
conformation of penicillin-binding proteins (PBPs) observed in certain types of 
penicillin resistance. This occurs in methicillin resistant strains of S. aureus (MRSA) 
which produce an altered penicillin-binding protein (PBP2a) that  β-lactam antibiotics  
fail to bind successfully, therefore, all of the currently available penicillins, 
cephalosporins and carbapenems are inactive against MRSA (Mulvey and Simor, 2009). 
In yet another example of resistance, most fluoroquinolones (e.g., ciprofloxacin, 
levofloxacin and moxifloxacin) resistance stems from alterations to DNA gyrase which 
are critical for DNA replication in bacteria (Alanis, 2005). 
1.6 Selected resistant microorganisms 
1.6.1 Staphylococcus aureus  
Since it was discovered in the 1880s, Staphylococcus aureus has been seen as a 
potential pathogenic Gram-positive bacterium, causing infections, such as post-
operative wound infections and minor skin infections. It is regarded as the second most 
common etiologic agent in bloodstream infections and lower respiratory tract 
infections. Penicillin-resistant S. aureus isolates started to appear in hospitals only two 
years after the introduction of penicillin in medical use, within a few years later the 
appearance of penicillin-resistant strains of S. aureus in the general community was also 
reported (Croft et al., 2007; Deurenberg and Stobberingh, 2008). By 1946, around 60%  
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of hospital isolates in the UK were resistant to penicillin (Lyon and Skurray, 1987). 
Staphylococcus aureus contain mobile genetic islands. DNA from these islands is 
readily exchanged within the S. aureus population. These mobile genetic elements are 
commonly referred to as S. aureus pathogenicity islands and are a possible mechanism 
for evolution in S. aureus (Holden et al., 2004).  
 
1.6.1.1 Methicillin Resistant Staphylococcus aureus (MRSA) 
The introduction of methicillin in 1960, a penicillinase-stable antibiotic, seemed to be 
the answer to increasing therapeutic problems resulting from antibiotic resistance. 
However, the relief was short-lived as the first resistant strain was reported in 1961 
(Livermore, 2000). Methicillin resistant Staphylococcus aureus owe their behaviour to 
an additional, low-affinity penicillin-binding protein (PBP-2a), encoded by mecA  gene 
which  is carried on a cassette chromosome (SCCmec) which is mobile and is an 
efficient transformer (Zinner, 2007). However, the incidence of hospital infection with 
multi resistant Staphylococci gradually declined during 1960s and 1970s, but this calm 
was shattered in the late 1970s and early 1980s, and after the gradual dissemination of 
new epidemic strains of methicillin-resistant Staphylococcus aureus has become 
endemic in hospitals worldwide (Livermore, 2000; Finch, 2003; Cooper et al., 2003). 
Epidemic strains of MRSA (EMRSA) were different from those MRSA strains of the 
1960s; while most antibiotic resistance in the MRSA strains of the 1960s was plasmid-
borne, resistance in EMRSA was carried on the chromosome. The first, EMRSA-1 
strain caused outbreaks in London hospitals before spreading beyond (Cooper et al., 
2003). In the UK, the most widespread strains of MRSA are EMRSA15 and EMRSA16 
(Livermore, 2000). MRSA have become resistant to virtually all-available systemic 
antibiotics, including the β-lactams, aminoglycosides, tetracyclines, macrolides and 
lincosamides (Finch, 2003). In general, MRSA is currently the most frequently 
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identified drug-resistant pathogenic bacteria among patients in health-care units 
(Mulvey and Simor, 2009). S. aureus–associated hospitalizations increased more than 
60%, and the approximated figure of MRSA-associated hospitalizations more than 
doubled during the period from 1999 to 2005, thereby suggesting that S. aureus and 
MRSA should be taken into account as a national priority in disease control plans in 
USA (Klein et al., 2007). 
 Recently, the problem of MRSA has involved two worrying developments. First is the 
emergence of community-acquired-MRSA (CA-MRSA). Initially MRSA infections 
were acquired nosocomially. CA-MRSA are becoming the most frequent causes of 
lung, serious skin and soft tissue infections  in previously healthy patients, even  when 
not in contact with hospitals or other health-care facilities (Zinner, 2007). CA-MRSA 
strains are associated with Staphylococcal cassette chromosome (SCCmec types IV-V 
or VI) and characterized by the presence of exotoxin gene profiles including Panton-
Valentine leukocidin (PVL), whereas hospital acquired MRSA (HA-MSRA ) generally 
carry the larger SCCmec types I-III and more resistant phenotypes (Croft et al., 2007; 
Deurenberg and Stobberingh, 2008; Zinner, 2007; Weber, 2005). 
  Another critical development is the emergence of vancomycin resistance in S .aureus 
Glycopeptides such as vancomycin have been widely used in the treatment of MRSA 
infections among hospitalized patients. Unfortunately, MRSA strains with reduced 
susceptibility to vancomycin have been increasingly reported in the last two decades. In 
1997 an MRSA strain with intermediate resistance to vancomycin (MIC 8 µg/mL) was 
reported in Japan. This strain is known as a Vancomycin-Intermediate S.aureus [VISA] 
(Tenover, 2006). Five years later, in 2002 a Vancomycin- resistant Staphylococcus 
aureus (VRSA) (MIC 32μg/mL) was isolated for the first time in the United States. 
VRSAs are being isolated in hospitals worldwide (Hiramatsu, 2001; Bataineh, 2006; 
Tiwari and Sen, 2006). This Vancomycin-resistant Staphylococcus aureus achieved 
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vancomycin resistance by acquiring the vanA vancomycin resistance gene from 
Enterococcus spp. (VRE) (Tenover, 2006). 
1.6.2  Escherichia coli 
This is a Gram-negative member of the family Enterobacteriaceae. Although most 
strains of E. coli are not regarded as pathogens, the bacterium plays an important role in 
nosocomial infections and is considered as a common cause of urinary tract infections 
(UTIs) (Tenover, 2006; Croft et al., 2007; Guyot et al., 1999; Feng et al., 2002). E. coli 
isolates accounted for 13·6% of nosocomial infections in an USA hospital and 
responsible for 12.7% of intensive care (ICU) acquired infections in many European 
countries (Guyot et al., 1999). 
E.coli has become frequently resistant to aminopenicillins, including amoxicillin or 
ampicillin and a limited spectrum of cephalosporins. This resistance is facilitated by the 
acquisition of plasmid-encoded β-lactamases, which degrade and inactivate these 
antibiotics (Tenover, 2006). The rates of decreased sensitivity to oxyimino-
cephalosporins among worldwide clinical isolates ranged from 3% in the United States, 
5% in Europe, to 8% in the Western Pacific and 9% in Latin America. This resistance 
was commonly linked with co-resistance to tetracycline (45-77%), gentamicin (15-
75%), ciprofloxacin (14-66%) and co-trimoxazole (6-26%). Fluoroquinolone-resistant 
Escherichia coli is an increasingly common problem in Europe, reaching prevalence 
rates of 5-l0% in many surveys (Finch, 2003). 
1.6.3 Mycobacterium tuberculosis 
Mycobacterium tuberculosis exists as multi-drug-resistant tuberculosis (MRD-TB) 
when it is resistant to isoniazid and rifampicin (two key first-line drugs) with or without 
resistance to other anti-TB drugs (Willcox, 2000; Nations and Walsh, 2006). Rifampicin 
and isoniazid are the most common first-line anti-TB agents. The action of isoniazid 
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against M. tuberculosis is achieved by an inhibition of the biosynthesis of mycolic 
acids, which is an essential component of the bacterium cell wall, whereas the action of 
rifampicin is achieved by it interfering with the synthesis of mRNA by binding to RNA 
polymerase. Resistance in Mycobacterium against these drugs mainly derives from the 
accumulation of individual mutations in several independent genes resulting in an over 
production or modification of the drug target (Willcox, 2000). 
   The development of (MRD-TB) is one of the most common public health problems in 
the world, especially in the developing countries where deaths from tuberculosis are 
common. In a rural hospital in South Africa for example, 41% of the confirmed cases of 
tuberculosis were found to be multidrug resistant (Lawn and Wilkinson, 2006). Only in 
2004, it has been estimated that nearly 424,200 cases of MDR TB occurred worldwide 
(Shah et al., 2007). MRD-TB is associated with high mortality rates in all patients, but 
especially so in people infected with human immunodeficiency virus (HIV), in which 
the mortality rates can reach to 90 % (Paramasivan, 1998; Finch, 2003). 
1.6.4  Pseudomonas aeruginosa 
Pseudomonas aeruginosa is one of the major causes of nosocomial infections and is 
highly associated with opportunistic infections among immunocompromised 
individuals. About 10% of all hospital-acquired infections are caused by Pseudomonas 
aeruginosa; these infections are difficult to treat due to the presence of numerous 
intrinsic and acquired mechanisms of antibiotic resistance. Multidrug resistance P. 
aeruginosa is increasingly being reported among clinical isolates collected in the USA 
(Tenover, 2006; Aloush et al., 2006). For example, about 30% of P. aeruginosa clinical 
isolates from intensive care units (ICU) in the USA were found to be resistant to 
fluoroquinolones and 21% were resistant to carbapenems (Mulvey and Simor, 2009). 
The situation in Europe and Latin America seemed to be worse, where the results of a 
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global survey done between 1997 and 1999  showed  that no antipseudomonal agent 
was still effective against >80 % of sampled hospital strains (Finch, 2003).  
As mentioned above, P. aeruginosa is characterized by intrinsic resistance and some 
kind of acquired resistance mechanisms. Intrinsically, P. aeruginosa is resistant to most 
β-lactam antibiotics, tetracyclines, chloramphenicol, sulfonamides and 
aminoglycosides, due to a combination of impermeability with multidrug efflux. This 
combination prevents the accumulation of antibiotics within the bacterium, pumps the 
antibiotics out from the cell before they have the opportunity to reach an internal 
concentration sufficient to react with the site of action (Tenover, 2006). Pseudomonas 
aeruginosa expresses many types of acquired β-lactam resistance, often in combination, 
these include: acquisition of transposon and plasmid-mediated ESBLs, hyperproduction 
of AmpC cephalosporinase, oxacillinases, or carbapenemases; mutational loss of porins 
or upregulation of efflux pumps. In general, acquired resistance in P. aeruginosa 
develops rapidly and can emerge in more than 10% of patients during treatment (Finch, 
2003). 
1.6.5 Candida albicans 
The yeast, Candida albicans is the most prevalent fungal pathogen of humans and 
causes oral, vaginal,
 
and systemic infections. These
 
infections are frequently associated 
with immunocompromised patients and are regularly found in acquired immune 
deficiency syndrome (AIDS) patients and bone marrow
 
transplant patients (Goldway et 
al., 1995; White et al., 2002). There are many antifungal agents such as the polyene 
amphotericin B and the azoles which are available to treat infections caused by C. 
albicans. In the 1990s, azole-resistant isolates of C. albicans emerged in HIV-infected 
patients after receiving extended doses of azole antifungals. Up to one-third of the oral 
HIV-positive patients' C. albicans isolates were documented as azole resistant. 
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Recently, multidrug resistant C. albicans have been also reported in other patient 
populations, such as those receiving bone marrow transplants (White et al., 2002) 
1.6.6  Enteroccoci 
Enteroccoci are Gram-positive bacteria which possess limited virulence. Although they 
are not regarded as highly pathogenic as Staphylococci and Streptococci species, 
Enterococcus species (e.g., Enterococcus faecalis, Enterococcus faecium) are 
increasingly encountered in nosocomial infections and  may also cause other severe, 
life-threatening infections (Croft et al., 2007; Mulvey and Simor, 2009). Enterococcus 
faecalis, Enterococcus faecium are responsible for the majority of human infections 
caused by enterococcal species, 80 to 90% of all clinical isolates were identified as 
E. faecalis whereas 5 to 15% of such clinical isolates were identified as E. faecium , 
while the remaining (>10) Enterococcus species accounted for less than 5% of clinical 
isolates (Cetinkaya et al., 2000). 
    Enterococci are intrinsically resistant to numerous regularly used antibiotics, such as 
aminoglycosides, where the uptake of the drug is compromised at the cell wall; this 
makes the choice of using antimicrobial agents to treat infections caused by Enterococci  
limited. Intrinsic resistance exists to the β-lactam antibiotics when they are used alone 
due to the presence of penicillin-binding proteins of the organism having a low affinity 
for these antibiotics. Intrinsic resistance to the quinolones is due to mutations of the 
quinolone resistance-determining region. As well as widespread intrinsic resistance, 
Enterococci are able to readily acquire resistance to all currently existing antibiotics 
through either mutations or by obtaining foreign genetic materials mediated
 
by mobile 
DNA including, plasmids and transposons (Cetinkaya et al., 2000) (Murray, 1990). For 
a long time, glycopeptide antibiotics particularly vancomycin, were considered as the 
most powerful antibiotics to treat infections associated with multidrug-resistant 
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enterococci. In 1988, the first isolation of vancomycin-resistant E. faecalis and 
E. faecium was reported in UK (Cetinkaya et al., 2000). Subsequently, Vancomycin 
Resistant Enterococci (VRE) has been reported worldwide (Croft et al., 2007). 
Enterococci developed this resistance by acquisition of gene clusters carried on plasmid 
that encode a modified cell-wall precursors which do not bind glycopeptides such as 
vancomycin (Mulvey and Simor, 2009).  
1.7 The impact of antibiotics resistance 
Due to the lack of worldwide comprehensive data, there is no accurate estimation as to 
the total economic cost of the emergence of the antibiotic resistant bacteria. However, it 
has been documented that infections with antibiotic resistance bacteria lead not always, 
but usually, to excessive lengths of stay in hospitals, excess mortality rates, increased 
duration of ICU admission, and to the increased attributable cost of medical care 
including the use of expensive broad spectrum antibiotics and the development of 
inappropriate antibiotic therapy complications, such as a necessity to perform surgery 
(McGowan Jr, 2001; Niederman, 2001; Sipahi, 2008). In 1995 the American Society for 
Microbiology estimated that the annual healthcare expenses related to the treatment of 
antibiotic resistant bacterial infections in the USA were more than US$4 billion (Sipahi, 
2008). One of the few studies examining the costs of antibiotic resistance showed that 
methicillin-resistant (MRSA) treatment in New York city cost  22%  more than 
methicillin-susceptible (MSSA) treatment (Levy and Marshall, 2004). The estimated 
cost of single case treatment (including drugs, procedures, and hospitalization) has 
increased from $12,000 for a drug-sensitive M. tuberculosis to $180,000 for a 
multidrug-resistant M. tuberculosis (Cohen, 1992). 
   The emergence of multi-antibiotic resistant strains can increase the morbidity and 
mortality as, for certain infections, the potential efficient treatment is delayed.  
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Moreover, because antimicrobial susceptibility tests are time consuming, complications 
or death can result during normally accepted treatment (Cohen, 1992). In a meta-
analysis carried out to investigate the effect of methicillin-resistance on the mortality 
among S. aureus bloodstream-infected patients, mortality rates was nearly double in 
methicillin-resistant S. aureus bloodstream infections compared to methicillin-
susceptible  S. aureus bloodstream infections (Mulvey and Simor, 2009). 
1.8  The decline of antibiotic research and development 
We are now facing two opposing and worrying trends. While the emergence of 
multidrug-resistant pathogen strains is rapidly growing, the innovation and the 
development of novel antimicrobial agents which are effective against these pathogens 
have declined significantly. Moreover, many large pharmaceutical companies as well as 
biotechnology companies have either reduced, or wholly eliminated, their research 
efforts in antibacterial agent innovation (Sipahi, 2008; Projan and Shlaes, 2004). Since 
the 1980s, the world market has witnessed the introduction of only two new classes of 
antibiotics of novel mechanisms of action (namely linezolid and daptomycin) 
(Jagusztyn-Krynicka and Wyszynska, 2008). 
   There are many reasons for this noticeable decline, the most significant one being that 
the current cost required to bring a new antibiotic agent to the market ranges between 
$100 million and $350 million in the United States (Gold and Moellering, 1996), and 
according to the US Department of Health and Human Services it may reach  US$1.7 
billion (Sipahi, 2008). There are several factors leading to high costs, for example, 
regulatory agencies have been increasing their requirements in the areas of 
manufacturing, safety,  and efficacy for drug development .In addition, the cost of the 
clinical trials have increasingly become more expensive. In the 1981–84 period, the  
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number of patients enrolled in clinical trials averaged 1321, whereas it increased to 
more than 4237 by 1994–95 (Projan and Shlaes, 2004). 
1.9 Alternative methods to antibiotic treatment 
The current situation, where antibiotic resistance is becoming increasingly common, 
and at the same time new antibiotics research and development has declined, has created 
a therapeutic challenge to the medical community where the development of new 
approaches and alternative treatments for such infections is becoming increasingly 
essential.  
  In this section some of the alternative approaches to the control of microbial infections 
will be discussed. One of these, is the unorthodox use of biological control that involves 
the application of living organisms, rather than the application of a metabolite they 
produce to the human infection; this includes for example, maggot therapy, 
bacteriophage therapy, the use of  probiotics and mycotherapy (Wainwright, 1998; 
Nicolle, 2006). The procedure basically relies on competition between two species of 
organism, one the parasite and the other a non-pathogenic saprophyte. The biggest 
limitation of some of these techniques is that it is mainly restricted to the treatment of 
surface infections of the skin and vulnerable mucous membranes. In addition to these 
living alternatives to antibiotics, honey, botanical extracts and essential oils are being 
used to treat some multi-resistance bacterial infections, notably; wound-associated 
infections (Bowler et al., 2001; Bowler, 2002). 
1.9.1 Maggot therapy 
Maggot debridement therapy (MDT), using larvae of certain species of flies to treat 
antibiotic resistant wounds, is increasingly being used in medicine with considerable 
success. There are hundreds of reports showing the successful use of maggots in chronic 
or infected wounds, including diabetic foot ulcers (Sherman, 2003), malignant 
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adenocarcinoma (Sealby, 2004), and for venous stasis ulcers (Sherman, 2009). It has 
also been used to combat infections following breast-conserving surgery (Steenvoorde 
and Oskam, 2005). 
   Maggot therapy appears to depend upon the production by the maggot of  natural 
antibiotic-like agents, the alkalinisation of the wounds with secreted ammonia, and the 
consumption of bacteria and the consumption of dead flesh (Whitaker et al., 2007). 
1.9.2  Bacteriophage therapy 
Bacteriophages are bacterial viruses that naturally invade and multiply in bacteria, 
including pathogens (Nicolle, 2006; Joerger, 2003).  They are often very specific to one 
bacterial species; they are harmless to animals and plants, and destroy their target 
bacteria (Summers, 2001). Interest in the therapeutic potential of phages dates back to 
nearly 100 years ago (Nicolle, 2006). According to Sulakvelidze et al. 2001, the first 
reported observation of phages may date as far back as 1896, when Ernest Hankin, a 
British bacteriologist, isolated a substance that was able to destroy Vibiro cholerae from 
the rivers Ganges and Jumma in India. Hankin assumed that an unknown filterable 
substance with bactericidal effect was behind this phenomenon and this limited the 
spread of cholera epidemics. However, the first clear discovery and description of “the 
bacteriophage phenomenon" was in 1915 by the English bacteriologist, Frederick Twort 
(Wainwright, 1990; Sulakvelidze et al., 2001; Mathur et al., 2003). The same 
phenomenon was then independently discovered by Felix d'Herelle, a French-Canadian 
microbiologist working at the Pasteur Institute in Paris in 1917 (Wainwright, 1990; 
Summers, 2001). He observed that filtrates from the faeces of dysentery patients 
stimulated a transmissible lysis of a broth culture of dysentery bacillus. He assumed that 
a virus was the lytic agent and named it as “Bacteriophage” (Mathur et al., 2003). 
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The efficacy of the bacteriophage was confirmed in 1927, when d'Herelle tried to use 
bacteriophage to treat Asiatic cholera in India. The phage was given to patients in 
spoonfuls while patients for whom it was denied acted as controls. D'Herelle claimed 
that it was a successful treatment, with mortality rates in the treated group being around 
8%, compared to over 60 % mortality amongst the controls (Wainwright, 1990). More 
intensive studies on the therapeutic use of phages were conducted until they were later 
abandoned, when cheap effective and wide spectrum antibiotics were introduced into 
clinical use (Mathur et al., 2003). However, a limited bacteriophage therapy continued 
to be performed in some Eastern European countries, while it was re-evaluated in the 
United States and Western Europe as a response to the increase in emergence of multi 
antibiotic-resistant bacteria (Joerger, 2003). 
  In a comparison with antibiotics, there are several special advantages which make 
phages potentially attractive therapeutic agents. Firstly, they are highly and specifically 
lytic against targeted pathogenic bacteria (Sulakvelidze et al., 2001); they are self-
replicating and keep multiplying as long as local infection as present; bacteriophages are 
harmless to normal intestinal microflora. In contrast to antibiotics that are well known 
to have some side effects, there are no reported side effects associated with 
bacteriophages use, despite their use in millions of patients (Mathur et al., 2003). The 
limited host range can be a problem; for example there is no single bacteriophage that 
can lyse all Salmonella serovars strains (Sulakvelidze et al., 2001; Joerger, 2003). Our 
poor understanding of the interaction between phage and its host; and low levels of 
stability of phage preparations also present difficulties (Sulakvelidze et al., 2001). 
1.9.3  Probiotics 
The use of probiotics involves applying live microorganisms, including certain bacteria 
and yeast species, to deliberately repopulate the harmful composition of intestinal  
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microflora with beneficial microbes (Nicolle, 2006; Ouwehand et al., 2002; Boehm and 
Kruis, 2006). Although the use of food, fermented with microorganisms, for the purpose 
of disease prevention and health protection was documented and described in the 
classical Roman literature (Boehm and Kruis, 2006), Elie Metchnikoff, the Russian 
Nobel prize winner, was the first one to suggest the therapeutic use of probiotics. He 
proposed that a high concentration of lactobacilli in the intestinal microflora plays an 
important role in the health and longevity of humans (Gionchetti et al., 2006). 
Heterogeneous lactic acid bacteria are the most commonly used as probiotics; these 
include Enterococci, Bifidobacteria and Lactobacilli (Ouwehand et al., 2002). Non-
pathogenic yeasts (Sacchromyces buolardii, Sac. cerevisiae) and filamentous fungi 
(Aspergillus oryzae) have also been used as potential probiotics (Fuller, 1992). There is 
considerable evidence, obtained from clinical trials, showing that probiotics could be a 
promising alternative to antibiotics, particularly in the treatment of inflammatory bowel 
disease (IBD) and ulcerative colitis (UC) (Gionchetti et al., 2006). 
1.9.4 Mould therapy  
This approach, also termed mycotherapy, is based on folk medicine, where moulds 
growing on various natural products and foodstuffs have been in use for centuries to 
treat wounds and cure superficial bacterial infections (Wainwright, 1998). In the early 
1940s, when purified penicillin was not widely available and very rare, doctors 
throughout the world successfully used bandages containing living cultures of 
Penicillium notatum (Fleming's original penicillin-producing mould) to treat some 
infected wounds, the mould then continued to grow and secrete penicillin and possibly 
other antibacterial metabolites. A modification of this approach termed Vivicillin, 
involved the use of a suspension of macerated fungal mycelium which was applied  
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directly to the infected wound. This probable alternative might deserve re-evaluating, 
especially as fungal mycelium is also known to aid healing (Wainwright et al., 1992). 
1.9.5 Antimicrobial peptides (AMPs) 
Recently, there is a growing interest in a group of naturally occurring small peptides 
produced by many tissues and cell types including human neutrophils (Bowler et al., 
2001). In general, antimicrobial peptides are characterized by their small molecular 
mass which ranges between 1 to 5 kDa (Joerger, 2003). Their mode of action involves 
attachment to bacterial cell walls and formation of pores, which induce leakage of the 
cell contents and resultant death. These types of molecules have a wide spectrum of 
antimicrobial activity and that can be formulated for use in wound management (Bowler 
et al., 2001). One group of these antimicrobial peptides are gallinacins, purified from 
chicken leukocytes. In 1994, these successfully exhibited antimicrobial activity against 
L. monocytogenes , E. coli and  Candida albicans in vitro (Joerger, 2003). 
1.9.6  Apitherapy (Honey therapy) 
Honey is one of these alternative treatments for antibiotic-resistant bacteria that has 
been gaining an increasingly interest. The antibacterial activity of honey has been 
extensively researched and is found to contain four main components. The main factor 
is hydrogen peroxide, which is produced by glucose oxidase (White Jr et al., 1963). 
Two other antibacterial factors are common to honey, namely acidity and osmolarity, a 
feature which is common to any concentrated sugar solution, the strong interaction 
between water molecules and the monosaccaride component leaves only a small and 
insufficient fraction of the water available for the growth of bacteria. Likewise the 
relatively high acidity of honey is antibacterial: the acidity varies between pH 3.2–4.5 
and is beyond the lower limits for growth of most animal pathogens. The fourth 
component are the phytochemical factors including benzyl alcohol, pinocembrin, 
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terpenes, 3, methyl 3,5-dimethoxy-4-hydroxybenzoate ,and 5-dimethoxy-4-
hydroxybenzoic acid (syringic acid) (Molan, 1997). Hundreds of in vivo studies have 
demonstrated the antibacterial activity of honey (e.g., Manuka honey) against a wide 
spectrum of bacterial species, particularly those related to wound infections like 
methicillin-resistant Staphylococcus aureus and, Vancomycin–resistant enterococci 
(Cooper et al., 1999; Cooper et al., 2002; Al-Waili et al., 2005). 
 
 
 
 
Aims of the work presented in this Thesis    
The overall aim of the work presented in this thesis was to add new information to our 
knowledge of some of these alternatives to antibiotics, concentrating on maggot 
therapy, Apitherapy (honey therapy) and to a lesser extent mycotherapy. 
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2.1 Introduction 
2.1.1 Honey  
Honey was used in the medicine of many ancient communities (Molan, 2006), including 
the ancient Egyptians. The ancient Chinese and Sumerians provided the first written 
prescriptions relating to the medical use of honey, found as clay tablets, dating back to 
2000 B.C. In such prescriptions, honey was used as an ingredient for ointments for use 
on infected wounds (Jones, 2001). No knowledge of the honey’s antibacterial properties 
was of course known during this early therapeutic use of honey. Molan (2006) has cited 
that according to Dustmann the modern application of antibacterial honey was first 
reported by Van Ketel in 1892, followed by Sackett in 1919. Research into the 
antimicrobial characteristics of honey continued from time to time during the 20th 
century. However, it was not until the 1980's that interest in the healing properties of 
honey was revived and clinical studies began again (Davis, 2005). 
   The antibacterial  potency of honey  has been attributed to the following; (i) an 
osmotic effect: honey has a strong osmotic effect since more than 80% of its 
composition is a mixture of different monosaccharides, thereby making water  available 
at a minimum level and  preventing the growth of many microorganisms ; (ii) a 
naturally low pH:, honey is relatively acidic; its pH ranging from between 3.2 and 4.5, a 
factor  which inhibits many pathogens (Molan, 1997); (iii) production of hydrogen 
peroxide: hydrogen peroxide plays a key role in the antimicrobial activity of honey. It is 
created when the hypopharyngeal gland of the bee secretes glucose oxidase into the 
nectar to help in the synthesis of honey; this reaction produces gluconic acid as well as 
hydrogen peroxide H2O2 (Wahdan, 1998); (iiii) phytochemical factors: many 
antibacterial phytochemicals have been recognized in honey such as: benzyl alcohol, 
pinocembrin, terpenes, 3, methyl 3,5-dimethoxy-4-hydroxybenzoate ,and 5-dimethoxy-
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4-hydroxybenzoic acid (syringic acid) (Molan, 1997), flavonoids and the phenolic acids 
(Wahdan, 1998). 
  Numerous reports and clinical studies have demonstrated the antimicrobial activity of 
honey against a broad range of microorganisms, including multi-antibiotic resistant 
strains. A study conducted by Cooper and  co-workers showed that more than 50 
clinical isolate strains of coagulase-positive Staphylococcus aureus were susceptible to 
less than 5% (v/v) of pasture honey (Cooper et al., 1999). In another study carried out 
by the same researcher, different honey samples exhibited bactericidal activity against 
17 strains of  P. aeruginosa isolated from infected burns, even when it was diluted more 
than 10-fold (Cooper et al., 2002). More recently, this anti P. aeruginosa activity was 
confirmed and it was shown to be significantly higher than many antibiotics including 
amoxicillin/clavulinic acid, sulbactam/ampicillin, and ceftriaxone (Abd-El Aal et al., 
2007). Honey samples collected from Northern Ireland and France showed a significant 
ability to inhibit the growth of community-associated methicillin-resistant 
Staphylococcus aureus (CA-MRSA) (Maeda et al., 2008). Other studies demonstrated 
the antibacterial activity of honey against: Escherichia coli, Campylobacter jejuni, 
Salmonella enterocolitis, Shigella dysenteriae (Adebolu, 2005),  Mycobacterium 
(Asadi-Pooya et al., 2003), methicillin-resistant Staphylococcus aureus and, 
Vancomycin –resistant enterococci (Cooper et al., 1999; Cooper et al., 2002; Al-Waili 
et al., 2005). The antifungal activity of the honey, especially anti-Candida activity 
(Theunissen et al., 2001; Irish et al., 2006; Koc et al., 2008) has also been reported. 
  Few studies have been conducted to investigate the antiviral activity of honey one 
however, was  conducted by  Zeina et. al. (1996) who compared the sensitivity of  
Rubella virus maintained in kidney cell cultures to a honey solution and to thyme 
extracts at varying concentrations; honey showed a potent antiviral activity while thyme 
did not (Zeina et al., 1996). In another work conducted by Al-Waili (2004) the effect of 
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the topical application of honey on recurrent attacks of herpes lesions was compared to 
widely-used antiviral drugs (acyclovir cream). The results showed that that application 
of honey was safe and effective in the management of symptoms associated with 
recurrent herpes lesions (Al-Waili, 2004).     
2.1.2 Leptospermum scoparium (Manuka) honey 
Results obtained from several studies show that honeys from different geographical 
locations and different floral origins exhibit different antibacterial activities (Allen et 
al., 1991; Al-Jabri et al., 2003; Shin, 2005; Küçük et al., 2007). One such famous 
product is Manuka honey which is derived from the Manuka tree (Leptospermum 
scoparium) a native of New Zealand (Snow and Manley-Harris, 2004). Manuka honey 
is known to have a unique extra antimicrobial activity which is not related to its low pH, 
osmolarity or hydrogen peroxide accumulation,   termed as a non-peroxide activity 
(Allen et al., 1991; Molan, 1999b). A general survey of 345 different New Zealand 
honey samples including Manuka honeys was carried to evaluate the variation in 
antibacterial activity among them. In order to remove hydrogen peroxide antibacterial 
activity, catalase was added to the tested diluted honeys. While most of the honeys 
demonstrated no detectable non-hydrogen peroxide antibacterial activity, Manuka 
honey exhibited a considerable range of non-peroxide antibacterial activity (Allen et al., 
1991). Australian jelly-bush honey also has been shown to have a significant non-
hydrogen peroxide antibacterial activity (Cooper, 2007). Much research effort has been 
made to identify the active component responsible for this non-peroxide antibacterial 
activity, although it was  thought that it may be due to plant derived components such as 
flavonoids and phenolic compounds (Weston et al., 2000), recent studies have 
successfully  concluded that this component  is methylglyoxal (MG), a highly reactive 
precursor in the formation of advanced glycation end products (AGEs) 
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(Adams et al., 2008; Mavric et al., 2008; Stephens et al., 2010). MG concentration is 
found to be 100-fold higher in  Manuka honeys than other conventional honey 
(Wittmann et al., 2008). Atrott and Henle (2009) found a perfect linear correlation 
between methylglyoxal levels in 61 samples of Manuka honey and their antibacterial 
activities, which clearly highlights the dominant bioactive compound in Manuka honey 
is methylglyoxal. 
 Manuka honeys have been given an industry standard called UMF® (Unique Manuka 
Factor), which reflects the relative ability of Manuka honey to inhibit the growth of 
Staphylococcus aureus. (e.g., UMF 20 is claimed to have equivalent antibacterial 
activity to 20% phenol w/v) (Allen et al., 1991). 
2.1.3 The use of Manuka honey in wound management  
The healing properties of honey have been known for thousands of years (Bell, 2007). 
The beneficial use of honey in wound treatment is not restricted to its well known 
antimicrobial activities, it can also prevent cross infections and fluid loss of the wound 
by creating a viscous protective barrier, it has a debriding effect, is anti-inflammatory 
and stimulates granulation and thereby tissue growth (Davis, 2005; Molan, 1999a; 
Mathews and Binnington, 2002). 
   The recognition of the significant non-hydrogen peroxide antimicrobial value of 
Manuka honey, particularly against strains of antibiotic resistant bacteria isolated from 
infected wounds, (Cooper, 2004; Davis, 2005; Molan, 1999a; Willix et al., 1992; Al 
Somal et al., 1994; Mathews and Binnington, 2002) has led to an increase in the use of 
this honey in wound management. Many reports have shown that  Manuka honey gives 
encouraging results in the treatment of leg ulceration (Gethin and Cowman, 2005), burn 
wounds and  severely infected cutaneous wounds (Visavadia et al., 2008). Manuka 
honey-impregnated dressings have been approved by the regulatory health  
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authorities in Australia and Europe and been used as an accepted topical treatment for 
wounds which commonly show a poor response to conventional therapy (Figure 2.1). 
(Simon et al., 2009). One of these medically certified honeys is   Medihoney™; Simon 
and his colleagues (2009) reported the successful use of Medihoney™ to treat 
methicillin-resistant Staphylococcus aureus (MRSA) infected wound in a 12-year old 
patient. 
2.1.4 The incidence of Clostridium botulinum in honey  
The incidence of Clostridium botulinum, a spore-forming anaerobic Gram-positive 
bacterium (Dodds, 1993), in honey has received widespread attention because of reports 
linking honey consumption to several infant botulism occurrences (Gilmore et al., 2010; 
Smith et al., 2010). Generally, the incidence of C. botulinum in honey samples is low 
(Simon et al., 2009; Gilmore et al., 2010; Schocken Iturrino et al., 1999). In a survey 
carried out in France, among 116 tested samples no botulinum spores were detected 
(Delmas et al., 1994), while 1.0% of Argentinean honey samples were contaminated 
with botulinum spores (De Centorbi et al., 1997).   
 
Figure 2.1:  Shows different types of medically certified honeys, Manuka honey-impregnated 
dressings and Activon medical grade Manuka.  
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The aim of the work reported in this  chapter was to:  
1. Investigate the antimicrobial activity of selected honeys from different origins; 
specifically to evaluate their non-hydrogen peroxide derived activity. 
 
2. Investigate the nature of the non-peroxide antibacterial activity of 
Leptospermum scoparium Manuka honey. 
 
3.  Evaluate Tregothnan English Manuka honey antibacterial activity and compare 
it to the New Zealand Manuka Honey. 
 
4. Conduct studies on the mechanisms of the antibacterial activity of the medical 
grade New Zealand Manuka against methicillin-resistant Staphylococcus 
aureus (MRSA) and to perform scanning electron microscope (SEM) and 
transmission electron microscope (TEM) studies on the morphological effects on 
Methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli.  
 
5. To investigate the possibility of the presence of non–hydrogen peroxide 
inhibitory components in Manuka honey derived from microbial sources. 
 
6. To determine the incidence of Clostridium botulinum spores in Manuka honey. 
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2.2 Materials and methods  
2.2.1 Honey samples  
Eighteen Honey samples from different origins were obtained from Rowse Honey Ltd, 
Wallingford, UK. Graded New Zealand Manuka honey samples were obtained from 
Comvita UK Limited, Berkshire, UK or from Littleover Apiaries Ltd, Derby, UK. 
Tregothnan English Manuka was obtained from Tregothnan Company, Cornwall, UK. 
2.2.2  Determination of pH 
The pH of the honey was determined as following; 5 g of honey was dissolved in 5 ml 
ultrapure MilliQ water, stirred until the solution became homogenous, The pH of the 
final solution was measured by using a calibrated Jenway 3310 pH meter (Bogdanov, 
2002) 
2.2.3  Test Organisms 
The following test organisms (bacteria) were used: Escherichia coli, Staphylococcus 
epidermidis, Serratia marcescens, Bacillus sphaericus, methicillin-sensitive 
Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA) 
and Bacillus subtilis; unless stated otherwise, the organisms were obtained from the 
Departmental Culture Collection. 
2.2.4  Turbidity standard for inoculum preparation 
In order to standardize the inoculum density for all susceptibility tests conducted in this 
thesis, a BaSO4 turbidity standard, equivalent to a 0.5 McFarland standard or its optical 
equivalent was used.  A BaSO4 0.5 McFarland standards were prepared as follows: a 
0.5-ml aliquot of 0.048 mol/L BaCl2 (1.175% w/v BaCl2. 2H2O) was added to 99.5 ml 
of 0.18 mol/L H2SO4 (1% v/v), the absorbance at 625 nm should be 0.008 to 0.10 for 
the 0.5 McFarland standard. The barium sulphate suspension was transferred into 
screw-cap tubes that had the same size and same volume of those used in growing the 
needed broth culture. Tubes were tightly sealed to prevent any loss by evaporation and 
stored in the dark at room temperature (Andrews, 2001). 
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2.2.5  Inoculum preparation was performed as follows 
Two to five well-isolated colonies of the same morphological type were selected from 
an agar plate culture.  The top of each colony was touched with a loop, and inoculated 
into a tube containing eight to ten ml of Mueller -Hinton broth medium and incubated 
overnight at 37C. The turbidity of the actively growing broth culture was adjusted with 
phosphate buffer saline (PBS) or broth to obtain turbidity optically comparable to that 
of the BaSO4 turbidity standard (0.5 McFarland standards). This resulted in a 
suspension containing approximately 1 to 2 x 10
6 
CFU/ml of the test  bacteria.   
2.2.6 Phenol calibration  
Different phenol concentrations ranging from 1% to 14 % ( w/v) were prepared and 
their antibacterial activities against Staphylococcus aureus were measured using the 
well diffusion method, The diameter of the clear zone around each well of the phenol 
references was measured, and plotted against the phenol concentration used, and the 
standard calibration curve equation shown in Figure 2.2 was used to compare phenol 
inhibitions with that of the various honey samples (Baltrusaityte and Ceksteryte , 2007).  
 
 
Figure 2.2: Calibration curves for the phenol reference solutions used in the agar well diffusion 
assay of antibacterial activity against S. aureus. 
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2.2.7 Agar diffusion assay 
The plates were prepared using 20 ml of sterile Nutrient Agar. The surface of the plates 
was inoculated using a 100 μL of 0.5 McFarland standardized inoculum suspension of 
bacteria and allowed to dry. Wells, 8.0 mm in diameter, were cut from the culture media 
using a sterile metal cylinder, and then filled with the test honey. The plates were 
incubated at 37ºC and observed after 24 hours for clear, circular inhibition zones around 
the wells; these were measured. 
2.2.8  Minimum inhibitory concentration (MIC) by tube dilution and dose-
response effect 
MICs were measured by Broth macro-dilution method. A series of 13 ×100 mm test 
tubes containing 9 ml Mueller -Hinton broth medium with honey concentrations ranging 
from 0% to 14% v/v were prepared. Each tube received 1 ml of bacterial suspension 
adjusted to 0.5 McFarland standards with further 1:100 dilution to get a final density of 
approximately 5 x 10
5
 cfu. The negative control test tubes received only 1 mL of 
Mueller–Hinton broth. MIC-values were recorded after 18 h of incubation at 37°C with 
shaking 250 rpm; MICs were defined as the lowest concentration of honey which 
showed no visible growth. In order to study the dose-response effect of Manuka honey, 
the initial optical density of the all previous culture  tubes were determined at 600 nm 
prior to incubation (T1) and measured after the cultures were incubated (T2). The growth 
inhibition for the test at each honey concentrations was determined using the equation:  
Percentage inhibition = 1 - (OD T2 test- OD T1 test /OD T2 control- OD T1 control) x 
100 (Akujobi and Njoku, 2010). 
2.2.9  Minimum Bactericidal Concentrations 
Bacterial culture (15 μl) was withdrawn from the tubes with no growth and plated onto 
nutrient agar (Oxoid) then incubated overnight at 37C to determine MBC. The lowest 
concentration which showed no growth on the agar was defined as the MBC. 
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2.2.10  Catalase treatment  
Honey samples were tested at a concentration of 50 % (w/v) for antibacterial activity. 
Catalase solution was made by dissolving 2 mg of catalase (Sigma, 1850 units/mg), in 
ultrapure distilled water (10 ml). The honey (2.00 g) was dissolved either in distilled 
water (2.00 ml) or in 2 ml of catalase solution (giving non-peroxide activity). 
2.2.11 Time killing curves 
 The effects of UMF25+ Manuka and 20+ Manuka on the viability of cells were 
monitored by inoculating 2 mL of an overnight culture of MRSA, adjusted to final 
density of approximately 5 x 10
6
 cfu, into 18 mL NB with and without 12% (v/v) of 
both Manukas and incubated at 37°C on a shaker (250rpm).100 μL samples were 
removed at known intervals , diluted serially and 100 µl of  the  diluted  samples were  
placed  on nutrient agar plates and incubated at 37°C for 24 h (Yagi and Zurenko, 
2003). Cfu were counted and time kill plots were constructed. 
2.2.12  SEM and TEM studies  
Overnight cultures of  Methicillin-resistant S. aureus and E. coli  (10ml) were 
centrifuged  at 4,000 g for 20 min, resultant cells pellets were washed with sterilized 
distilled water, MRSA cells were re-suspended in 10 ml of phosphate-buffer saline 
(PBS) pH 7.4 with and without  12 % v/v 25+ Manuka honey and incubated for 4 h at 
37°C, whereas E. coli cells were re-suspended in 10 ml of phosphate-buffer saline 
(PBS) pH 7.0 with and without  18 % v/v 25+ Manuka honey and incubated for 6 h at 
37°C. After incubation, cells were harvested by centrifuging at 4,000 g for 20 min and 
then washed with sterilized distilled water. 
   For scanning electron microscopy (SEM), harvested cells were fixed in 3% 
glutaraldehyde in 0.1M phosphate buffer for 4 hours at 4°C, and then washed twice 
times with 15 min intervals at 4°C in 0.1M phosphate buffer. Cells were then subjected 
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to a secondary fixation with 2% osmium tetroxide aqueous for 1 hour at room 
temperature, and the previous wash step was repeated.  After this, cells were serially 
dehydrated with 75%, 95%, and three times 100 % ethanol, the last one dried over 
anhydrous copper sulphate for 15 min. For hexamethyldisilazane (HMDS) drying, cells 
were immersed in 100% hexamethyldisilazane for 30 min after the second 100% 
ethanol step. Cells were then allowed to air dry overnight. On completion of drying, the 
cells were mounted on 12.5mm diameter stubs and attached with Sticky Tabs and then 
coated in an Edwards S150B sputter coater with approximately 25nm of gold. The cells 
were examined in a Philips XL-20 Scanning Electron Microscope at an accelerating 
voltage of 20Kv. 
For transmission electron microscopy (TEM), harvested cells were fixed in 3% 
glutaraldehyde in 0.1M phosphate buffer overnight at 4°C, and then washed twice times 
with 30 min intervals at 4°C in 0.1M phosphate buffer. Cells were then subjected to a 
secondary fixation with 2% osmium tetroxide aqueous for 2 hour at room temperature. 
Previous wash step was repeated. After this, cells at room temperature were serially 
dehydrated with 75%, 95%, and three times 100 % ethanol the last one dried over 
anhydrous copper sulphate for 15 min. The cells were then placed in an intermediate 
solvent, propylene oxide, for two changes of 15 min duration. Infiltration was 
accomplished by placing the cells in a 50/50 mixture of propylene oxide/Araldite resin. 
The cells were then left in this 50/50 mixture overnight at room temperature. Once this 
incubation was finished the cells were transferred into full strength Araldite resin and 
left for 6-8 hours at room temperature after which time they were embedded in fresh 
Araldite resin for 48-72 hours at 60°C. Semi-thin sections approximately 0.5 µm thick 
were cut on a Reichert Ultracut E ultramicrotome and stained with 1% toluidine blue in 
1% borax. Ultrathin sections, approximately 70-90nm thick, were cut using on a 
Reichert Ultracut E ultramicrotome and stained for 25 mins with 3% uranyl acetate in 
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50% ethanol followed by staining with Reynold’s lead citrate for 25 mins. The sections 
were examined using a FEI Tecnai Transmission Electron Microscope at an accelerating 
voltage of 80Kv. 
2.2.13 Isolation of bacterial and fungal strains from Manuka honey. 
In order to isolate bacteria from the honey, 0.1ml of each 5% (v/v) Manuka honey 
samples (Comvita UMF 25+ Manuka, 20+ Manuka, 15+ Manuka, and 12+ Manuka) 
solution was spread on nutrient agar plates. The plates were then incubated at 37 °C for 
48 h or until the bacterial colonies were of sufficient size to lead to colony replication. 
The bacterial isolates were streaked onto fresh nutrient agar plates and preserved at 4 °C 
for further study (Lee et al., 2008). In order to isolate fungi 0.1ml of each 5% (v/v) 
Manuka honey solution was spread on Czapek agar plates supplemented with 0.01% 
chloramphenicol to inhibit bacterial growth. The plates were incubated at 25 °C for 1-2 
weeks, morphologically different  colonies  were  isolated (Pereira et al., 1996). For 
yeast isolation  tryptone glucose yeast extract chloramphenicol (TGY)  agar was used 
(100 g glucose, 5 g tryptone, 5 g yeast extract, 0.1g chloramphenicol, 15 g agar per litter 
(Senses-Ergul and Ozbas, 2006). 
2.2.14  Antimicrobial activity tests of bacterial and fungal isolates from honey. 
 
All of the bacterial isolates from honey were streaked onto a Mueller-Hinton agar plate 
and incubated for 4 days at 25 °C to allow any probable water soluble antimicrobials to 
diffuse into the agar.  All test organisms  were streaked  at right  angles  to  the honey 
isolate, starting from  the point  furthest away  from  the part   on which  the honey 
isolate had grown. Plates  were incubated  overnight  at  37°C  and  observed for any 
inhibition  of  growth  of  the  test organism. The test organisms used were E .coli, S. 
marcescens, B. subtilis, S. aureus and B. sphaericus. Fungal isolates were grown in  
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Czapek broth medium at 25 °C for 2 weeks. Fungal mycelium was filtered and screened 
for any antibacterial activity by well diffusion assay (Arasu et al., 2008). 
2.2.15 Identification of bacterial isolates exhibiting antibacterial activity. 
Two isolates were identified using 16s rRNA gene sequencing dependant-technique. 
DNA was extracted using a Anachem Key prep- Bacterial DNA Extraction kit, and then 
bacterial 16S rRNA gene was amplified and sequenced (as described in section 2.2.16). 
 
2.2.16 The incidence of Clostridium botulinum in Manuka honey 
2.2.16.1  Clostridium botulinum isolation  
Dilution centrifugation (DC) (Kuplulu et al., 2006) was used to isolate Clostridium 
botulinum; 20 g of honey were diluted in 80 ml sterile distilled water with 1% Tween 80 
(Sigma-Aldrich) and shacken until the solution became homogenous. The solution was 
held at 65 °C water bath for 30 min then centrifuged two times for 30 min at 8700-9000 
× g. The pellets were suspended in 10 ml of sterile 1% peptone-water and were subject 
to a heat shock (80 °C for 10 min) (Bianco et al., 2008). These suspensions were then 
transferred into 9 ml TPGY (Trypticase-Peptone-Glucose-Yeast Extract Broth) and 
incubated in anaerobic conditions at 30°C for up to 10 days, 0.1ml of each tube showing 
a signiﬁcant growth was   inoculated onto SPS Agar (Sulfite Polymyxin Sulfadizine 
Agar) plates (Angelotti et al. 1962), and incubated under the same conditions for 3 days. 
Colonies which grew only anaerobically were considered to be pure cultures and were 
confirmed by 16S rRNA PCR (as described in section 2.2.16). 
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2.2.17   16SrRNA sequencing 
2.2.17.1 Extraction of genomic DNA from pure cultures for PCR  
Genomic DNA was extracted from honey isolates using Key Prep-Bacterial DNA 
Extraction kit the following procedure. 4 ml of culture grown overnight in LB medium 
was centrifuged at 6,000×g for two minutes at room temperature. The supernatant was 
decanted completely. The cell pellet was then washed with TE buffer and completely 
resuspended in 100 μl of buffer R1 by pipetting it up and down. Then10μl of lysozyme 
(50mg/ml) was added to the cell suspension and mixed thoroughly. After 20 minutes 
incubation at 37°C, the digested cells were collected by centrifugation at 1000×g for 3 
minutes and the supernatant was decanted immediately. Collected pellet was then 
resupended in 180μl of Buffer R2 and 20 μl of Proteinase K, mixed thoroughly and 
incubated at 65 °C for 20 minutes in a shaking water bath. In order to obtain a RNA-
free DNA, 20 μl of RNase A (DNase-Free, 20mg/ml) was added and followed by 
incubation at 37°C for 5 minutes. Homogeneous solution was obtained by adding 2 
volumes of Buffer BG to the previous mixture and mixed thoroughly by inverting tube 
several times then incubated at 65 °C for a further 10 minutes, immediately 200 μl of 
absolute ethanol was added and mixed carefully. The samples were transferred into a 
column assembled in a clean tube and centrifuged for 1 minute at 10,000×g, 
supernatants were discarded. The column was then washed with 750 μl of the wash 
buffer and centrifuged twice for 1 minute at 10,000×g in order to remove the residual 
ethanol, supernatants which were also discarded. Finally, the column was placed into a 
clean microcentrifuge tube and 100 μl of preheated Elution Buffer, TE buffer or sterile 
water was added directly onto column membrane and left for 2 minutes which then 
centrifuged at 10,000×g for 1 minute to elute DNA, to verify its presence and purity, 10 
μl of each resultant DNA was mixed with 2 μl of Blue/Orange 6x loading dye and 
electrophoresed using 1% agarose gel. The checked DNA was stored at -20°C. 
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2.2.17.2 PCR amplification of 16S rRNA genes and purification.  
Amplification of 16S rRNA was performed in a total volume of 50 μl containing 2.0 μl 
Genomic DNA, 1.0 μl dNTPs, 0.5 μl Taq DNA polymerase (Bioline), 2.5 μl 50mM 
MgCl2, 0.5 μl Forward Primer, 0.5 μl Reverse Primer, 5.0 μl 10x buffer and 38μl of 
sterile distilled water (sdH2O). The PCR reaction mixtures, after incubation at  94°C for 
3 minutes as an initial denaturation, were cycled 30 times through the following 
temperature profile: denaturation for 1 minute at 94°C; annealing for1 minute at 60°C; 
and elongation for 5 minutes at 72°C with final incubation for 5 minutes at 75°C, after 
which 10 μl of each PCR amplification mixture was mixed with 2 μl of Blue/Orange 6x 
loading dye and analysed by 1% agarose gel electrophoresis. In addition, 6 μl of 1 Kb 
Hyper ladder loading was used to confirm the correct sized product. 
Table 2.1 Oligonucleotide primers used. 
Oligonucleotide Sequence, 5'-3 
Forward primer 5' CCG AAT TCG TCG ACA ACA GAG GAT CCT GGC TCA G 3' (34) 
Reverse primer 5' CCC GGG ATC CAA GCT TAC GGC TAC CTT GTT ACG ACT T 3' (37) 
 
2.2.18 Quantification and purity of nucleic acid  
2.2.18.1 Agarose gel electrophoresis 
The presence, size and quantity of the DNA were checked and determined by 
electrophoresis in 1% agarose gel which was prepared as follow: 0.5g of molecular 
biology grade agarose was dissolved in 1ml of 50x TAE buffer and 40ml distilled water. 
The agarose was completely dissolved by heating in a microwave oven. The solution 
was mixed gently and allowed to cool to 55°C, and then 2.5 μl ethidium bromide was 
added. After mixing, the solution was poured into a sealed gel rack and a comb was 
inserted at one side of the gel and allowed to stand in room temperature for 20 minutes. 
Then the comb and seal were removed and gel was placed into an electrophoresis tank 
and submerged in 1x TAE buffer. 10 μl of the DNA sample was mixed with 2 μl of 
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Blue/Orange 6x loading dye and loaded into the wells. 6 μl of Hyper Ladder was loaded 
as well into one of the wells as a reference. The samples were electrophoresed for 40 
minutes at 80V to allow DNA to migrate toward the anode. The DNA fragments were 
visualized under a UV transilluminator and the images were captured using a connected 
digital camera.  
2.2.18.2 16SrRNA sequencing and phylogenetic analysis 
After checking, the purified PCR products were sent to the Medical School Core 
Genetics Unit (University of Sheffield) to be sequenced. 16SrRNA gene sequences 
were adapted using the Finch TV software and then exported into The Basic Local 
Alignment Search Tool (BLAST), available from the website of National Centre for 
Biotechnology Information (NCBI)http://www.ncbi.nlm.nih.gov,  to identify matches 
with existing characterized reference sequences. 
2.2.19 Statistical Analysis  
 
All observations were presented as Mean ± SD. (Standard deviation). The data was 
analyzed by SigmaPlot
© 
11.0. P<0.05 was considered as significant. 
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2.3 Results and discussion  
2.3.1 Investigation of the antimicrobial activity of selected honeys from different 
origins. 
 
A total of eighteen honey samples from different origins were evaluated for their 
antibacterial activity against selected bacteria species representing the Gram-positive 
species, Staphylococcus epidermidis Bacillus sphaericus, and Bacillus subtilis, and the 
Gram negative species, Serratia marcescens, and Escherichia coli. Bacillus subtilis, 
S.epidermidis, B.sphaericus and S.marcescens; are all opportunistic pathogens, which 
commonly cause persistent wound infections in immunocompromised patients, while 
E.coli is an enteric organism. In general, as shown in (Table 2.2) all tested honeys, 
except Kent and Gain Japan honeys, showed a measurable antibacterial activity against 
all of the tested bacteria with different values. Four of the tested bacteria were most 
sensitive to Greek pine honey comparable to other tested honeys showed a significant 
inhibition zone against Gram-negative bacteria, S. marcescens, and E.coli, 17.0±1.0 and 
18.3±1.2 respectively. Kent honey and Gain Japan honey either showed no or limited 
inhibition to the tested bacteria, especially Gram-negative bacteria. Scottish heather 
honey displayed a potent activity against S.epidermidis, 23.7±1.2 mm, and moderate 
activity against other bacteria. New Zealand beech honey displayed a potent activity 
against only B. subtilis, 20.7±0.6 mm, and moderate activity against other bacteria. S. 
marcescens displayed the highest resistance for 61% (11 out of 18) of tested honeys, 
whereas B. subtilis   was the most sensitive bacteria for 56% (10 out of 18) of tested 
honeys. These data do not agree with the results reported by El-Sukhon et al (1994) 
who showed that the Gram-positive bacteria are more resistant to the inhibitory action 
of honey than are Gram negative bacteria (El-Sukhon et al., 1994).  
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Table 2.2  Antibacterial activity of selected honeys from different origins against five different bacterial species, determined by agar diffusion. The values are means 
of replicates (well (8.0mm))  ± Standard deviation.  NT: not tested. 
Honey  
Inhibition zone (mm)±SD 
E.coli S. marcescens B. sphaericus S. epidermidis B. subtilis 
Greek  Pine 17.0 ±1.0 18.3 ±1.2 16.3 ±1.5 17.3 ±2.1 20.3 ±1.2 
Yorkshire  15.8 ±2.2 12.6 ±1.1 13.8 ±1.5 13.2 ±1.3 16.2 ±0.8 
Chilean ulmo  15.7 ±0.6 15.3 ±0.5 15.3 ±0.5 19.0±0.0 16.0 ±1.0 
Australian Eucalyptus  14.3  ±0.5 12.3 ±0.5 14.3 ±0.5 13.6 ±0.5 16.6 ±1.2 
Himalayan wild flower 13.8 ±0.3 11.2 ±0.3 14.0 ±1.0 16.2 ±0.8 13.0 ±1.0 
Scottish  heather 13.7 ±1.2 12.7 ±0.6 15.7±0.6 23.7 ±1.2 17.0 ±0.0 
Chilean    13.6 ±0.6 13.5 ±0.7 14.3 ±0.6 14.0 ±0.0 14.3 ± 0.6 
New Zealand  Clover 13.0 ± 0.6 12.3 ±0.5 16.2 ±0.8 15.2 ± 0.0 14.3 ±0.6 
Cuban Comparitan 11.7 ±0.6 12.8 ±1.1 11.7 ±0.6 12.3 ±0.6 13.0 ±1.0 
Acacia Hungarian 11.3 ±0.6 12.0 ±0.0 12.0 ±0.0 12.7 ±1.2 11.3 ±0.6 
Spanish Orange blossom 11.0 ± 0.5 13.2 ±0.6 11.3  ± 0.6 11.8 ±0.3 10.7 ±0.3 
Tasmanian Leatherwood  13.2 ±1.3 12.7 ±0.6 13.7 ± 0.6 13.3  ±0.6 15.7  ±2.5 
Organic honey 12.3 ±0.6 11.2 ±0.3 12.3 ±1.2 13.0 ±2.0 15.3 ±0.5 
New Zealand beech 12.3 ±0.6 14.3 ±0.5 16.0 ± 1.0 15.7  ±2.5 20.7 ±0.6 
Jarrah honey  13.0 ± 1.0 14.0 ±2.0 15.7 ±1.5 18.3±1.2 17.0 ±1.0 
Kent honey  0.00 11.3 ±0.6 11.3 ±0.6 11.7 ±1.2 14.0 ±2.6 
Gaint Japan  0.00 0.00 11.0 ±0.0 11.3 ±1.5 NT 
Troway Hall 13.8 ±0.3 14.3 ±1.5 NT 16.3 ±2.1 16.7 ±1.5 
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Table 2.2 shows that the majority of tested honeys have broad-spectrum antibacterial 
activity, particularly Greek Pine, Scottish Heather, Chilean Ulmo, New Zealand Beech 
and Jarrah Honey.  
In further attempts to determine if this broad-spectrum antibacterial activity was due to 
the activity of hydrogen peroxide or due to another factor, comparable to different 
medical grade Manuka honeys, eighteen different origin honeys (Table 2.3) were 
evaluated for their total antibacterial activity and non-peroxide activity against 
methicillin-sensitive S. aureus (MSSA), expressed as equivalent phenol concentration 
(% w/v). In order to measure non-peroxide activity, tested honeys were diluted in a 
catalase solution to breakdown the inherent hydrogen peroxide. The lowest phenol 
concentration able to produce a measurable inhibition zone was 3% (w/v) and absence 
of zones of inhibition indicated activity lower than 3% (w/v) phenol equivalent. The 
results of the pH of the tested honeys (Table 2.3) indicated that all fell within the ranges 
normally expected for honey’s pH, i.e.between 3.1 and 4.5 (Molan, 1992a). 
All of the  investigated different origin honeys exhibited some antibacterial activity 
(total activity, peroxide + non-peroxide activity) as shown in (Table 2.3) but levels were 
lower than the most of the medical grade Manuka honeys  and ranged from 4.4% (w/v) 
to 8.8% (w/v).  
   Except for medical grade Manuka honeys that are well known to have unique non-
peroxide activity, none of the tested honey had a detectable non-peroxide activity, more 
than 3.0 w/v phenol. As expected Comvita UMF +25 Manuka had the largest non-
peroxide activity equivalent to 10.7% (w/v) phenol while  Comvita UMF +20 Manuka 
had the lowest non-peroxide activity equivalent to 8.1% (w/v) phenol among referenced 
medical grade Manuka honeys.  
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Table 2.3 The total antibacterial activity and the non-peroxide activity of selected honeys from different origin against methicillin-sensitive S. aureus (MSSA), 
expressed as equivalent phenol concentration (% w/v), determined by agar diffusion, and the pH of these honeys. (Only the honeys with the highest activity were 
investigated to determine their non-peroxide activity). NT: not tested  
Honey  
 
pH 
 
Total antibacterial activity as phenol 
equivalent (w/v) % 
(peroxide + non-peroxide activity 
 
Non-peroxide activity as phenol 
equivalent (w/v) % 
Comvita® UMF® 25+ Manuka  3.6 11.9 10.7 
Manuka 250MGO 3.8 10.6 10.3 
Comvita® UMF® 15+ Manuka  3.8 9.8 8.9 
Littleover Apiary   Manuka active 10+  4.1 9.3 8.7 
Greek  Pine 3.4 8.8 < 3.0 
Comvita
®
 UMF
®
 20+ Manuka  3.2 8.3 8.1 
Scottish heather honey  4.5 7.5 < 3.0 
Organic honey  NT 7.3 < 3.0 
Australian Eucalyptus  3.7 7.2 < 3.0 
Yorkshire Honey  3.5 6.9 < 3.0 
New Zealand Beech 4.6 6.7 < 3.0 
Chilean Honey  4.1 6.5 < 3.0 
Himalayan Wild Flower NT 6.5 < 3.0 
Tasmanian Leatherwood  3.8 6.3 < 3.0 
Spanish Orange Blossom  3.5 6.1 < 3.0 
Chilean Ulmo  4.2 5.9 < 3.0 
Troway Hall NT 5.6 < 3.0 
Jarrah Honey  4.5 5.6 NT 
New Zealand  Cclover 3.4 4.8 < 3.0 
Kent Honey  3.5 4.8 NT 
Cuban Comparitan 3.5 4.4 < 3.0 
Hungarian Acacia  3.3 4.4 < 3.0 
Gaint Japan  3.1 < 3.0 NT 
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Surprisingly, another medical grade Manuka obtained from different company 
(Littleover Manuka 10+ active) had a non-peroxide activity equivalent to 8.7 % (w/v) 
phenol which more than Comvita UMF +20 Manuka (Figure 2.3), although both 
companies use the same standard to evaluated their Manuka honey grades.  This means 
that UMF may be subject to large variations depending on the producing company. 
 
 
Figure 2.3 Comparison of the results of agar diffusion assay for two medical grade Manuka 
honeys obtained from two different companies and phenol 10% (w/v) solution. Plates seeded 
with MSSA: (a) the zone of inhibitions caused by phenol 10 %, (b) the zone of 
inhibitions  caused by Littleover Apiary honey and  Manuka active 10+,  (c) the zone of 
inhibitions caused by Comvita® UMF® 25+ Manuka .  
 
 
All tested honeys showed a detectable activity except Gaint Japan Honey which did not 
exhibit any antibacterial activity against methicillin-sensitive S. aureus (MSSA). Ten of 
these honeys were equivalent to more than 6.0 w/v % phenol; eight types were 
equivalent to 4.4-5.9 w/v %phenol. 
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  The variation in the honey antibacterial potency has been well reported; it can be vary 
much as 100-fold (Molan, 2001). Peter Molan, a pioneer researcher in the Waikato 
Honey Research Unit, concluded that not all honeys can be used for therapeutic 
purposes, and he recommended that some care must be taken before a honey is chosen 
as a wound dressing, such honeys should have a high level, and a wide spectrum of 
antibacterial activity, particularly against bacteria commonly associated with wound 
infections, and should also have a marked non-peroxide activity. Non-peroxide 
antibacterial activity is essential due the fact the wound exudate may contains catalase 
which might destroy to some extent the honey’s peroxide activity when applied to the 
wound surface, while any-peroxide activity would be still active. Leptospermum 
scoparium, Manuka honey has been advocated for wound care for those reasons 
(Molan, 2004; Molan, 2006).  
   Searching for honeys with exceptionally high non-peroxide antibacterial activity has 
been a core aim of many studies. In a large survey for 345 New Zealand honeys, Allen 
et al. (1991) found that only 25 samples of Manuka and vipers bugloss honeys exhibited 
a detectable non-peroxide activity. Another study of selected Portuguese honeys showed 
that all of them had a peroxide antibacterial activity while only 23% (7 out of 30) 
showed a measurable non-peroxide activity (Henriques et al., 2005). 
    The results shown in Table 2.3, show that  none of tested honeys exhibited an 
exceptionally high non-peroxide activity, thereby suggesting that  none  of tested 
honeys could achieve medical grade status  and act as an alternative to currently  used 
Manuka medical grade honeys. However, the wide spectrum antibacterial activity of 
some tested honeys, obtained commercially in retail outlets, like Greek Pine, Scottish 
heather, Chilean ulmo, New Zealand beech and Jarrah honey suggests that they might 
be used in treating opportunistic infections where expensive Manuka honeys are not 
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vailable particularly in developing countries; these honeys might also be used in 
veterinary medicine, where less regard to the safety is required.  
2.3.2 Further investigation on the nature of non-peroxide antibacterial activity in 
Leptospermum scoparium Manuka honey. 
 
 The data shown in Table 2.3 strongly confirmed the non-peroxide antibacterial activity 
of the Manuka honey, a fact which has been well documented (Allen et al., 1991; 
Molan, 1999b), and showed that the use of a catalase concentration up to 100-fold failed 
to remove this kind of activity. Why Leptospermum scoparium Manuka honey should 
have this unique activity has been extensively investigated. One suggested hypotheses is 
that Manuka honey has a residual high level of hydrogen peroxide concentration that the 
normal catalase treatment is not sufficient to eliminate (Weston, 2000). To test this 
hypothesis the antibacterial assays were repeated using 10, 40, 50, 75 and 100-fold 
excess of catalase concentration.  
  The data given in Figure 2.4 shows however, no significant differences between the 
test performed using the normal amount of catalase and the test performed using a 10, 
40, 50, 75 and 100 fold excess of catalase, P values of t-test were 0.988, 0.957, 0.972, 
0.980 and 0.949 respectively.  
The results presented here, therefore, show that the unusual non-hydrogen peroxide 
activity of the Manuka honey is unlikely to be due to accumulated residual hydrogen 
peroxide that cannot be destroyed by the normal catalase concentration. 
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Figure 2.4: Antibacterial assay of 50% (w/v) Manuka honey  treated with 10, 40, 50, 75 and 100 
fold excess of catalase concentration (non-peroxide activity) compared with non treated 50% 
(w/v)% Manuka honey ( Total activity) , the assay carried out against MSSA, expressed as a 
mean zone of inhibition of the replicates ± standard deviation. 
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2.3.3  Evaluation of the antibacterial activity of Tregothnan English Manuka 
antibacterial activity  
 
In 2008, the Tregothnan Company (Cornwall, UK) introduced the first Manuka honey 
to be produced in the UK. The following work was aimed at investigating the 
antibacterial efficiency of Tregothnan English Manuka and compares it with New 
Zealand Manuka and specifically to evaluate its non-hydrogen peroxide-derived 
activity. A comparison of the antibacterial activity of Tregothnan English Manuka and 
New Zealand Manuka was performed by assessing their activity against selected 
bacterial strains including MRSA and also to determine their non-peroxide activity. 
Figure 2.5 shows that except for Serratia marcescens, all tested bacteria were 
significantly more resistant to the Tregothnan English Manuka than to New Zealand 
Manuka. For example, the zone of inhibitions caused by New Zealand Manuka were 
significantly larger than those caused by Tregothnan English Manuka against MRSA, 
MSSA and particularly, B. subtilis which was 22.0 ±0.8 to New Zealand Manuka and 
12.3±1.2 to Tregothnan English Manuka, while there was no statistical significant 
difference (P = 0.168) between the two honeys against Serratia marcescens; 13.0±1.2 
and 14.7±0.6, respectively. Although Tregothnan English Manuka exhibited an 
antibacterial activity against all tested bacteria, no exceptionally high activity was seen. 
It is clear from the data in Figure 2.5 and in the data in Table 2.2 that bacteria were not 
uniformly affected by the honeys and the Gram-positive bacteria are more susceptible to 
honey than Gram-negative. 
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  Since New Zealand Manuka honey is well known to have a high non-peroxide activity, 
the non-peroxide activity of Tregothnan English Manuka was determined. The total 
antibacterial activity and non-peroxide activity of Tregothnan English Manuka are 
shown in Figure 2.6, Tregothnan English Manuka lost more than 90% of its 
antibacterial activity when it treated with catalase enzyme which indicated that the 
antibacterial activity in Tregothnan English Manuka is mainly to be due to hydrogen 
peroxide, i.e., Tregothnan English Manuka has not a high non- peroxide activity as does 
New Zealand Manuka honey. 
 
 
 
Figure 2.5: A comparison of the sensitivity of some selected bacteria to the antibacterial 
activity of New Zealand Manuka and Tregothnan English Manuka. Expressed as a mean zone of 
inhibition (including well (8.0mm)) of the replicates ± standard deviation.  
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Figure 2.6:  Total antibacterial activity and non-peroxide activity of Tregothnan English Manuka. 
Assay was carried out against MSSA, Expressed as a mean zone of inhibition of the replicates ± 
standard deviation.  
 
 
 
However, Basson and Grobler (2008) have reported that not all Manuka honey have 
exceptionally high antibacterial activity and marked  non-peroxide activity, it seems that the 
most common is Manuka honey produced from the East Cape region of the North Island of 
New Zealand (Basson and Grobler, 2008).  
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2.3.4 Studies on the mechanisms of the antibacterial activity of the medical grade New 
Zealand Manuka. 
Although a large body of work exists which describes the antibacterial activity of New 
Zealand active Manuka honey, the mechanisms of such activity have not been fully explored. 
In the subsequent experiments, the antibacterial activity of two of the highest UMF medical 
grade New Zealand Manuka honey (25+ and 20+ Manuka) were further investigated by 
determining their MICs and the MBCs values against selected seven bacterial species, 
including MRSA; the MICs values were determined using a broth macrodilution, performing 
a time kill study on  MRSA and showing their surface morphology effects by SEM, TEM 
studies.  
2.3.4.1 Zones of inhibition, MICs and MBCs  
The zones of inhibition, the minimum inhibitory concentrations MIC and the minimum 
bactericidal concentrations (MBCs) values of 20+ Manuka and 25+ Manuka for selected 
bacteria, including methicillin-resistant S. aureus (MRSA) are shown in the Table 2.4. 
Generally, and as expected, 25+ Manuka was more powerful than 20+ Manuka, for example, 
25+ Manuka displayed larger zones of inhibition against all tested bacteria. For both Manuka 
honeys S. marcescens was the most resistant bacteria, the zones of inhibition were 15.3 ±0.6 
for 25+ Manuka and 13.0 ±0.5 20+ Manuka, while methicillin sensitive S. aureus (MSSA) 
bacteria was the most sensitive tested bacteria with zones of inhibition equal to 24.0 ±0.8 for 
20+ Manuka and 26.0 ±0.8 for 25+ Manuka. However, these differences between both 
Manuka were not significant except towards B. subtilis where the zone of inhibition was 20.5 
±0.5 for the 20+ Manuka and 25.0 ±0.9 for 20+ Manuka. The results shown previously in 
Table 2.2 and in Table 2.4 show that both Manuka honeys had an exceptionally wide 
spectrum of antibacterial activity compared to the eighteen different honeys tested before. 
Chapter Two: Studies on the activity of Leptospermum scoparium … 
56 
 
 
 
 
 
 
 
Table 2.4: The zone of inhibition (mean±SD), (diameter mm including well (8.0mm)), the minimum inhibitory concentrations (MICs) (% v/v) and the 
minimum bactericidal concentrations (MBCs) values of 20+ Manuka and 25+ Manuka for selected bacteria including methicillin-resistant S.aureus (MRSA).  
    UMF®20+ Manuka    UMF®25+ Manuka  
Tested  bacterial 
strains 
 
Zone of inhibition (mm) 
 
MICs   
 
 MBCs 
 
Zone of inhibition (mm) 
 
MICs  
 
MBCs 
E.coli 
 
22.2 ±1.0 
 
9% 
 
11% 
 
23.0  ±0.0 
 
8% 
 
10% 
S. marcescens 
 
13.0  ±0.5 
 
12% 
 
> 15% 
 
15.3  ±0.6 
 
12% 
 
13% 
B. sphaericus 
 
19.0  ±0.9 
 
11% 
 
12% 
 
22.2  ±0.2 
 
8% 
 
9% 
S. epidermidis 
 
19.4  ±0.5 
 
11% 
 
12% 
 
21.8  ±0.7 
 
10% 
 
12% 
B. subtilis 
 
20.5  ±0.5 
 
10% 
 
12% 
 
25.0  ±0.9 
 
9% 
 
12% 
MSSA 
 
24.0  ±0.8 
 
7% 
 
8% 
 
26.0  ±0.8 
 
6% 
 
8% 
MRSA  
 
21.3  ±1.2 
 
9% 
 
12% 
 
25.7  ±1.5 
 
6% 
 
10% 
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In order to obtain more quantitative and precise results the agar well diffusion method 
was compared with the MIC and MBC values. In Table 2.4, it can be seen that MIC 
and MBC values of 25+ Manuka against all tested bacteria were somewhat less than 
from the 20+ Manuka. The MIC and MBC of both Manuka honeys against MSSA 
were found to be relatively lower than those against other tested bacteria, and ranged 
from 7 to 8% for 20+Manuka and from 6-8% to 25+Manuka. This result is 
in agreement with the findings of Cooper (2008) who concluded that generally 
speaking, Staphylococci appear to be the species most sensitive to the antibacterial 
effects of honey. MICs and MBCs values obtained in this assay are agreed with the 
results obtained from the agar well diffusion and show that   S. marcescens was the 
least sensitive among tested bacteria and had the largest MICs and MBCs. It is worth 
noting the similarity in susceptibility to 25+ Manuka honey between methicilin-
resistant S. aureus and methicillin-sensitive S. aureus strains where both strains were 
completely inhibited at 6%.   
 The results show that both Manuka honeys,  at a concentration ranging from 6% to 
12% , inhibit the growth of all tested bacteria, which means that the growth of these 
tested bacteria will  be prevented even when New Zealand medical grade Manuka 
honey is diluted by exudates of the wound up to 9-to 18-fold. 
Manuka honey with 25+ UMF showed more inhibitory effects than Manuka honey 
with 20+ UMF, which emphasises the credibility  of the UMF standard and showed 
the necessity to use the Manuka  with the available highest UMF in wound 
management.    According to Cooper et al. (1999) the growth of S. aureus can be 
prevented by sugar solution with water activity of 0.864, equivalent to a concentration 
of 29% (v/v). Our results showed that S. aureus was completely inhibited by 6% (v/v) 
of New Zealand Manuka which showed that the osmolarity of honey does not play a 
key role in Manuka’s antibacterial activity mechanism.                                           
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 The ratio between the MBC and MIC has been used to distinguish between the 
bactericidal and bacteriostatic mode of action. If the ratio is less than 4 the 
antimicrobial agent being tested is considered to have a bactericidal mode of action 
whilst if it is more than 4 the activity of the antimicrobial agent is considered to be 
bacteriostatic (Forlenza et al., 1981). In this study the ratios between the MBC and 
MIC of the both Manuka against all tested bacteria were less than 4, indicating that the 
mode of action for both Manuka honeys is a bactericidal rather than a bacteriostatic. 
Manuka bactericidal effect could accelerate the wound healing process as it reduces 
the microbial population density inside the infected wound.   
 
2.3.4.2 Time kill and dose response curves for 25+Manuka and 20+Manuka 
against methicillin-resistant Staphylococcus aureus (MRSA). 
  
Since MRSA is currently the most frequently identified antibiotic-resistant pathogen 
among hospital patients (Mulvey and Simor, 2009) it was chosen as the organism used 
to investigate the time kill and dose response curves for 25+Manuka and 20+Manuka. 
The dose response curve obtained from plotting the concentration of 25+Manuka and 
20+Manuka present against the resultant inhibition of MRSA growth over 20 h 
incubation is shown in  Figure 2.7, it can be seen that the overall performance of 25+ 
Manuka was significantly more effective against MRSA than +20 Manuka. Manuka 
+25 achieved complete inhibition of growth at a concentration of 6% (v/v) whereas 
+20 Manuka accomplished it at 9% (v/v).  
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Figure 2.7 : Dose-response curve for the antibacterial activity of 25+ Manuka and 20+ 
Manuka against methicillin-resistant S. aureus (MRSA). The activity is expressed as the 
percentage inhibition of growth of the bacteria; growth is measured as the increase in the O.D 
at 600 nm of the culture after 20 hours of incubation. 
 
Both Manuka honeys at low concentrations (1%, 2% and 3%) achieved similar 
inhibition levels then, as the concentration increased, the inhibition achieved by +25 
Manuka gradually becomes significantly more than that achieved by +20 Manuka. It 
can be concluded that the osmolarity effect does not play a key role in the activity of 
New Zealand Manuka and that the most effective components of New Zealand 
Manuka is strongly related to the UMF. 
 
Regarding to the time-to-kill curve of both Manuka honeys against MRSA, shown in 
Figure 2.8, 12% v/v concentration of both Manuka honeys was used because this 
concentration is equal to twice the MIC of the 25+ Manuka and greater than its MBC 
while it is equal 1.5 times of the MIC of the 25+ Manuka and equal to its MBC.  
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In contrast to the MICs and MBCs values, time-to-kill curve enable us to determine 
how quickly Manuka honey acts on the MRSA. In  the time-kill curves, a gradual 
decline over 8 h was seen in the number of viable cells of MRSA bacteria  treated 
with  12%  v/v of both tested Manuka honeys, but this decline was more rapid in 25+ 
Manuka than it was in 20+ Manuka. In other words, the total number of MRSA cells 
did not decrease at the same rate when they treated with 12% v/v of both tested 
Manuka honeys, after 8 h incubation. Manuka 25+ caused nearly a 3 log reduction in 
viable MRSA bacteria counts while 20+ Manuka caused less than a 2 log reduction in 
counts of viable MRSA. 
   As the fresh dressings of honey that are used in wound management are changed 
three times daily (Willix et al., 1992), an incubation period of 8 h was chosen to 
evaluate the bactericidal concentration of Manuka honey against the most frequently 
identified antibiotic-resistant pathogen MRSA. Data  shown in Figure 2.8 indicates 
that MRSA started to die after 2 hours of incubation with 12% New Zealand Manuka 
honey which somewhat agree with data obtained from a study carried by Molan 
(1992b) that showed that the Gram-positive bacteria start to die after 1 hour of honey 
exposure (Molan, 1992b).  
 
 
 
 
.  
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Figure 2.8: Time-kill curves of the effect of 12% (v/v) of 25+ Manuka and 20+ Manuka on   
methicillin-resistant S. aureus (MRSA). 
 
 
It should be noted however, that although New Zealand Manuka honey is well 
accepted as an exceptionally effective antibacterial agent with non-peroxide activity, 
the overall time-to-kill results show that it should not be expected that New Zealand 
Manuka honey can inhibit or eliminate bacteria within a matter of seconds or minutes. 
As revealed in the time-to-kill test, New Zealand Manuka honey with the high UMF 
standard takes at least two hours to begin to exhibit a bactericidal effect on MRSA 
cells when used at a concentration of 12% and almost certainly takes longer when a 
lower concentration is used. Nevertheless, results shown in previous experiments 
support the bactericidal mode of inhibition from New Zealand Manuka honey against 
the tested bacteria, especially MRSA. 
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2.3.4.3 Scanning electron microscope (SEM) and transmission electron 
microscope TEM studies on the morphological effects of 25+Manuka on 
Methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia 
coli. 
 
Exploration of the physical effect of the Manuka honey on bacterial cells may allow 
us to determine the bioactive gradient that causes its exceptional non-peroxide 
activity; such physical effects can be investigated using electron microscopy. Only 
Manuka 25+ was chosen for use in these experiments; methicillin-resistant 
Staphylococcus aureus (MRSA) and Escherichia coli were used to represent Gram-
positive and Gram-negative bacteria respectively.  
 
Figure 2.9: External morphology of Methicillin-resistant Staphylococcus aureus 
(MRSA) observed by scanning electron microscopy (SEM).(a) and (b) untreated 
bacteria (control) incubated in  phosphate-buffered saline pH 7.4 for 4 h at 37°C. (c) 
and (d) treated bacteria incubated in  phosphate-buffered saline pH 7.4 containing 
12% v/v 25+ Manuka honey for 4 h at 37°C. Note black arrows that indicate cells with 
partially damaged and irregular shape. 
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The resultant SEM and TEM images are shown in Figure 2.9 and Figure 2.10 which 
show the effects of 25+ Manuka on the external and internal morphology of MRSA. 
They show that untreated cells, not exposed to 25+ Manuka, retained their coccal 
morphology and seemed to be normal while some of the MRSA cells treated with  12 
% v/v 25+ Manuka for 4 hours exhibited physical damage (ruptured walls and 
irregular shape) and some released cellular contents (Figure 2.10, e) . This obviously 
suggests that some cells underwent lysis and became completely disrupted.  It should 
be noted that the majority of the treated cells were however, still indistinguishable 
from untreated cells.  
 
Figure 2.10: internal morphology of Methicillin-resistant Staphylococcus aureus 
(MRSA) observed by transmission electron microscopy (TEM) .(a ), (b) and (c) 
untreated bacteria (control) incubated in  phosphate-buffered saline pH 7.4 for 4 h at 
37°C. .(d),  (e) and (f)treated bacteria incubated in  phosphate-buffered saline pH 7.4 
containing 12% v/v 25+ Manuka honey for 4 h at 37°C. Note the separation of cell 
membrane from the cell wall (black arrows) and released cellular contents and cell 
debris (red arrows).  
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Figure 2.11: External morphology of Escherichia coli observed by scanning electron microscopy (SEM) .(a ), (b) and (c) untreated bacteria (control) incubated 
in  phosphate-buffered saline pH 7.4 for 6 h at 37°C.(d), (e) and (f) treated bacteria incubated in  phosphate-buffered saline pH 7.4 containing 18% v/v 25+ 
Manuka honey for 6 h at 37°C. Note abnormal shortened cells with rough surface (black arrows)
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SEM and TEM images of Escherichia coli (shown in Figure 2.11 and Figure 2.12) 
show that 18% 25+Manuka honey had little effect on the appearance of the E. coli 
cells, compared to the untreated cells.  Escherichia coli cells that incubated with 18% 
25+Manuka for six hours however, appear shortened and as distorted shapes and some 
have lost their integrity. Some cells also occur with localized separation of the cell 
membrane from the cell wall (Figure 2.12, f). In conclusion, generally, both bacteria 
SEM and TEM images don not show significant morphology changes.  
 
 
 
Figure 2.12: Internal morphology of Escherichia coli observed by transmission electron 
microscopy (TEM) .(a ), (b) and (c) untreated bacteria (control) incubated in  phosphate-
buffered saline pH 7.4 for 6 h at 37°C. (d), (e) and (f) treated bacteria incubated in phosphate-
buffered saline pH 7.4 containing 18% v/v 25+ Manuka honey for 6 h at 37°C. Note the 
separation of cell membrane from the cell wall (black arrows) and cells with released cellular 
components (red arrows). 
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2.3.5  Microbial  inhibitory components in New Zealand Manuka honey 
 
One hypothesis that has been suggested elsewhere to explain the unidentified 
antibacterial activity of honey is that some of this unidentified antibacterial activity 
might be attributed to antibacterial substances produced by honey microflora and even 
by honeybee- indigenous bacteria prior to honey maturation (Lee et al., 2008). In this 
experiment medical grade New Zealand Manuka honey samples (Comvita UMF 25+ 
Manuka, 20+ Manuka, 15+ Manuka and 12+ Manuka) were selected to examine the 
potential of the microorganisms they contain to produce antimicrobial agents. 
   As shown in Table 2.5 ten bacteria species, three filamentous fungi and two yeasts 
were isolated from the selected New Zealand Manuka honey samples. Neither isolated 
yeasts nor isolated filamentous fungi exhibited any antibacterial activity. Only two 
isolated bacteria showed antibacterial activity; these were subsequently identified 
using 16S rRNA (Figure 2.13 and Figure 2.14) were found to be Bacillus pumilus and 
Bacillus atrophaeus. 
 
 
Table 2.5: The number of isolated microorganisms and number of bacteria exhibited 
antibacterial activity  
Microorganism   No. of isolates   No. isolates exhibited antibacterial activity  
Bacteria   10  2* 
Filamentous fungi 3  0 
Yeasts  2  0 
 
* These two species were identified as Bacillus pumilus and Bacillus atrophaeus. 
 
 
 
Gram-positivespore-forming bacteria, mainly Bacillus genus, and some yeasts are the 
most commonly found organism in honey due to their ability to survive the harsh 
conditions present (Olaitan et al., 2007; Snowdon and Cliver, 1996). According to 
Snowdon and Cliver (1996) primary and secondary contamination sources including   
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pollen, the digestive tracts of honey bees, dust, air, dirt, flowers,  humans, equipment, 
containers, wind, dust, insects, animals and water; all of these will contribute to the 
microflora present in honey.   
 
  In this study the focus was on the Manuka honey microflora which exhibit 
antibacterial activity and only isolated bacteria showing antibacterial activity were 
indentified. Both of the isolated   Bacillus pumilus and Bacillus atrophaeus are Gram-
positive spore-forming bacteria. Bacillus pumilus is well known to be present in honey 
(Tolba et al., 2007) and is known to produce some substances that could be act as 
antagonistic factors to fungal and bacterial pathogens, notably a bacteriocin called  
Pumilicin 4 (Aunpad and Na-Bangchang, 2007), and a surfactin, which is used as 
an antibiotic (Morikawa et al., 1992). Antifungal metabolites (Banerjee et al., 2007; 
Bottone and Peluso, 2003; Munimbazi and Bullerman, 1998), alkaline protease 
(Kumar, 2002) and endoxylanase are also produced by this bacterium (Panbangred et 
al., 1983). The potential of Bacillus atrophaeus to produce bacteriocin subtilosin A 
has been recognized (Stein et al., 2004). This bacteriocin was proven to have 
antimicrobial activity against a wide spectrum of bacteria (Shelburne et al., 2007).  
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Figure 2.13: Agarose gel electrophoresis revealing a successful DNA extraction from 
unknown isolated bacteria exhibited antibacterial activity. Lane M, molecular marker. S1 and 
S2, two bacteria samples. 
 
 
 
 
 
 
Figure 2.14:  Agarose gel electrophoresis revealing a successful amplification of 16S rRNA 
from unknown isolated bacteria exhibited antibacterial activity. Lane M, molecular marker. S1 
and S2, two bacteria samples.  
 
 
The intrinsic properties of honey including the low pH and high sugar content are 
considered to provide harsh conditions which bacteria cannot withstand. In addition, 
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these harsh conditions stimulate bacteria to begin starvation-induced activities such as 
sporulation (Snowdon and Cliver 1996), which is known to have a link with antibiotic 
and degradative enzyme production (Marahier et al., 1993; Msadek, 1999; Yan et al., 
2003). Recently, a compound called, bee defensin-1 was discovered in a medical-
grade honey sample and was shown to make a detectable contribution to the 
antibacterial activity of tested honey samples (Sherlock et al., 2010). 
 Gram-positive spore-forming bacteria present in honey might provide a source of 
antibacterial substances produced as a response to the honey-harsh conditions and 
sporulation  process.  
2.3.6  Determination of the incidence of Clostridium botulinum spores Manuka 
honey. 
 
Twenty-one samples of seven medical grade New Zealand Manuka honeys obtained 
from two different companies were analyzed for the presence of Clostridium 
botulinum spores. The results are given in Table 2.6. After being processed according 
to the dilution centrifugation (DC) method, samples were incubated in TPGY broth 
media for 10 days. As shown in Table 2.6 in this step 11 out of 21 samples yielded 
positive results; positive samples were further inoculated onto SPS (Sulfite Polymyxin 
Sulfadiazine) Agar plates. Only 1 of 11 samples (Littleover Manuka Active 10+) was 
able to grow anaerobically in SPS Agar. An isolated strain from this positive sample 
was then identified by 16S rRNA sequencing analysis as Bacillus licheniformis. It 
seems from this study, therefore, that C. botulinum spores are not likely to be 
detectable in tested medical grade New Zealand Manuka honey samples. According to 
Kuplulu  et al (2006) the dilution centrifugation (DC) method is more effective at 
determining the incidence of  
Clostridium botulinum spores in honey than other methods such as direct addition 
(DA) and supernatant filtration (SF). The results presented here show that although 
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one presumptive Clostridium was isolated from honey using both TPGY broth and 
SPS Agar, this was identified, by 16S rRNA sequencing, as Bacillus licheniformis and 
not Clostridium botulinum. Clearly, confirmatory tests should be followed on the 
isolation of any presumptive Clostridium botulinum isolation. Like Clostridium 
botulinum, B. licheniformis is a spore forming Gram-positive bacteria that can grow 
anaerobically, these shared characterises may explain why Bacillus licheniformis  
gave a false positive when the DC isolation method was used.  
 Another health issue related to the incidence Clostridium botulinum spores in honey 
was raised by Molan and Allen (1996). They argued that the application of 
unsterilized honey to wounds could increase the risk of wound infection with C. 
botulinum (Molan and Allen, 1996) and recommended that the honey should be 
subjected to a commercial sterilization process using gamma-irradiation before using 
it in wound care. Vardi and colleagues (1998) considered this to be merely as 
theoretical risk because they did not find a single report in the literature of C. 
botulinum wound infection associated with honey dressings and in their own studies 
no wound cultures they studied yielded C. botulinum. 
Recently, Simon et al (2009) confirmed that he and his co-workers could not detect a 
single case report linking the use of unsterilized honey in wound care and C. 
botulinum wound infection. Beside this, local unsterilized honey has widely been used 
to treat infected wounds and burns without any adverse C. botulinum wound 
infections (Postmes et al., 1996; Postmes, 2001; Subrahmanyam, 1994; Al-Waili and 
Saloom, 1999). 
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Table 2.6 Various Medical grade New Zealand Manuka honey samples examined for C. botulinum spore incidence 
  
Step one 
 
Step two 
 
Step three 
Manuka honey  
No. of tested 
 
Positive growth 
 
Positive growth in 
 
16S rRNA dependant 
 
samples 
 
in TPGY broth 
 
SPS Agar (anaerobically) 
 
identification 
Comvita   UMF 25+ Manuka  
 
3 
 
0 
 
0 
 
  
Comvita   UMF 20+ Manuka  
 
3 
 
2 
 
0 
  Comvita  UMF  15+ Manuka  
 
3 
 
2 
 
0 
  Comvita  UMF 12+ Manuka  
 
3 
 
0 
 
0 
  Littleover   Manuka Active 15+  
 
3 
 
3 
 
0 
  Littleover   Manuka Active 10+  
 
3 
 
2 
 
1 
 
   Bacillus licheniformis 
Littleover   Manuka Active 5+  
 
3 
 
2 
 
0 
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   The aforementioned facts, and reports as well as the results obtained in this study (no 
C. botulinum spores were detected in twenty one samples of seven different medical 
grade New Zealand Manuka honey), suggest that these commercial medical grade New 
Zealand Manuka honey could be used directly to treat infected wounds in emergency 
cases, as well as in veterinary practice, when sterilized samples are available. Of course 
the use of sterilized honey, although an additional expense, is preferable to the use of 
non-sterilized products.    
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3.1 Introduction  
3.1.1 Essential oils 
 
The essential oils of aromatic plants have long been used in embalming to prevent 
bacterial growth and avoid decay, a practise generally associated with the Ancient 
Egyptians (Edris, 2007). The first modern report on the therapeutic use of essential 
plant oils appeared in 1928, when a French chemist reported that lavender oil 
facilitated healing of his own hand- burn injury. Many essential oils exhibit 
antimicrobial activity, including Tea tree oil (derived from the Australian native 
plant Melaleuca alternifolia), and have been recognised for their potential in the 
treatment of MRSA-related infection as well as an alternative for the treatment of 
mupirocin-resistant MRSA (Bowler et al., 2001). A range of mechanisms of actions 
by which essential oils can inhibit microorganisms have been proposed. Of 
particular importance is hydrophobicity, which causes the lipid bilayer to detach 
from the cell membrane, thereby leading to leakage of whole cell contents. Essential 
oils may also destroy one, or more, of the bacteria’s vital enzyme systems (Edris, 
2007). 
3.1.2 Manuka oil  
 
Manuka oil from the plant Leptospermum scoparium is being investigated as an 
antimicrobial agent; its activity being based on its high content of  triketones 
(Douglas et al., 2004; Carr, 1998), which inhibits the growth of methicillin-resistant 
Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE) 
and multi-drug-resistant tuberculosis (MDR-TB) (van Klink et al., 2005). 
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A comparative study of the biological activity of different tree oils including 
Australian Tea tree (Melaleuca alternifolia), the New Zealand Manuka 
(Leptospermum scoparium) and Kanuka (Kunzea ericoides) carried out by Lis 
Balchin and his co-workers (2000) showed that Manuka oil has a consistently high 
antioxidant activity and a marked antifungal effect. In another comparative study, 
Manuka oil was shown to have a remarkable bactericidal effect against several oral 
pathogens, and was more active than tea tree oil, eucalyptus oil, lavandula oil, and 
romarinus oil (Takarada et al., 2004).    
 
 
 
The aims of the work reported in this chapter were to:  
1. Investigate the antimicrobial activity of manuka oil 
2. Investigate the Anti-Trichophyton terrestre activity of manuka oil 
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3.2 Materials and methods  
 
3.2.1 Manuka oil  
  
The Manuka oil used was a commercially produced by Phytomed Medicinal Herbs, 
Auckland, New Zealand. 
3.2.2  Test Organisms 
The following test organisms were used: Escherichia coli, Staphylococcus epidermidis, 
Serratia marcescens, Methicillin-resistant Staphylococcus aureus (MRSA), 
Mycobacterium phlei NCIMB8573, Bacillus subtilis and Trichophyton terrestre (IMI 
277732 obtained from the CAB, Kew); unless stated otherwise, the organisms were 
obtained from the Departmental Culture Collection. 
3.2.3 Paper disk diffusion assay  
 The Kirby Bauer paper disc method was used (Bauer et al., 1966). Overnight cultures 
of the respective test bacteria were standardised (McFarland standardisation), and 
transferred to MH (Mueller-Hinton) agar plates, which were seeded with 100 μL of each 
bacterium. Manuka Oil (10 μL) was  applied to a sterile filter paper disk (4 mm) placed 
on the surface of inoculated plates; triplicate plates were used, each one had 3 paper 
disks and two 30 µg Cefoxitin discs as a positive control. After 24 h incubation at 37°C 
the zones of inhibition were measured. 
3.2.4 Measurement of minimum inhibitory concentration (MIC) using 
macrodilution: 
 
MICs were measured by broth macro-dilution method. A serial doubling dilution of 
Manuka oil was prepared in (0.05% Tween 80), with concentrations ranging from 
0.002% to 4% v/v. Diluted oil was sterilized and filtered using a 0.20 μm membrane 
filter, 0.5 McFarland standardised 100 μl of bacteria culture  were aseptically added to 
each dilution. MIC-values were recorded after 18 h of incubation at 37°C with shaking 
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at 250 rpm; MICs were defined as the lowest concentration of Manuka oil which 
showed no visible growth.  
3.2.5 Determination of minimum bactericidal concentration (MBC). 
 
Diluted broth (15 μl) was transferred into a Petri dish containing MH agar. The plates 
were incubated overnight at 37°C. The MBC was read as the lowest concentration of 
manuka oil that did not permit any visible growth on agar plate.  
3.2.6 Time killing assay   
 
Inocula for the time kill assays were prepared by inoculating one to two colonies of test 
bacteria into 8 ml of MH broth and incubating for 18 h at 35°C with shaking, adjusting 
to a 0.5 McFarland 5 x 10
6
 CFU ml
-1
. 1 ml of the initial inoculum was then added to 9 
ml broth containing either 1.5% (v/v) Manuka oil (> 3 MIC) and 0.05% Tween 80 (test) 
or only 0.05% Tween 80 (control). Treatments were incubated with shaking at 37°C and 
samples were taken at 0, 1, 2, 4, 6 and 8 h. Viable counts were performed by serially 
diluting each sample 10-fold in PBS and spreading 100 μL volumes from the 
appropriate dilutions onto NA in duplicate. After incubation at 37°C, cfu were counted 
and time to kill plots were constructed.  
3.2.7 Scanning electron microscopy (SEM) and Transmission electron 
microscopy (TEM).  
 
Overnight cultures (10mls) of Methicillin-resistant S. aureus and E. coli were 
centrifuged  at 4,000 g for 20 min, resultant cell pellets were washed with sterilized 
distilled water; MRSA were cells re-suspended in 10 ml of phosphate-buffer saline 
(PBS) pH 7.4 with and without 3 % v/v Manuka oil and incubated for 4 h at 37°C, 
whereas E. coli cells were re-suspended in 10 ml of phosphate-buffer saline (PBS) pH 
7.0 with and without  6 % v/v Manuka oil and incubated for 6h at 37°C. After  
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incubation, cells were harvested by centrifuging at 4,000 g for 20 min and then washed 
with sterilized distilled water. SEM and TEM were carried out as described in 2.2.11 
section.  
3.2.8 The anti-Trichophyton terrestre activity of Manuka oil  
 
The Trichophyton terrestre inoculum was prepared as follows; a standard-sized 
inoculum of T. terrestre was prepared from 7- to 14-day old cultures grown on PDA at 
25°C. Mature colonies were covered with approximately 5 ml of sterile PBS (pH 7.4), 
PBS was then gently rubbed over the surface with a sterile spreader. The resulting 
mixture of conidia and hyphal fragments was drawn off with a pipette and transferred to 
sterile tubes. Heavy particles of the suspension were allowed to settle for 10 to 15 min 
at room temperature, and the upper homogeneous suspension was used for further 
testing. The optical densities of the suspensions were read at 530 nm and adjusted to 
0.15 to 0.17 to yield 0.6 × 10
6
 to 1.4 × 10
6
 spores/ml of strains. The suspensions 
containing conidia and hyphal fragments were further diluted to obtain the final desired 
inoculum size of approximately 0.4 ×10
4
 to 5 × 10
4
 spores/ml. In order to determine the 
MIC, a standardized culture was mixed with various concentrations (0.008–0.25 % v/v ) 
of manuka oil then 15 μl of this mixture was placed in PDA media plate and incubated 
at 25°C for 7 days (Koroishi et al., 2008).  The agar dilution method was used to 
determine the anti-Trichophyton terrestre activity of Manuka oil. Trichophyton terrestre 
was inoculated onto PDA (Potato Dextrose Agar) plates and incubated at 25°C for 7-10 
days to obtain young, actively growing cultures consisting of mycelia and conidia. 
Sterilised diluted Manuka oil with 0.5 Tween 80 was incorporated into PDA sterilised 
pre-poured medium to give different final concentrations (0.25%, 0.125 and 0.063%).  
A mycelial disc, 8 mm in diameter, cut from the periphery of the 7-10-day-old cultures, 
was then aseptically inoculated onto the medium. The inoculated plates were then 
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incubated at 25 °C and the colony diameter measured and recorded after 10 days. The 
percentage of mycelial inhibition was calculated as follows:  % mycelial inhibition = 
[(dc-dt)/dc] × 100; dc= colony diameter in the control, dt = colony diameter in treatment, 
three replicate plates were used for each treatment. 
 
3.3 Results and Discussion. 
3.3.1 Antibacterial activity (Disc diffusion assay, MICs and MBCs values) 
 
As listed in Table 3.1, manuka oil effectively inhibited the growth of all tested Gram-
positivebacteria and inhibited Gram-negative bacteria to some extent. The inhibition 
zones were 18.6±1.5 mm against MRSA which as expected was totally resistant to 
Cefoxitin 30µg antibiotic disk, 19.5±0.6 mm against M. phlei, 18.0±1.0 mm against S. 
epidermidis and 19.9± 1.1 mm against B. subtilis, whereas manuka oil caused inhibition 
zone less than 8 mm against both tested Gram-negative bacteria, S. marcescens and 
E.coli, 6.0±0.6 mm, 7.6±0.5 mm, respectively. Except  S. epidermidis, where  the 
minimum inhibitory concentration was 0.25%, the MICs were  0.03% against all tested  
Gram-positive bacteria including MRSA , M. phlei and B. subtilis (as shown in Table 
3.1 ). As the results obtained by disk diffusion assay, MICs values of S. marcescens and 
E.coli (> 4.0%) confirmed the poor activity of manuka oil against Gram-negative 
bacteria. After  the measurement of minimum inhibitory concentration,15 µl of cultures 
were taken from tubes showing no bacterial growth, inoculated onto MH agar plates, 
and cultured for overnight. The concentration that did not permit any visible growth on 
agar plate was considered as the MBC. Since the ratio between the MICs and MBCs 
values for MRSA and B. subtilis were larger than four, manuka oil seemed to act 
bacteriostatically against them. 
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Table 3.1: The zone of inhibition (mean±SD), (diameter mm including disk (4.0mm)), showing 
the minimum inhibitory concentrations (MICs) (% v/v) and the minimum bactericidal 
concentrations (MBCs) values of manuka oil for selected bacteria including methicillin-resistant 
S. aureus (MRSA). 
Inhibition zone (mm) ±SD 
Bacteria strain  Cefoxitin 30µg Manuka oil MIC (V/V) MBC (V/V) 
MRSA 0.0 18.6±1.5 0.03% 1.0% 
S.marcescens 22.3±2.1 6.0±0.6 > 4.0% > 4.0% 
M. phlei 22.0±2.1 19.5±0.6 0.03% NT* 
S. epidermidis 21.5±2.6 18.0±1.0 0.25% NT* 
E.coli 23.5±0.7 7.6±0.5 > 4.0% > 4.0% 
B.subtilis  24.5±0.7 19.9± 1.1 0.03% 0.50% 
*NT: Not tested  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
Figure 3.1:  A minimal inhibitory concentration (MIC) test determined by macrodilution 
method. The tube to the right is yellow indicating bacterial growth; the tubes to the left are clear 
indicating no growth. The MIC is 0.031 % where the bacterial growth halted. 
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3.3.2  Kill assays. 
 
In order to assess the effect of manuka oil on bacterial cell viability, MRSA and E. coli 
were chosen to represent both Gram-positive (highly susceptible to manuka oil) and 
Gram-negative bacteria. The (time-kill) curves for MRSA and E. coli in MHB at 1.5% 
v/v concentration of manuka oil are shown in Figure 3.2 and Figure 3.3. As shown in 
Figure 3.2, treatment of MRSA with manuka oil at a concentration of > MBC (1.5% 
v/v) was successful in killing >10
3
 CFU ml 
–1 
within 8 hours, while as shown in Figure 
3.3 treatment of  E. coli with manuka oil at this concentration (1.5% v/v), that is less 
than MIC of tested bacteria did not (as expected) show a lethal effect on E. coli cells.  
This concentration exhibited a limited inhibition, where the cell multiplication process 
was less than the E. coli control.  
 
 
 
 
 Figure 3.2: Killing of methicillin-resistant Staphylococcus aureus (MRSA) by 1.5% (v/v) of 
manuka oil  
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                     Figure 3.3: The effect of 1.5% (v/v) of manuka oil on E. coli growth curve 
 
 
 
3.3.3 Scanning electron microscope (SEM) and transmission electron microscope 
TEM studies showing the morphological effects of manuka oil on 
Methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli. 
 
 
The SEM and TEM images in Figure 3.4  and Figure 3.5 show the effects of manuka oil 
on the external and internal  morphology of MRSA, show that  untreated cells, which 
were never exposed to manuka oil, retained their coccal morphology and appeared 
normal, while MRSA cells treated with  1.5 v/v manuka oil for 4 hours underwent 
considerable morphological alterations including  seriously damaged cells and free 
cellular contents, Figure 3.5 (c) and (d), shows that a bactericidal concentration of 
manuka oil induce marked cellular lysis  a completely disruption to the MRSA cells.   
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Figure 3.4: External morphology of Methicillin-resistant Staphylococcus aureus (MRSA) 
observed by scanning electron microscopy (SEM) .(a) and (b) untreated bacteria (control) 
incubated in  phosphate-buffered saline pH 7.4 for 4 h at 37°C. (c) and (d) treated bacteria 
incubated in  phosphate-buffered saline pH 7.4 containing 3% v/v Manuka oil for 4 h at 37°C. 
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Figure 3.5: Internal morphology of Methicillin-resistant Staphylococcus aureus (MRSA) 
observed by transmission electron microscopy (TEM) .(a ) and (b) untreated bacteria (control) 
incubated in  phosphate-buffered saline pH 7.4 for 4 h at 37°C. (c) and (d) treated bacteria 
incubated in  phosphate-buffered saline pH 7.4 containing 1.5% v/v  Manuka oil for 4 h at 37°C. 
Note the cell lysis (green arrowheads) and released cellular contents and cell debris (red 
arrowheads). 
 
 
The SEM and TEM images shown in Figure 3.6 and Figure 3.7 revealed that 6% v/v 
manuka oil had little effect on the appearance of the E. coli cells, compared to the 
untreated cells. Cells of E. coli cells incubated with 6% v/v manuka oil for six hours 
appear shortened and distorted shapes and have lost some of their integrity; cells empty 
of contents and possessing irregular shape were observed (Figure 3.7,(c) and (d)).  
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Figure 3.6: External morphology of Escherichia coli observed by scanning electron microscopy 
(SEM) . (a ) and (b) untreated bacteria (control) incubated in  phosphate-buffered saline pH 7.4 
for 6 h at 37°C. (c) and (d) treated bacteria incubated in  phosphate-buffered saline pH 7.4 
containing 6% v/v  Manuka oil for 6 h at 37°C. Note abnormal shortened cells with rough 
surfaces (c) and (d).  
 
 
 
A 6% manuka oil solution failed to induce marked cellular lysis in E. coli treated cells. 
Generally, the SEM and TEM observations for both MRSA and E. coli confirmed that 
manuka oil has a potent antibacterial activity against Gram-positive and a moderate 
effect against Gram-negative bacteria. 
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Figure 3.7: Internal morphology of Escherichia coli observed by transmission electron 
microscopy (TEM). (a) and (b) untreated bacteria (control) incubated in  phosphate-
buffered saline pH 7.4 for 6 h at 37°C. (c) and (d) treated bacteria incubated in phosphate-
buffered saline pH 7.4 containing 6% v/v Manuka oil for 6 h at 37°C. Note cells without cell 
contents (red arrowheads) and irregular cell shape (black arrowheads).  
 
 
 
 
The therapeutic properties of plant-essential oils have been known for many thousands 
of years. Essential oils have been considered as potential sources of novel antimicrobial 
agents and considerable in vitro studies have demonstrated their antimicrobial activity 
(Prabuseenivasan et al., 2006).  
In this Chapter, manuka oil was shown to exhibit a strong activity against selected 
Gram-positive bacterial strains. Limited studies, in the literature, have shown that 
manuka oil has marked and consistent inhibitory effects on oral pathogens (Takarada et 
al., 2004). Studies have also reported a more marked antimicrobial activity for manuka 
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oil against Gram negative bacteria than was shown in this thesis (Lis Balchin et al., 
2000). Earlier studies have suggested that the antibacterial activity of manuka oil is 
probably due to having high levels of triketones (Carr 1998; Douglas et al.,2004; van 
Klink et al.,2005). 
 In conclusion, a marked inhibitroy activity of manuka oil against Gram-positive 
bacteria, including  MRSA, M. phlei and B. subtilis  was demonstrated where the 0.03% 
v/v of manuka oil inhibited the growth of these tested bacteria. Such findings could 
support the use of manuka oil to treat wounds infected with these, and other bacteria; 
this usage is  however best retstricted to Gram-positive bacteria and not to infections 
caused  by Gram-negatives such as E. coli and S. marcescens, where a high 
concentration (> 4 %) is required to inhibit their growth. Such a high concentration may 
produce side effects and could be cytotoxic to the host cells (Takarada et al., 2004). 
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3.3.4  The Anti-Trichophyton terrestre activity of manuka oil  
Trichophyton terrestre is keratinophilic fungus, which causes dermatophytoses 
(Bokhari, 2009), i.e. superficial fungal infections of skin, hair, nail, or keratinised tissue 
in humans and animals (Koroishi et al., 2008).  
The anti-Trichophyton terrestre activity of manuka oil was assessed by determining the 
MIC and in the inhibition of radial growth of mycelia. As shown in Figure 3.8, the 
minimum inhibitory concentration of manuka oil towards Trichophyton terrestre is 
0.25% v/v.  
   The results shown in Figure 3.9 show that mycelial growth was significantly inhibited 
by manuka oil, 47.1±1.0 % of the radial growth of mycelia was inhibited at 
concentration 0.063 % v/v, 76.2 ± 3.7 % of the radial growth of mycelia was inhibited 
at concentration 0.123 % v/v and 100% of the radial growth of mycelia was inhibited 
at concentration 0.25 % v/v, i.e. these results confirm the previous findings showing that 
MIC is 0.25% v/v.   
 
 
Figure3.8: Growth inhibition test with Trichophyton terrestre. Each spot was placed with 15-μl 
sample containing various concentrations (0.008–0.25 % v/v) of manuka oil. (PBS) Phosphate 
buffered saline (control). The minimal concentration of manuka oil that resulted in inhibition of 
the Trichophyton terrestre was 0.25% v/v.   
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Figure 3.9: Percent inhibition of mycelial growth of Trichophyton terrestre in the presence of 
several concentrations of manuka oil.  Percentage of mycelial growth inhibition respective to the 
control (no oil added). Means of three replicates ±SD.  
 
 
The observed significant antifungal activity of manuka oil against Trichophyton 
terrestre could indicate its activity in general against dermatophytes. The addition of 
manuka oil to hair oils used for hair dressings in many developing countries, where 
dermatophytoses are common (Lakshmipathy and Kannabiran, 2010), e.g. India (Garg 
and Miller, 1992), could help reduce the incidence and distribution of hair–related 
dermatophytoses. 
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4.1 Introduction  
 
 
Tamarind (Tamarindus indica Lit) is a tree belonging to the Caesalpinaceae family, it is 
native to tropical Africa but it has been widely cultivated also in many other regions 
including subtropical China, Pakistan, Indochina, Philippines, Spain and more 
commonly in India (Globale, 2010; Biao, 1994). Tamarind has been used for centuries 
in folk medicine for the treatment of many health problems such as asthma, dysentery, 
vaginal complaints, gonococci and gastrointestinal disorders (Khanzada et al., 2008; 
Tayade et al., 2009). The most valuable part of the tamarind is its fruits which are 
characterized by their reddish-brown colour which can turn black- brown (Biao, 1994). 
The curative effects of tamarind’s fruits  have been reported in several pharmacopoeias 
(Julio et al., 2010).  
  Tamarind paste is a commercially available product made from the fruit of the 
leguminous, tamarind tree; it is used widely in the tropical Africa, Asia, and elsewhere, 
as a refreshing drink and food flavouring. Tamarind is non-toxic (LD50=5000mg per 
Kg,(Abubakar et al., 2010) and has been used in folk medicine for millennia as a mild 
laxative and in the treatment of sore throat, dysentery and erysipelas, medical uses 
which suggest that it possesses antibacterial properties.  
   Since, as has been detailed above, Manuka honeys are widely used to treat indolent 
(particularly methicillin resistant, MRSA),it was considered of interest to compare the 
antimicrobial properties of these two products with a view to using tamarind paste as an 
alternative to Manuka honey for use in treating infected wounds.  
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 Although the antimicrobial effects of tamarind seeds and other plant components have 
been previously reported (Doughari, 2006; Nwodo et al., 2010), the antimicrobial 
activity of commercially available tamarind paste, and the suggestion that it might be 
used to treat infected wounds, appears to have been overlooked. 
   
The aim of the work reported in this Chapter was to determine the antibacterial and anti-
Candida properties of tamarind paste and compare these with the antimicrobial activity 
of a highly antibacterial Manuka (unique Manuka factor, UMF 25) honey.    
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4.2 Materials and methods  
4.2.1 Tamarind Paste  
The tamarind used was a commercial paste produced by TRS Foods, Southall, UK. 
4.2.2 Test Organisms 
The following test organisms were used: Escherichia coli, Mycobacterium phlei 
(NCIMB8573), Staphylococcus epidermidis, Serratia marcescens, Bacillus sphaericus, 
Staphylococcus aureus, Bacillus subtilis and Candida albicans (CA 3153); unless stated 
otherwise, the organisms were obtained from the Departmental Culture Collection.  
4.2.3 Agar well diffusion assay 
 
The antimicrobial activities of tamarind or Manuka were determined using the well 
diffusion method. The individual test organisms (100 μl of a 0.5 McFarland 
standardized inoculums) were spread on the surface of Muller Hinton agar using a 
flame-sterilised glass spreader, and the surface was allowed to dry. Wells (8.0 mm dia.) 
were cut from the inoculated medium using a flame-sterilized cork borer, and then filled 
with tamarind. The plates were incubated at 37ºC and observed after 24 hours for the 
presence of inhibition zones around the wells; these were measured. The same process 
was repeated for testing the antifungal activity of tamarind, using Candida albicans (CA 
3153) which was adjusted to a concentration of 10
6
 cfu/ml and suspended in PBS 
(phosphate buffer saline), and  100 µL suspension was spread onto the surface of 
Saboraud Dextrose agar (Oxoid).   
4.2.4 Determination of MIC and MBC 
 
The MIC of the tamarind paste (subsequently referred to as tamarind) (using each of the 
test organisms) was determined using the broth microdilution (microplates) and agar  
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dilution methods. In broth microdilution, cultures of each tested bacteria was diluted in 
2X Muller Hinton and  adjusted to a 0.5 McFarland standardized inoculum, while the 
Candida inoculum was diluted in 2 x in Saboraud Dextrose broth and adjusted to 10
6
 
cfu/ml;  standardized 100 μl aliquots were then aseptically dispensed in wells of a 96-
well plate. A series of two fold dilutions of tamarind was prepared in sterile distilled 
water ranging from 5% (v/v) to 0.008 %( v/v) to the bacteria and ranging from 2% (v/v) 
to 0.02 %( v/v) to the yeast. Diluted tamarind was sterilized and filtered using a 0.20 μm 
membrane filter, and 100 μl of diluted Tamarind were added to wells and cultured for 
24 hr at 37°C. Sterile distilled water with no tamarind was used as a control. The lowest 
concentration of tamarind which inhibited the growth of each organism was recorded as 
the MIC. In order to determine the MBC, 15 μl of inoculum was collected from those 
tubes which did not show any growth and inoculated on sterile nutrient agar (for 
bacteria) and Saboraud dextrose agar (for C. albicans ).The plates were then incubated 
overnight at 37 °C. The MBC was read as the lowest concentration of tamarind or 
Manuka which did not permit any visible growth on agar plate. In agar dilution, 
sterilised tamarind was incorporated into sterilised Muller Hinton agar pre-poured 
medium to give different final concentrations (20%, 19%, 17%, …., 1.0% v/v), the 
medium poured and the agar in the plates allowed to set. Standardized 10 μl of tested 
bacteria was placed on the surface of agar plate and then incubated overnight at 37°C. 
4.2.5 Determination of time killing curves for S. aureus 
 
The effect of  tamarind or honey on the viability of cells were monitored by inoculating 
2mL of an overnight culture of Staphylococcus aureus, adjusted to final density of 
approximately 5 x 10
6
 cfu, into 18 ml  Muller Hinton broth with and without 1%(v/v) of  
tamarind and incubated at 37°C with shaking (250rpm). Samples (100 μl ) then were 
removed at known intervals , diluted serially and 100 µl of  the  diluted  samples were  
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transferred to Nutrient Agar plates (Oxoid) and incubated at 37°C for 24 h. The number 
of cfu’s was then counted and time kill plots were constructed. 
 
4.2.6 Effect of the autoclaving on the antimicrobial activity of tamarind 
 
Suspensions of tamarind (50% v/v) were autoclaved at 120°C for 15 minutes, and then 
its antimicrobial activity was assessed against Staphylococcus aureus using the well 
diffusion assay. A non-autoclaved (50% v/v) suspension of tamarind was used as the 
control. 
4.2.7 Statistical Analysis  
 
All observations were presented as Mean ± SD. (Standard deviation). The data was 
analyzed by SigmaPlot
© 
11.0. P<0.05 was considered as significant. 
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4.3 Results and discussion 
4.3.1 Well diffusion assay  
 
Figure 4.1 shows the antimicrobial activity of undiluted tamarind paste in comparison to 
25+ Manuka honey against six bacteria and Candida albicans. It is clear that  undiluted 
commercially available tamarind paste significantly inhibited all of the bacteria tested as 
well as Candida albicans and that the effect was more pronounced than that produced 
by 25+ Manuka honey. Tamarind showed particularly marked inhibitory effect against 
C. albicans and M. phlei. Tamarind inhibited C. albicans 1.5 times more than 25+ 
Manuka honey, (zone sizes 44.6±2.5 mm and 29.3±0.6 mm, respectively), whereas 
tamarind inhibited M. phlei nearly twice as much as 25+ Manuka honey (zone sizes, 
42.3±2.5 mm and 22.3±3.2 mm, respectively). The fact that tamarind exhibited a greater 
inhibitory effect on C. albicans than did manuka 25 is confirmed visually in Figure 4.2. 
Generally, Gram-positive bacteria were more sensitive to both of the tested agents than 
were Gram-negative bacteria but the difference between the susceptibility of both 
Gram-negative and Gram-positive was more obvious with 25+ Manuka honey.  
 
The marked inhibitory effect of tamarind on Candida albicans is confirmed by the data 
given in Figure 4.3 which shows that tamarind also inhibited the growth of  C. albicans 
even when diluted by 10,20 and 50% with water; the inhibitory effect is seen not to be 
linear, with the inhibition produced by the 10% v/v being approximately 70% of the 100 
percent tamarind value, this suggest that an osmotic effect is not involved in tamarind’s  
inhibitory activity.  
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Figure 4.1: The antimicrobial activity of undiluted tamarind paste  in comparison to 25+ 
Manuka honey against six bacteria and Candida albicans, determined by the agar well diffusion 
assay (n = 3). The values are represented as means of the replicates (including the size of the 
well (8.0mm)) ± Standard deviation. 
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Figure 4.2:  Zone of inhibition of the growth of Candida albicans formed around wells filled 
with tamarind and 25+ Manuka, determined by the agar well diffusion method. Note: Marked 
zone of inhibition caused by tamarind.  
 
 
 
 
Figure 4.3: Anti-Candida albicans activity of different tamarind dilutions (50%, 20% and 10% 
v/v), determined by the agar well diffusion method, expressed as means of zone of inhibition 
(including well (8.0mm))  ± standard deviation.   
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4.3.2 Minimum inhibitory concentration values  
 
Two methods were used to quantify the minimum inhibitory concentrations (MICs), 
agar dilution and microplate dilution.  Agar dilution was performed by incorporation  of 
different concentrations of the antimicrobial agent into agar media followed by adding a  
standardized inoculum of test microorganisms to the surface of the agar plate; this is  
the most commonly used methods to quantify the MIC (Wiegand et al., 2008), 
particularly when the antimicrobial agents are available in large volumes. Microplate 
dilution was carried out using 96-well microtiter plates where a standardized inoculum 
of test microorganisms were added to liquid medium containing different concentrations 
of an antimicrobial agent. In contrast to the agar dilution method, the main advantage of 
the broth dilution method is the ability to determine the MBC or MFC (Minimal 
Fungicidal Concentration) by making a further liquid subculture from the resultant broth 
culture. Initially, we performed agar dilution assay as a general screening to explore the 
range of tamarind’s MIC, using agar incorporated with tamarind concentrations ranging 
from 20% to 1% v/v. Surprisingly, none of tested bacteria showed any growth even in 
the plates with lowest tamarind concentration (1% v/v), therefore, subsequent 
microplate dilution assays were started from a concentration  of 5%  to  0.008 % ( v/v).   
  MICs and MBCs values of tamarind paste against tested bacteria and C. albicans are 
listed in Table 4.1. All MIC values determined by the agar dilution method were less 
than 1% v/v; more accurate values were given by microplate dilution where only S. 
marcescens showed MIC above 1% v/v, whereas the MIC for other tested bacteria 
ranged from 0.32% to 0.63% v/v and 0.13% for C. albicans. These low MICs value 
reflect the highly exceptionally antimicrobial activity of tamarind paste comparable to  
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Table 4.1: Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations 
(MBCs) of Tamarind for six bacteria and Candida albicans, assessed by agar dilution and 
microplates dilution methods.  
Microorganism 
  Agar dilution    Microplates dilution 
 
MIC (v/v)% 
 
MIC  (v/v)% 
 
MBC (v/v)% 
M. Phlei 
 
<1 
 
0.63 
 
1.25 
S.epidermidis 
 
<1 
 
0.32 
 
0.63 
E.coli 
 
<1 
 
0.63 
 
>5 
B.subtilis 
 
<1 
 
0.32 
 
>5 
S. marcescens 
 
<1 
 
1.25 
 
1.25 
MRSA 
 
<1 
 
0.63 
 
1.25 
Candida albicans  NT* 
 
0.13 
 
0.13 
* NT: Not tested 
 
 
high grade 25+ manuka honey the MICs values of which, as shown in Chapter Two 
Table 2.4 ranged from 6% to 12% v/v  to the same tested bacteria, for example, MRSA 
was completely inhibited by 0.63 % v/v of tamarind  while 6% v/v of 25+manuka 
achieved the same level of inhibition by MRSA. Tamarind’s inhibition activity was 
more pronounced against C. albicans than against bacteria where the MIC was 
0.13%v/v.  
 There are some marked variations between the MBC /MIC ratios of the tested bacteria, 
≤ 2.0 for M. phlei, S.epidermidis, S. marcescens and MRSA and > 7.0 for E. coli and B. 
subtilis, which suggest that the mechanism of the tamarind’s antimicrobial activity may 
not be uniform against individual bacteria independent of their cell wall structures. In 
the case of M. Phlei, S.epidermidis, S. marcescens and MRSA, tamarind appeared to be 
bactericidal, while for E. coli and B. subtilis, it seemed to be bacteriostatic. However, all 
tamarind’s MBCs values were less than 25+ manuka honey MICs and MBCs values.   
The results obtained here suggest that tamarind paste will still be active against a wide 
spectrum of bacteria as well as C, albicans even when diluted by wound exudates up to 
100-fold. 
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4.3.3 Time kill curve of the effect of tamarind paste against methicillin-resistant 
Staphylococcus aureus (MRSA). 
 
The effect of the above used MIC concentrations of tamarind on the cell counts of 
MRSA is shown in Figure 4.4. MRSA cells exposed to 1% of tamarind paste were 
found to lose the ability to multiply and nearly 1 log reduction was achieved after 8 h of 
incubation, at the same time, the growth control showed at least a 5 log increase in 
bacterial numbers by 8 h.  
 
 
Figure 4.4: The effect of 1% (v/v) Tamarind on the growth of   methicillin-resistant 
S.aureus (MRSA). 
 
This data confirms tamarind’s pronounced antibacterial activity at 1% v/v, preventing 
MRSA cells multiplication and causing a reduction in CFU over 8 h of incubation time, 
whereas the previous time-to-kill results given in Chapter two showed that more than  
10% v/v of 25+Manuka is needed to  cause a reduction in the MRSA cells. 
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4.3.4 The effect of autoclaving on the tamarind’s inhibitory activity. 
  
As shown in Figure 4.5 autoclaved tamarind paste was as equally effective in inhibiting 
MRSA as non-autoclaved material (there was no statistically significant difference 
between both activities (P = 0.897). This is particularly important in relation to the 
possible use of tamarind to treat wounds, since before it could be used for this purpose it 
would need to be sterilised; autoclaving provides a cheap and readily available means of 
achieving this sterilization without obviously impairing its antibacterial effects. Medical 
grade manuka honey in contrast needs to be sterilized using cobalt 60 gamma radiation 
in order to maintain its activity (Postmes et al., 1995) – very expensive process when 
compared with autoclaving. 
 
Figure 4.5: The antibacterial activity of 50 % v/v autoclaved tamarind paste and 50 % v/v of 
non-autoclaved tamarind paste against MRSA, expressed as means of zone of inhibition 
(including well (8.0mm)) ± standard deviation. There was no statistically significant difference 
between activities (P = 0.897). 
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In conclusion, the in vitro antibacterial activity of tamarind was evaluated and compared 
with 25+ Manuka honey. Data obtained from the agar diffusion, MICs, MBCs values 
and time to kill study shows that tamarind exhibits a stronger antimicrobial effect 
against the six tested bacteria and C. albicans than a high medical grade manuka honey. 
The marked anti-Candida activity of tamarind and antibacterial activity against M. phlei  
and MRSA are particular noticeable.  As a result of such marked antibacterial 
properties, which exceed those of 25+ manuka honey, it is suggested that a autoclaved, 
sterilized, commercially available tamarind paste should be clinically evaluated for the 
treatment of wounds and indolent ulcers with are infected with bacteria, notably MRSA, 
and b) that it might also prove effective in the treatment of mucosal membranes infected 
with C. albicans (i.e.thrush).  
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5.1 Introduction    
5.1.1 Biosurgical debridement (maggot therapy) 
Biosurgical  debridement or "maggot therapy" is defined as the use of  live, sterile 
maggots of certain type of flies to remove the necrotic tissue from non-healing tissue or 
wounds and thereby promote healing of the remaining healthy tissue (Zacur and 
Kirsner, 2002; Graninger et al., 2002). The approach involves applying sterile larvae of 
Lucilia sericata, commonly called the green bottle fly (Borak, 2008; Zacur and Kirsner, 
2002; Chan et al., 2007) to a wound, while a bandage is applied to keep them in place, 
the number of maggots used varies according to the type and the size of the wound and 
to the amount of necrotic tissue. The maggots are replaced regularly until the wound is 
healed (Borak, 2008). In order to obtain sterilized larvae, the surfaces of unhitched fly 
eggs are soaked in a bichloride solution for one hour, subsequently, the emerging larva 
remain sterile (Bunkis et al., 1985). To avoid physical discomfort to the patient, a new 
technique, was developed by Fleischmann et al. ( 2004), which involves the use of so-
called Biobag, where living larvae are applied to the wound contained in a nylon gauze 
(Blake et al., 2007; Steenvoorde et al., 2005).  
    Although the use of larvae to improve wound healing has long been recognized in 
ancient cultures, including the Chinese, Ambrose Paré, Charles IX's surgeon in chief, 
was the first to systematically report the beneficial effects of the use of larvae to treat 
wounds in 1557. In 1829, Baron Larrey reported that while he was working in 
Napoleon’s army a significant enhancement of granulation formation occurred after 
maggots were applied to battle wounds (Chan et al., 2007; Sherman et al., 2000). 
During the 1930s, maggot therapy became popular In Europe and North America to 
treat some chronic or infected wounds, especially when William Baer used maggot 
therapy successfully to treat more than 80 cases of intractable osteomyelitis. Not 
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surprisingly however, the use of maggot therapy declined immediately after the 
widespread introduction of penicillin (Chan et al., 2007). The increase in the  
emergence of multi antibiotic resistance in the late 1990s however, has led to a revival 
in interest in bio-surgical debridement  therapy and it is now being used in many 
countries to treat surface wounds (Sherman et al., 2000), including diabetic foot ulcers 
(Sherman, 2003), malignant adenocarcinoma (Sealby, 2004), and for venous stasis 
ulcers (Sherman, 2009); it is also used to combat infection after breast-conservation 
surgery (Church, 2005). 
 The beneficial effects of maggots on wounds have been attributed to various 
mechanisms notably the debridement (degradation) of necrotic tissue. It was originally 
believed that this debriding action of maggots was restricted only to their mechanical 
wriggling, but recently many proteolytic enzyme classes have been isolated from 
maggot excretions and secretions (ES) which are able to specifically dissolve the 
laminin and fibronectin of the extracellular matrix in the necrotic tissue. This liquefies 
the dead tissues enabling the maggot to take it up by suction (Chan et al., 2007; 
Graninger et al., 2002); Several recent studies have demonstrated that the maggots ES 
from aseptically-raised Lucilia sericata larvae exhibit antibacterial actions against both 
Gram-positive and Gram-negative bacteria, including MRSA, Escherichia coli and 
Pseudomonas aeruginosa (Bexfield et al., 2004; Kerridge et al., 2005; Thomas et al., 
1999; Jaklic et al., 2008; Jukema et al., 2008). In addition, maggots can ingest bacteria 
as part of their  normal feeding process (Zacur and Kirsner, 2002; Chan et al., 2007; 
Bowler et al., 2001). Finally, maggots promote wound healing, stimulate granulation 
and promote the formation of human fibroblasts (Zacur and Kirsner, 2002). 
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5.1.2 The potential therapeutic use of maggot fumes  
There exists a less well known potential use of maggots in medicine, namely the use of 
maggot-produced volatiles to treat bacterial lung infections. Wainwright (2007) detailed 
how gases and volatiles produced by maggots were used during the early 1900s to treat 
pulmonary tuberculosis and he discussed the claims that consumptives from the Leeds-
Bradford area were cured by breathing in the fumes produced by maggots (Wainwright, 
2007). Only one subsequent study aimed at investigating the antibacterial activity of  
Lucilia cuprina blowfly gaseous excreta/metabolites (gEMol) has been conducted by 
(Arora and Baptista, 2010) where it was demonstrated that the gaseous 
excreta/metabolites (gEM) caused a partial growth inhibition in Escherichia coli and 
methicillin-sensitive Methicillin-resistant Staphylococcus aureus (MRSA) (MSSA) 
(Arora and Baptista, 2010). 
 
 
Figure 5.1: (a) Blue blow-fly larva (Calliphora quadrimaculata), (b) green bottle fly larva 
(Lucilia sericata) 
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The aim of the work reported in the Chapter was to:  
1. Investigate the antimicrobial activity of Calliphora quadrimaculata maggot 
gases.  
2. Attempt to extract the antibacterial agents of Calliphora quadrimaculata maggot 
gases and quantify their activity against Mycobacterium phlei and Methicillin-
resistant Staphylococcus aureus (MRSA). 
3. Investigate the anti-MRSA activity of Lucilia sericata pupa hemolymph 
extracts. 
4.  Determine in vitro  ability of   Lucilia sericata maggots to control fungi 
involved in  superficial  fungal infections, i.e. fungal burn wound infections  and 
dermatomycoses. 
5.  Determine the incidence of Mycoplasma species in the Calliphora 
quadrimaculata and Lucilia sericata maggot guts.   
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5.2 Materials and methods  
5.2.1 The effect of the Larvae fumes on the bacteria growth  
Three plastic containers were prepared, one contained 400 g of the blue blow fly larvae 
(Calliphora quadrimaculata) (Figure 5.1) fed on beef heart, whereas the control 
container had 400 g of dead blue blowfly larvae (Calliphora quadrimaculata) with the 
same amount of beef heart. The container had holes in the top to allow for gas exchange. 
Another container with only 1% ammonium hydroxide vapour was used to check 
whether the effect of maggot fumes comes as a result of low pH due to ammonia gases 
that may be produced by maggots. Three glass beakers were placed upside down inside 
the containers and three inoculated Petri dishes were fixed at the top of the beakers, then 
incubated overnight at 37°C and the paired cultures examined with the naked eye, 
comparing individual colony diameters and the number of colonies present. 
 In order to determine the effect of larvae gases on the viability of Mycobacterium phlei, 
an airtight container containing 600 g of the blue blowfly larvae (Calliphora 
quadrimaculata) fed on beef heart was prepared.  Larval fumes were pumped at 
intervals from the container into a flask containing 200 ml of a Mycobacterium phlei 
suspension. The pumped air was sterilized by inline filters pore size 0.2μm fixed to 
silicone tube. The flasks were placed and fixed in a water bath at 37°C. Controls were 
identical except that that the jar contained only beef heart meat. Bacteria (100ml) were 
removed from the flasks at various time intervals and serial dilutions were plated on 
agar plates were made and any colonies which developed were counted (Figure 5.2). 
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5.2.2 Attempts to extract maggot gases and determine their antibacterial activity.  
    In order to produce a minimum steady stream of bubbles, the maggot gases were 
passed through 20 ml of sterilised d H2O alone (Ertel et al., 1991) or with 0.05% Tween 
80, and onto activated charcoal, which then was washed with chloroform which was left 
to evaporate, the precipitate was then re-suspended with sterilised d H2O with 0.05% 
Tween 80. All resultant gas-extraction solutions were filtered using 0.2μm vacuum 
filters in order to sterilize them. The effect of the resultant solutions on the growth of 
Mycobacterium phlei and Methicillin-resistant Staphylococcus aureus (MRSA) was 
 
Figure 5.2: Airtight container contains 600 g of the blue blow fly larvae (Calliphora 
quadrimaculata) fed on beef heart; larval fumes were pumped un-continuously from the jar into a 
flask contained 200 ml of Mycobacterium phlei suspension through silicone tube. Pumped air was 
sterilized by inline filters pore size 0.2μm fixed to silicone tube. The flasks were placed and fixed 
in a water bath at 37°C for 16 h. 
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determined by either direct count methods according to (Thomas et al., 1999) with some 
modifications or by measuring the final optical density.  
5.2.3 Antibacterial properties of Lucilia sericata pupae hemolymph 
5.2.3.1 Lucilia sericata pupa hemolymph collection 
Samples (200g) of 3− 4-day-old larvae were left without food at room temperature until 
pupation. Hemolymph was collected from pupae by clipping the anterior end near the 
cephalopharyngeal skeleton. The abdomen often had to be squeezed gently to make the 
hemolymph flow from the wound. The collected hemolymph was dissolved in 0.1 µ 
g/mL aprotonin, in 0.1% trifluoroacetic acid (TFA) 1: 10 v/v. The suspension was 
placed on ice for 6 h and centrifuged four times at 14000 g for 30 min. The 
supernatant was then harvested and kept frozen until assayed (Sahalan et al., 2007; 
Huberman et al., 2007).  
5.2.3.2 Antibacterial activity assay  
Antibacterial activity was determined as follows: Viable counts : the effect of Lucilia 
sericata pupae extracts on the viability of MRSA cells were monitored by inoculating 
1mL of an overnight culture of MRSA, adjusted to a final density of approximately 5 x 
10
6
 cfu, into 9 mL NB with and without both extracts and incubated with shaking at 
37°C (250rpm). Samples (100 μL) were removed at intervals, diluted serially and 100 µl 
of the diluted samples were placed on nutrient agar plates and incubated at 37°C for 24 
h. The colonies were counted after overnight incubation and the results expressed as 
colony forming units (CFU)/ml. Turbidimetric assay: MRSA cells were incubated the 
extracted hemolymph.  The final optical density of the treated and untreated cultures 
was measured at 600 nm. 
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5.2.4 Fungal ingestion by Blowfly larvae 
5.2.4.1 Trichophyton terrestre strain 
Trichophyton terrestre (IMI 277732) was maintained on PDA (Potato dextrose agar). 
5.2.4.2 Filamentous fungi feeding experiments  
Five-ten larvae of L. sericata were transferred either onto PDA (Potato dextrose agar) or 
PDA plates inoculated with Trichophyton terrestre. Larvae fed on only PDA (Potato 
dextrose agar) were used as controls. After being incubated for 60 minutes at 25°C, 
larvae were removed from the plate and washed twice with PBS. Larvae were then 
surface sterilized for 2 min in 70% ethanol and rinsed in sterile water. The larval 
posterior and anterior ends were removed, and then mild pressure was applied at the 
middle of the larval body to release the entire digestive tract. 
5.2.4.3 Filamentous fungi ingestion confirmation 
Collected digestive tract were mixed with 50 ml of sterile distilled water; 
vigorously vortexed for 3 minutes and 100 ul of gut suspension were plated on PDA 
(Potato dextrose agar) medium supplemented with chloramphenicol (50 mg/l) and 
cycloheximide (500 mg/l). After incubation for two weeks, plates were checked for any 
Trichophyton terrestre growth (Deshmukh, 2004). 
5.2.4.4 Yeast strain 
S. cerevisiae (BY4742) GFP was labelled with green fluorescent protein (GFP) using 
transformation plasmid Pex3p-GFP. S. cerevisiae Pex3p-GFP was maintained on YPD 
Agar (Sigma).   
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5.2.4.5 Yeast feeding experiments  
Ten well washed larvae of L. sericata were transferred onto agar plate inoculated with 
S. cerevisiae Pex3p-GFP.  Unfed larvae were used as controls. After being incubated for 
60 minutes at 25 °C, larvae were removed from the plate and washed twice with PBS. 
Larvae were then surface sterilized for 2 min in 70% ethanol and rinsed in sterile water. 
The larval posterior and anterior ends were removed, and then a pressure was applied at 
the middle of the larval body to release the entire whole digestive tract. (Lerch et al., 
2000).  
5.2.4.6 Detection of fluorescence  
To check that the yeast were ingested by the larvae, the digestive tract contents were 
fixed and then examined using a Nikon Eclipse E400 fluorescent microscope. Results 
were documented by photography. 
5.2.5 Collection of excretion/secretion (ES) from Lucilia sericata larvae 
  In order to collect Lucilia sericata larva secretions the following protocol was 
followed:10 g of Lucilia sericata larvae were placed in individual, sterile 50 ml 
universal falcon tube containing 4 ml of sterile Milli-Q ultrapure water and  incubated 
over night at 25°C in the dark. The resulting ES was collected from the larvae with a 
sterile syringe or pipette and centrifuged at 4000rpm for 10 minutes to remove 
particulate material, after which the supernatant was filter-sterilised (0.20um) and 
lyophilized. Prior to use, freeze-dried ES was resuspended in sterile Milli-Q ultrapure 
water at a final concentration of 40 mg/mL (Bexfield et al., 2004). 
 
5.2.6 Preparation of Trichophyton terrestre inocula 
A standard sized inoculum of T. terrestre was prepared from 7- to 14-day old cultures 
grown on PDA at 25°C. Mature colonies were covered with approximately 5 ml of 
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sterile PBS (pH 7.4), PBS was then gently rubbed over the surface with a sterile 
spreader. The resulting mixture of conidia and hyphal fragments was drawn off with a 
pipette and transferred to sterile tubes. Heavy particles of the suspension were allowed 
to settle for 10 to 15 min at room temperature, and the upper homogeneous suspension 
was used for further testing. The optical densities of the suspensions were read at 530 
nm and adjusted to 0.15 to 0.17 to yield 0.6 × 10
6
 to 1.4 × 10
6
 to spores/ml of strains. 
The suspensions containing conidia and hyphal fragments were further diluted to obtain 
the final desired inoculum size of approximately 0.4 ×10
4 
to 5 × 10
4
 spores/ml (Karaca 
and Nedret Ko 2004). The spore suspension (5 μl) was mixed with 20 μl of various 
concentrations of extracts, fractions (or active compounds) and transferred to Petri 
dishes containing SDA (Sabouraud Dextrose Agar). After incubation at 28 °C for 7 days 
the plates were photographed.  
 
5.2.7 Anti-Trichophyton terrestre activity of Lucilia sericata ES  
The agar dilution method was used to assess the activity of L. sericata ES on T. 
terrestre, Trichophyton terrestre was inoculated onto PDA (Potato dextrose agar) plates 
and incubated at 25°C for 7-10 days to obtain young, actively growing cultures 
consisting of mycelia and conidia. Sterilised ES was incorporated into PDA sterilised 
pre-poured medium to give a range of final concentrations (µg ml
-1)
, the medium poured 
and the agar in the plates allowed to set. A mycelial disc, 8 mm in diameter, cut from 
the periphery of the 7-10-day-old cultures, was aseptically inoculated onto the medium. 
The inoculated plates were then incubated at 25 °C and the colony diameter measured 
and measured after 5, 10, 15 days. The percentage of mycelial inhibition was calculated 
as follows:  % mycelial inhibition = [(dc-dt)/dc] × 100;  dc= colony diameter in control, 
dt = colony diameter in treatment, three replicate plates were used for  each treatment. 
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5.2.8 Mycoplasma Detection 
Mycoplasma species were detected  by using EZ-PCR Mycoplasma Test Kit 
(Geneflowltd,Cat No.20-70-20) which designed to detect various Mycoplasma species 
(M. fermentans, M. hyorhinis, M. pulmonis, M. arthritidis, M. arginini, M. orale, M. 
bovis, M. salivarium, M. hominis, M. pneamoniae, M. pirum and M. capricolum), as 
well as Spiroplasma and Acholeplasma species, with high sensitivity and specificity. 
EZ-PCR Mycoplasma Test Kit manufacturer's protocol was followed; 
5.2.8.1 Test sample preparation: 
Larvae were surface sterilized for 2 min in 70% ethanol and rinsed in sterile water. The 
larval posterior and anterior ends were removed aseptically; the entire larval gut was 
removed and suspended in sterile distilled water, vortexed for 5 minutes. To pellet 
cellular debris, 0.5-1.0ml of the entire gut suspension was transferred into a centrifuge 
tube and centrifuged briefly at 250 x g. The supernatant was then transferred into a fresh 
sterile tube and centrifuged again for 10 minutes at 15,000-20,000 x g to sediment 
Mycoplasma. The supernatant was carefully decanted and the pellet was re-suspended 
with 50µl of the Buffer Solution and mixed thoroughly with a micropipette, heated to 
95'C for 3 minutes. 
5.2.8.2 PCR amplification: 
The reaction mixture was prepared in a PCR tube containing the following reagents; 
10µl Reaction Mix, 5µl test sample and 35µl of sterile distilled water (sdH2O). 40µl of 
mineral oil was overlaid to prevent the evaporation of the reaction mixture. All PCR 
tubes were then placed in a DNA thermal cycle. The PCR reaction mixtures, after 
incubation at   94°C for 30 seconds as an initial denaturation, were cycled 35 times 
through the following temperature profile: denaturation for 30 seconds at 94°C; 
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annealing for 120 seconds at 60°C; and elongation for 60 seconds at 72°C, then one 
final cycle with the following incubations; 94°C for 30 seconds, 60°C for 120 seconds 
and 72°C for 5 minutes. 
5.2.8.3 Analysis of amplified products by gel electrophoresis:  
In order to check the amplified products and their size, 2% gel electrophoresis was 
prepared as previously described 2.2.17.1, 20µl of the amplified PCR product and 1µl 
of the Positive Template Control were applied to the gel electrophoresis. The size of 
DNA fragments amplified using the specific primers in this kit was 270bp. After being 
electrophoresed the DNA fragments were visualized under a UV transilluminator and 
the images were captured using a connected digital camera. 
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5.3 Results and discussion 
5.3.1 Anti- Mycobacterium activity of (Calliphora quadrimaculata) maggot gases  
    As shown in Figure 5.3 the growth of Mycobacterium phlei, (a non-pathogenic strain 
was used as a model to avoid using M. tuberculosis) was inhibited by gases from the 
blue blow-fly (Calliphora quadrimaculata) larvae (maggot) grown on beef heart. In 
contrast, the growth of Methicillin-resistant Staphylococcus aureus (MRSA) was not 
inhibited by maggot gases. Ammonia vapour from (ammonium hydroxide) did not 
inhibit the growth of M. phlei and (MRSA).  
 
Figure 5.3: The effect (a) of (Calliphora quadrimaculata) maggot gases on the growth of 
Mycobacterium phlei, (b) The effect of maggot gases   on the growth Methicillin-resistant 
Staphylococcus aureus (MRSA), (c) The effect of ammonium hydroxide vapour   on the growth 
of 1. E. coli, 2. M. phlei, 3. (MRSA) and 4. S. marcescens. Number  2 (M. phlei) and 3 (MRSA) 
were not inhibited.  
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The ability of the gasses from the Calliphora quadrimaculata maggot to inhibit M. phlei 
but not (MRSA) indicated that the germicidal effect of these gases are not general and 
target a specific spectrum of bacteria. According to Wainwright (2007) , ammonia 
vapour is one of the main components  of maggot gases, results shown in  Figure 5.3  
revealed that ammonia vapour was unable to suppress M. phlei growth which mean that 
maggot gases  have other components  cause  this anti M. phlei activity. Recently, Arora 
and Baptista (2010) have detected in Lucilia cuprina maggot gases several compounds 
with antibacterial activity including aromatic aliphatic esters of furanone and 
tetrahydrofuran esters (Arora and Baptista, 2010).  
5.3.2 Extraction of maggot gases and evaluation their antibacterial activity.  
In order to quantify the anti- Mycobacterium activity of (Calliphora quadrimaculata) 
maggot gases, an attempt was made to dissolve these gases into d H2O, by passing them 
through 20 ml of sterilised d H2O and form steady stream of bubbles.   
  The antibacterial activity of the resultant gas extraction d H2O solution was determined 
against Mycobacterium phlei and Methicillin-resistant Staphylococcus aureus (MRSA). 
Figure 5.4 and Figure 5.5 shows that the gas-extract failed to inhibit both 
Mycobacterium phlei and Methicillin-resistant Staphylococcus aureus (MRSA). It 
appears therefore that the active ingredients are non-water soluble compounds which do 
not dissolve in the d H2O extraction solution. In order to overcome this problem and to 
enhance the solubility of these expected non-water soluble compounds, Tween 80 was 
added to d H2O extraction solution in final 0.05% concentration. 
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 Figure 5.4: The effect of maggot gases extracted by d.H2O on the growth of M. phlei, 
results are expressed as means of O.D at 600nm ± SD. There is no a statistical 
significant difference between the input groups (P = 1.000).        
 
Figure 5.5: The effect of maggot gases extracted by d.H2O on the growth of Methicillin-
resistant Staphylococcus aureus (MRSA), results are expressed as means of O.D at 
600nm ± SD. There is no  statistical significant difference between the input groups (P 
= 0 .542). 
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The effect of maggot gases extracted by d.H2O with 0.05% Tween 80 on the growth of 
M. phlei and MRSA is shown in Figure 5.6 and Figure 5.7, again, no significant 
inhibitory effect of the gas extraction solution was observed against M. phlei and 
(MRSA).  
 
 
Figure 5.6: The effect of maggot gases extracted by d.H2O with 0.05% Tween 80 on the growth 
of M. phlei, results are expressed as means of O.D at 600nm  ± SD. There is no  statistical 
significant difference between the input groups (P = 0.107).  
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Figure 5.7: The effect of maggot gases extracted by d.H2O with 0.05% Tween 80 on the growth 
of Methicillin-resistant Staphylococcus aureus (MRSA), results are expressed as means of O.D 
at 600nm  ± SD. There is no statistical significant difference between the input groups (P = 
0.484). 
 
Activated charcoal was next employed as a potential adsorbent of the antibacterial agent 
present in maggot gasses. Activated charcoal is an efficient gas absorbent (Ray and 
Box, 1950) and a gram of activated charcoal  has a total surface area in range of 500 to 
2000 m
2
 (Von Blucher and De Ruiter, 1991). Maggot gases were passed through 
activated charcoal which was then washed with chloroform and left to evaporate. The 
precipitate was then re-suspended in sterilised d H2O with 0.05% Tween 80. Again 
Figure 5.8 and Figure 5.9 show that no significant antibacterial effect was seen and that 
no inhibitor was extracted by the use of activated charcoal.   
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Figure 5.8: The effect of maggot gases extracted by activated charcoal on the growth of M. 
phlei, results are expressed as means of O.D at 600nm  ± SD. There is no statistical significant 
difference between the input groups (P = 0.561). 
 
Figure 5.9: The effect of maggot gases extracted by activated charcoal on the growth of 
Methicillin-resistant Staphylococcus aureus (MRSA), results are expressed as means of O.D at 
600nm  ± SD. There is no statistical significant difference between the input groups (P = 0.136). 
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As shown in previous three experiments attempts to extract the anti-Mycobacterium 
activity of maggot gases were unsuccessful.  One final attempt was made to determine 
the effect of maggot gases on M. phlei cell viability. As shown in Figure 5.10, there was 
no significant inhibitory effect of the maggot gases exposure on the M. phlei cell 
number. This successive absence of inhibitory influence of gases extraction is hard to 
explain, but it could be due that the extracted gases were highly diluted in extraction 
solutions and extracts showing that other extraction techniques need to be applied.     
 
 
Figure 5.10: Effect of maggot gases on the growth of M. phlei, using approach shown in Figure 
5.2. Treated cells were exposed to fresh maggot gases. 
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5.3.3 The anti-MRSA activity of Lucilia sericata pupal hemolymph. 
Invertebrates, predominantly insects, have been considered as a potential sources of 
antimicrobial agents, notably peptides (Chernysh et al., 2002). In contrast to the higher 
animals, insects lack immunoglobulin and use antimicrobial peptides to protect 
themselves from bacterial infections, such peptides are commonly found in the 
hemolymph of all life stages of the insects (Sahalan et al., 2007). 
    The antibacterial activity of excretions of Lucilia sericata maggots has been 
extensively reported (Arora and Baptista, 2010; Bexfield et al., 2004; Kerridge et al., 
2005; Thomas et al., 1999; Jaklic et al., 2008; Jukema et al., 2008).  Furthermore, 
whole body extracts and haemolymph of Lucilia sericata maggots have been shown to 
have antibacterial activity (Huberman et al., 2007).  Since the whole body extracts and 
haemolymph of Lucilia sericata maggots have been reported to have antibacterial 
activity, we assumed here that the haemolymph of the pupa would have similar 
antibacterial activity as well. In this section the antibacterial activity of haemolymph 
extracted from Lucilia sericata pupa was investigated.  
Effect of hemolymph from pupae of Lucilia sericata on the viability of Methicillin-
resistant Staphylococcus aureus (MRSA) is illustrated in Figure 5.11, whereas the effect 
of hemolymph from pupae of Lucilia sericata on the on the final optical density of 
MRSA is illustrated in Figure 5.12. As clearly shown in these two figures, hemolymph 
from the pupae of Lucilia sericata does not exhibit any inhibitory effect on MRSA.  
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Figure 5.11: Effect of hemolymph from pupae of Lucilia sericata on the viability of  
Methicillin-resistant Staphylococcus aureus (MRSA). Values are represented as means of the 
replicates± standard deviation.  
 
Figure 5.12: Effect of hemolymph from pupae of Lucilia sericata on the final optical density of  
Methicillin-resistant Staphylococcus aureus (MRSA) after overnight incubation with Pupal 
hemolymph. Values are represented as means of the replicates± standard deviation.  
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5.3.4  Potential use of Lucilia sericata maggot to control superficial 
fungal infections, i.e. fungal burn wound infections and 
dermatomycoses. 
 
Fungal infections are considered as an important cause of morbidity and death of 
patients with burn wounds (Horvath et al., 2007; Murray et al., 2008; Becker et al., 
1991); according to Rode et al., (2008) fungal infections complications that delay the 
healing process are associated with 30% of burn wounds. 
 Dermatomycoses, such as ringworm or tinea (Lakshmipathy and Kannabiran, 2010; 
Weitzman and Summerbell, 1995), are infections of the keratinized layers of  skin, hair 
and nail (Lakshmipathy and Kannabiran, 2010). Dermatomycoses are among the most 
widespread infectious diseases in the world, mainly in the tropical and subtropical 
countries (Brasch and Graser, 2005; Lakshmipathy and Kannabiran, 2010). Such 
infections are difficult to control and expensive to treat (Bokhari, 2009). It has been 
estimated that the worldwide annual cost of dermatophytosis drug development is   over 
USD $ 0.5 billion (Gräser et al., 2008). The prolonged systemic use of  antifungal drug 
treatment of dermatomycoses  is highly linked to fungal resistance, drug toxicity and 
interactions (Koroishi et al., 2008) although  positive outcomes in dermatophytosis 
control are generally associated with topical antifungal therapy (Karaca and Nedret Ko 
2004). 
 The introduction of maggot therapy to treat heavily fungal colonized burn wounds and 
dermatomycoses such as athlete's foot might prove a viable alternative to the use of 
conventional antibiotics, especially where antibiotic resistance is found.  
  In order to evaluate the use  of Lucilia sericata maggots in fungal wound infections 
and superficial fungal infections management, two questions need to be answered; 
firstly, do the Lucilia sericata maggot excretions/secretions have antifungal activity ?- 
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and  secondary, can Lucilia sericata maggots ingest pathogenic fungi ? To the best of 
our knowledge there are no previous reports on the antifungal activity of maggots 
against filamentous fungi, but in regard to the yeast fungi, complete lysis of Candida 
albicans  has been shown in vitro after 24 h of maggot application  (Margolin and 
Gialanella, 2010), and  Jarczyk et al. (2008) have reported the elimination of Candida 
spp. from chronic foot ulcerations after treatment with maggots(Jarczyk et al., 2008).  
   In this section attempts were made to, a) investigate the ability of  Lucilia sericata 
maggots to ingest filamentous fungi and yeasts, b) investigate the antifungal activity of 
Lucilia sericata maggot excretions/secretions against filamentous fungi only (as it has 
already been demonstrated against yeasts). Trichophyton terrestre was chosen as a 
model dermatophyte filamentous fungi.  
 
  As shown in Figure 5.13, after placing the Lucilia sericata maggots into the agar plates 
inoculated with S. cerevisiae (BY4742) GFP for 60 minutes at 25 °C, under fluorescent 
microscope  a significant fluorescence was observed in the gut contents of  ten different 
maggots out of ten examined (i.e.100%), whereas no fluorescence was seen in maggots 
fed on only agar. This clearly shows that the Lucilia sericata maggots successfully   
ingested yeasts.  
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Figure 5.13: Left and Right microscopy images correspond to bright field and GFP 
fluorescence, respectively. (a) bright field microscopy image of the   digestive tract of maggots 
fed on S. cerevisiae (BY4742) GFP (b) GFP fluorescence microscopy image of the   gut content 
of maggots fed on S. cerevisiae (BY4742) GFP (c)and (d) bright field and GFP fluorescence 
microscopy images of the   gut content of  control maggots 
 
 
When excretions/secretions (ES) of Lucilia sericata maggots were tested against 
Trichophyton terrestre by the agar dilution method, 1mg/ml of ES showed a 
considerable inhibition of growth of mycelium as illustrated in Figure 5.14. The radial 
growth inhibition after 10 days of incubation reached 41.2 ±1.8 % in relation to the 
control. This appears to be the first time that the antifungal activity (i.e filamentous)   of 
maggot’s excretions/secretions has been both tested and observed.  
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Figure 5.14: Percent inhibition of mycelial growth of  Trichophyton terrestre in presence of 
1mg/ml  Lucilia sericata maggot excretions/secretions. Percentage of mycelial growth 
inhibition respective to the control  (no ES added). Means of three replicates ±SD. 
 
 
In investigation of the ability of L. sericata maggots to ingest filamentous fungi, no 
growth of  Trichophyton terrestre was observed  in 16 different samples after 10 days  
of  incubation  of a subcultures of the maggot’s gut suspensions fed on 
Trichophyton terrestre. This observation could indicate that   L. sericata maggots are 
unable to ingest Trichophyton terrestre mycelium and spores, or that the fungus is killed 
as the result of ingestion. Results obtained here show that maggots are able to ingest 
yeasts and as mentioned above, it has been shown that maggots application led to a 
completed lysis and elimination of Candida spp. (Jarczyk et al., 2008; Margolin and 
Gialanella, 2010). With regarding to filamentous fungi, the results show that the maggot 
ES have moderate  antifungal  activity , but  the results failed to provide evidence about 
5 Chapter Five: Maggot Debridement Therapy 
 
130 
 
whether the  maggots are able  to ingest filamentous fungi. However, this does not 
necessarily mean that maggots are unable to deal with such fungi as maggots are mainly 
feed through extracorporeal digestion where a mixture of digestive enzymes (such as 
tryptase, peptidase, and lipase ) are continuously produced by larval salivary glands into 
the surroundings (Lerch et al., 2000; Andersen et al., 2010), the secreted digestive  
enzymes could lead to the destruction and lysis of  the fungal  mycelium ,to be 
subsequently adsorbed by the maggot’s powerful suction apparatus (Andersen et al., 
2010) especially since maggots are  known to have an ability to ingest as much 
as half of their body weight within a few minutes (Fleischmann et al., 2004). 
  The moderate antifungal activity (yeast and mould) of ES of Lucilia sericata maggots 
and the ability of these maggots to ingest yeast and probably to destroy and lyse mould 
mycelium, could lead to the possible application of maggot therapy in the treatment of  
wounds undergoing fungal infection and with superficial fungal infections i.e. athlete's 
foot (Summers and Kaminski, 2003; Namias et al., 2000). Further studies are now 
needed to help confirm this possibility.  
 
5.3.5 Determine the incidence of Mycoplasma species in the Calliphora 
quadrimaculata and Lucilia sericata maggot hemolymph.   
 
Mycoplasma are the smallest prokaryotic organisms and since they lack a cell wall 
(Greenwood, 1997) are resistant to all antibiotics that target cell wall synthesis, such as 
penicillin and cephalosporin (Tadesse and Alem, 2006). Mycoplasmas are found in 
humans, animals, plants, insect, soil and sewage (Greenwood, 1997). Genetically, 
Mycoplasma have a small single circular chromosome containing  0.58 to 2.2 Mbp with 
a low G+C content (23 to 40 mol%) which drastically reduces their biosynthetic 
capabilities and explains why they tend to be dependent on a host, phylogeny. Studies 
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have showed that Mycoplasmas are strongly related to the Gram-positive eubacterial 
subgroup like  streptococci  and lactobacilli (Waites and Talkington, 2004). As a result 
of them lacking cell wall, mycoplasma are highly pleomorphic bacteria, their final shape 
varies depending on environmental conditions and the stage of the growth cycle. Thirty 
species have been placed in the genus Mycoplasma including: M. fermentans, M. 
genitalium, M. hominisa and  M. pneumonia, all of which are of medical importance 
due to their pathogenicity and role in human disease (Greenwood, 1997; Tadesse and 
Alem, 2006). Mycoplasma pneumonia, is a human pathogen which causes atypical 
pneumonia and other lower respiratory tract infections, while M. genitalium, is   the 
presumed cause of pelvic inflammatory disease (Goulet et al., 1995).  
  Insect vectors are among the  most important means of spread Mycoplasma and 
rickettsia like organisms in nature(D'Arcy and Nault, 1982). There have been relatively 
few reports of the isolation of Mycoplasmas from insect and flies larvae; these include 
isolation from
  
moth larvae, Leucoma salicis (Oduori et al., 2005); larvae of Melolontha 
melolontha (L.) (Devauchelle et al., 1970) and flies(Museux et al., 2009). 
 
The aim of the present work was to determine if Mycoplasmas can be detected in the 
hemolymph of maggots of Calliphora quadrimaculata and Lucilia sericata. 
 
Table 5.1: The presence or absence of Mycoplasma in Calliphora quadrimaculata and Lucilia 
sericata larvae  
Larvae of  No. samples  Positive  results  Negative results  
Calliphora quadrimaculata  3 0 3 
Lucilia sericata 3 0 3 
 
In order to detect Mycoplasma, EZ-PCR Mycoplasma Test Kit was used. In this kit 
specifically designed primers that target a highly conserved sequences in  Mycoplasma 
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DNA only   ( not bacterial or animal DNA sequences) was used. Generally, this PCR 
dependant technique is highly sensitive, specific and rapid method compared with 
conventional direct culture procedures. 
The results obtained after conducting a search for Mycoplasmas in 6 different maggots 
samples are shown in Table 5.1. Agarose gel electrophoresis in Figure 5.15 did not yield 
a 270bp fragment expected for the positive template kit control. Mycoplasmas were not 
therefore detected in any of the maggot samples tested. These observations suggest that 
Calliphora quadrimaculata and Lucilia sericata larvae are unlikely to act as 
transmission vectors for Mycoplasmas.  
 
 
Figure 5.15 : Blue arrow head shows 270bp product of DNA of PCR amplification from 
positive template kit control and white arrow head shows the ladder type which was used with 
16s rRNA. All samples showed no bands (negative results). Sterilized d H2O sample was used 
as negative control.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 Chapter Six: Fungi isolated from mouldy foods 
inhibit Staphylococcus including MRSA. A 
Rationale for the Re-introduction of Mycotherapy? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Six: Fungi isolated from mouldy foods inhibit Staphylococcus including MRSA…. 
134 
 
6.1 Introduction  
   Well before Fleming's famous discovery of penicillin in 1928, moulds had been 
widely used in all cultures as curative agents. Imhotep, for example, an ancient Egyptian 
practitioner, used mouldy bread to treat face infections. Literature from more recent folk 
medicine has documented some other examples of the use of moulds on infections. 
Mouldy jam and mouldy bread were for example, widely used in Quebec, Devon, 
Kansas and USA and poultices made from mouldy chewed barley and apple have been 
used in Asia to cure surface wounds. In 1640, one of London’s apothecaries advised 
that moulds have a curative effect when applied to infections (Wainwright, 1989). 
    The difficulties facing researchers attempting the large-scale production of penicillin 
during 1940s encouraged some workers to re-evaluate the therapeutic properties of 
crude penicillin filtrates for use in hospitals. They developed a number of different 
methods to apply the crude penicillin topically, such as the application of lint saturated 
with liquid filtrates or dressings inoculated with the penicillin-producing mould, P. 
notatum. In addition, crude penicillin was applied in agar. Even though many successful 
cures were achieved using crude penicillin, its unrestrained production and potential 
purity problems restricted its use and it became completely ignored once purified 
penicillin became widely available (Wainwright, 1987). 
    Wainwright and co-workers (Wainwright et al.1992) investigated the scientific basis 
of the mycotherapy; their results suggested that the active ingredient that responsible for 
this curative effect is not penicillin, but patulin. 
 The aim of the work reported in this Chapter was to determine if fungi growing as 
contaminants on mouldy foods produce penicillin and patulin filtrates (when grown on 
Czapek Medium) which are inhibitory to MRSA. 
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6.2 Materials and methods  
6.2.1 Test organisms 
The following test organisms (bacteria) were used: Methicillin-Sensitive 
Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus 
(MRSA); unless stated otherwise, the organisms were obtained from the Departmental 
Culture Collection. 
6.2.2  Sources of the moulds 
A variety of naturally mouldy food, vegetables and fruits were collected from local 
retail outlets; these were: bread, apple, lemons and beetroot. Two penicillin-producing 
fungi, Penicillium chrysogenum IMI 37767 and Penicillium chrysogenum IMI 24317, 
were used as controls. 
6.2.3  Mould cultivation  
Indigenous fungi were isolated from a variety of collected mouldy foodstuff. Either skin 
(2 x2 mm) or heavily sporulating colonies were picked off and maintained on Czapek 
Dox liquid medium (Oxoid) and incubated at 25°C with shaking 150 rpm for two 
weeks.  
6.2.4 Screening of the fungal isolates for antibacterial activity. 
Isolated fungal cultures were identified after visulisation under the low power 
microscope and grown as described above. The mycelia of these cultures were separated 
by filtering with Whatman filter paper. The antibacterial activity of the harvested 
mycelia and the filtrates was evaluated directly by using the agar plate diffusion assay 
as described (2.2.6), but here the wells were filled with either 100 μL of filtered broth or 
air-dried fungal mycelia. Plates were incubated at 37°C for 24 h. The diameter of the 
inhibition zone (mm) produced was then measured.    
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6.2.5  Detection of patulin in fungal liquid cultures. 
Pure crystalline patulin (Sigma 5mg) was dissolved in 5ml of chloroform (Fluka) to 
produce a concentration of 100 μg ml-1. The solution was kept in well-wrapped, 
aluminium foil bottle and stored at 4°C. The standard was used at room temperature 
(Gimeno and Martins, 1983).  
6.2.5.1 Preparation and development of TLC plates 
Sigma-Aldrich® TLC (thin layer chromatography) plates, cellulose matrix, H × W 
10 cm × 20 cm with fluorescent indicator were used as a stationary phase. Two 10 μl 
aliquots of  fungal extracts were spotted along a line 3 cm from the lower edge of the 
plate. 5 μl of patulin standard were spotted as a reference standard solution. The plates 
were then placed in Latch-lid™ TLC chambers (Aldrich) for one dimensional 
development for about 2 hours  in benzene: methanol: acetic acid - BMA (90:5: 5 v/v/v) 
( mobile phase); they were left  at room temperature until the solvent front had reached 
a line marked 2 cm from the top of the plate. The plates were then removed and air-
dried in a fume cabinet and sprayed with a freshly prepared mixture of 0.5 ml p-
anisaldehyde (in 85 ml of methanol  containing 10 ml of glacial acetic acid and 5 ml of 
concentrated sulphuric acid)  and then heated at 110° in a hot-air oven for 10 minutes. 
Plates were then were visualized by 2UV Transilluminator (300–360 nm) connected to 
Kodak DC290 camera.  After being air-dried and sprayed with a freshly preparation p-
anisaldehyde (Fluka), developed chromatograms were viewed under visible and UV 
light for the presence of fluorescent spots. The p-anisaldehyde spray allows patulin to 
be detected as faint brown spots under the visible light and as yellow-orange under UV 
light. According to Scott et al., 1970 using ethanol instead of methanol in the spray 
reagent will improve the detection of patulin at a detection limit of 0.1 μg (Scott et al., 
1970; Scott and Somers, 1968). 
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6.2.5.2 Extraction of patulin from fungi liquid cultures. 
The contents of all fungal liquid culture flasks were filtered through Whatman No.1 
filter paper. All extract solutions were then centrifuged (in 50 ml Universal) at 4000 
rmp for 15 minutes; supernatants were transferred into 250 ml separating funnel 
contained tow equal volumes of ethyl acetate. The separating funnel was shaken for 2 
minutes and the contents allowed to settle and layers to be separated. The bottom 
aqueous (fungal culture) layer was removed and discarded, while the top layer ( ethyl 
acetate ) was collected and combined with 2 g of anhydrous sodium sulphate( Na2SO4), 
then left to evaporate to dryness.  
6.2.6  Beta-Lactam detection in the isolated fungi liquid cultures  
The SNAP* MRL Beta-Lactam Kit (IDEXX, USA) is a test for Beta lactams which 
depends on an enzyme-linked receptor-binding assay, designed to detect most beta-
lactam antibiotics, notably penicillin G. The Kit contains : a SNAP Device, a sample 
tube containing reagent pellet, a pipette, SNAP positive controls and a heater block 
capable of maintaining an operating temperature of 45°C  +5°C .(see Appendix). 
6.2.6.1 Test Preparation 
The heater block was preheated to 45°C +5°C, the SNAP device, the pipette and sample 
tube were removed from the bag and the reagent pellet was checked to be present at the 
bottom of the sample tube. 
6.2.6.2 Test Procedure 
The SNAP device was placed in the heater block; 2ml of the liquid culture(sample) 
were added, shaken  thoroughly, and then the sample tube cap was removed and 
discarded, 450 μl of the sample was drawn up with the IDEXX pipette, the sample was 
then added carefully from the pipette to the tube. To dissolve the reagent pellet the 
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sample tube was shaken. The sample tube was then incubated in the preheated heater 
block at 45°C for 5 minutes. 
   The contents of the sample tube was poured into the sample well of the SNAP device, 
and the tube was discard. The sample flowed across the results window toward the blue 
activation circle. When the blue activation circle began to disappear, the activator button 
was pushed firmly until it snapped flush with the body of the SNAP device, during 
colour development the SNAP device was left in the heater block. After 4 minutes, the 
result was ready to be read. Before interpreting results, the SNAP device with the 
sample well was positioned to the left, as shown in the (Figure 6.1).  
 
 
 
Figure 6.1 Interpreting  SNAP* MRL Beta-Lactam Kit test results  
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6.3 Results and Discussion  
The ability of mycelium of Penicillium species to inhibit both methicillin-sensitive and 
methicillin-resistant S.aureus is shown in Table 6.1 and Figure 6.2; in the case of the 
apple isolate, an illustration of the zones produced on the test plate is shown in Figure 
6.2. As expected, a paper test disc containing penicillin G inhibited MSSA, but not 
MRSA. Mycelium from all of the Penicillium cultures isolated from foods inhibited 
both MSSA and MRSA. The obvious question is what antibacterial agent responsible 
for this inhibition? Tests using SNAP (Figure 6.3) to test for penicillin and TLC (Figure 
6.4) for patulin showed that penicillin was found in culture filtrates from all of the 
individual fungi, while patulin was produced by the apple and beetroot isolates. The 
isolation of a patulin-producing fungus from apples is however, to be expected since 
patulin is commonly produced on both apples and in apple juice (Beretta et al., 2000).    
 
 
Figure 6.2: The antibacterial activity of mycelia (M) and the filtrates (F)  
of the fungus isolated from apple liquid culture against MRSA. 
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Table 6.1: The antibacterial activity of the mycelium of fungi (zone of inhibition, mm) isolated 
from different foodstuffs.  
Test  MSSA MRSA Penicillin      Patulin 
Penicillin G disk (6µg) 29 0 + - 
Penicillium chrysogenum IMI 24317 25 23 + - 
Penicillium chrysogenum IMI 37767 13 14 + - 
Lemon Penicillium 19 19 + - 
Beetroot    “ 16 17 + + 
Bread         “  17 18 + - 
Apple         “ 17 17 + + 
 
 
Although penicillin and patulin were tested here it is, of course, possible that other 
antibacterial agents were also produced which act alone, or together with penicillin or 
patulin to inhibit the MSSA or MRSA. This would explain how the MRSA was 
inhibited when this bacterium is known to be resistant to penicillin. In relation to 
mycotherapy is the nature of the antibacterial agent or agents produced by the mycelium 
important? Certainly from normal clinical viewpoint, a clinician would be expected to 
know what agents are being produced by a mould which is being used to treat a wound. 
This is especially true in the case of Penicillium species which are known to produce 
various potentially dangerous toxic mycotoxins.  Patulin, for example is toxic and its 
long term intake into the body may lead to the formation of cancers. The application to 
wounds, of a mould which is known to produce penicillin and or patulin, as well as 
other unknown antibacterial (or otherwise) compounds would obviously be frowned 
upon by regulatory authorities and would not pass ethical panel scrutiny.  
    Under what conditions might moulds, isolated from common foods, be used to treat 
Staph. infected wounds, including those infected with MRSA? During clinical 
experience gained in the period when P.notatum was used as a filtrate, as macerated 
mycelium in filtrates, or when growing on agar or other substrates applied to wounds 
exposed no examples of toxic contradictions.  
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Figure 6.3: SNAP devices showing different results according to samples sources. Note in 
positive control,  lemon and  beetroot samples the control spot are darker than the sample spot 
(positive results), whereas  in the negative control (sterilized Czapek Dox liquid medium) 
control spot was lighter than the sample spot.   
 
Clearly then,  a pure culture of a Penicillium, known to produce penicillin and not 
patulin or other toxicant (like the two IMI strains used here) could be safely used to 
treat wound infections in hospitals at the present time. Is there ever likely then to be 
situation when the results obtained in this study could be put to practical use? The 
obvious answer is that Penicillium moulds isolated from mouldy foods could be applied 
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to wounds in extremis, that is when no other medical intervention is available to treat an 
infected wound, e.g. following an event which leads to the total breakdown of society 
(e.g. following a nuclear war, or during local extreme living conditions such as in a 
prisoner of war camp. Under these conditions, Penicillium cultures could be isolated 
from mouldy foods (a mixture of such moulds from various foods might prove 
particularly effective) and could be applied to wounds in the knowledge that they would 
contain penicillin and or patulin, or other antibacterial metabolites, which could prove 
the difference between life and death for a patient with an critically infected wound. 
Alternatively, food-moulds could be applied prophylactic to prevent the infection of an 
open wound. 
 
 
 
 
 
 
 
 
 
Figure 6.4: TLC plate showing that patulin was detected in sample number 3 (extracted from 
liquid culture of fungus isolated from apple). TLC plate sprayed with 0.5 ml p-anisaldehyde in 
85 ml of methanol  containing 10 ml of glacial acetic acid and 5 ml of concentrated sulphuric 
acid, heated at 110ºC for 10 min and observed under UV light (300–360 nm). (Left to right) 
Three samples and one standard are shown. 
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7.1 Final Discussion    
In a review in which the history and potential use of maggot therapy was discussed 
Wainwright, (1988) stated that “it is unlikely that we will ever see a return to the use of 
maggot therapy”. At the time, this seemed to be a rationale and safe prediction, but as 
with many similar predictions about the future of medicine and science it turned out to 
be wrong, much to the subsequent embarrassment of the author! This prediction did not 
of course take into account the desperate situation in infective disease control which 
would eventually result from the widespread development of antibiotic resistance to its 
current highly worrying state. Clearly no one would advocate the application of living 
maggots to infected wounds in place of effective antibiotics, even ignoring the relative 
effectiveness of the two approaches a move away from “scientific medicine” to a 
primitive biocontrol technique would undoubtedly be seen  as an embarrassment by 
most of the medical profession.  
   The return of maggot therapy highlights the desperate state in which modern medicine 
finds itself, a situation which is made embarrassing by the fact that it largely down to its 
own making due to the miss-prescribing and wasteful way in which antibiotics have 
been squandered over the last half century and more.  
     Medical science has, at least for the moment, had to turn away from highly 
sophisticated approaches to infection control to the use of old fashioned approaches 
which are based on folklore or even old wives tales. Such a picture is however, 
misleading as all of the alternative approaches studied in this Thesis are backed up by 
scientific rationales, many of them developed at a time before the introduction of 
antibiotic therapy. The classic example of this is the scientific rationale behind maggot 
therapy which was extensively worked out in the 1930s by Baer, his co-workers and 
followers (Wainwright, 1988). In the same way, all of the necessary method required to 
successfully apply maggot therapy in medical practise were well-worked out before 
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1940, when the method was made redundant. It is interesting to note that while maggot 
therapy was widely used in the USA in pre-antibiotic days, its use was never sanctioned 
in the UK, despite its obvious effectiveness. As a result, while US patients who suffered 
from   disgusting, suppurating indolent infections could be relieved of their symptoms, 
those in the UK, who were denied maggot therapy, largely on the basis of bigotry had to 
continue suffering (Wainwright, 1988). 
     The response to the use of honey as a therapeutic agent has been less extreme than 
that seen in regard to the use of maggot therapy simply because the former approach is 
obviously seen as inherently less unpleasant, less intrusive and complicated. Simply put, 
few patients would elect to have living maggots applied to their bodies when more 
benign and healthy-appearing honey could be used in its place. Again however, as we 
have seen, a mass of scientific knowledge has accumulated to back up the use of honey 
in wound therapy. 
  The most potentially important result of this Thesis is the demonstration that tamarind 
has marked antibacterial properties. This presents the possibility of using autoclave-
sterilized tamarind in the treatment of indolent, antibiotic resistant wounds. It appears 
that tamarind has not previously been used for this purpose, and so could provide a new 
approach to wound therapy.  
    In a similar way the finding that maggot-derived gasses, and volatiles, inhibit 
Mycobacterium phlei, and therefore potentially also M. tuberculosis, is of considerable 
potential significance in relation to the treatment of tuberculosis. While maggot gasses 
themselves could be used, it is potentially more desirable that the active ingredient of 
such gas mixtures be isolated and used. Unfortunately it was not possible to find a 
means of isolating such an active ingredient(s) during the work presented here. In some 
way this situation is similar to that facing Fleming from 1928 onwards, in that he had 
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demonstrated the antibacterial properties of penicillin but was unable to chemically 
purify it in order to convert it into an effective antibiotic for use in medicine.   
   In relation to maggot therapy,for first time- in vitro evidence ( such as antifungal and 
yeast (S. cerevisiae (BY4742) GFP) ingestion ability),  was provided in support of the 
use of Lucilia sericata maggot to control fungi involved in superficial  fungal 
infections, i.e. fungal burn wound infections  and dermatomycoses. A study was made 
to determine if Mycoplasmas can be detected in the hemolymph of maggots of 
Calliphora quadrimaculata and Lucilia sericata maggots. Mycoplasmas were not 
detected in any of the maggot samples tested. These observations suggest that 
Calliphora quadrimaculata and Lucilia sericata larvae are unlikely to act as 
transmission vectors for Mycoplasmas. 
 The results presented in this thesis also show that Manuka oil has the potential for use 
on wounds in order to inhibit Gram-positive, but not Gram-negative bacteria; it could 
also be used to treat dermatophytes. It is suggested for example, that this oil might be 
added to shampoos, or used directly, in countries such as India where dermatophytes are 
common amongst large sections of the population. 
   The work presented here makes it clear that there are a number of potentially effective 
non antibiotic treatments which are available for use in treating wound infections caused 
by antibiotic–resistant bacteria and in the case of manuka oil, against the pathogenic 
fungus Trichophyton. Such work provides motivation for the search for other alternative 
approaches to wound control. While considerable effort has been directed towards 
investigating herbal medicine, less attention has been given to other alternatives, 
examples of which include the use of : cod liver oil, chlorophyll, pectin and silicon and 
on-clays (Pugh, 1942). Cod liver has been used during war time to treat infected 
wounds, either by filling wound-cavities, by using soaked dressings by using a mixture 
of 30-50 % in Vaseline. Cod liver oil is particularly effective in killing bacteria when in 
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the oxidized, odorous state, suggesting that vitamin D is the active ingredient.  Highly 
ground silicon has been used to treat wounds and can be given by mouth to cure 
bleeding ulcers (Pugh,1942). In 1906, Stumpf used clay as a paste to treat indolent 
infections; it was shown not only reduce infection, but also deodorized the wound, 
stopped irritation and enhanced healing (Pugh,1942) The clay kaolin has traditionally 
been used to treat cholera in India and elsewhere; in one study mortality rates dropped 
from 44% to near zero following its use (Nadkarni, 1908) ; kaolin and morphine was an 
old  remedy for stomach infections which could be found in the medical cabinets of 
most of UK households until the 1960s. Clearly, all of the above mentioned alternatives 
are worth re-evaluating and following the application of modern scientific approaches 
could be used in the future to treat antibiotic–resistant, indolent infections and even 
perhaps, in the case of clay-based remedies, in the treatment of cholera. 
    Some very new approaches to wound infection control are worth considering and, 
hopefully, might form the basis for further continuation of the research discussed here. 
One such approach is to combine non-antibacterial bioactive drugs with antibiotics in 
order to overcome problems associated with antibiotic resistance. The antibiotic 
minocycline provides a good example of this approach. Minocycline, an antibiotic 
which inhibits protein synthesis in bacteria and to which bacteria developed resistance 
has recently been re-evaluated for its antibacterial activity when combined with other 
previously approved bioactive drugs. Over 1000 compounds were evaluated and 69, 
which had never before been used to treat bacterial infections, improved the 
antibacterial properties of the previously useless antibiotic.  Imodium, the commonly 
used anti-diarrheal drug, also improved the antibacterial activity of minocycline, 
possibly because it disrupts the membrane potential across bacterial membranes, 
allowing the antibiotic to become effective again. 
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  Finally, it is worth considering the prevailing view considering the future 
developments which might solve the problem of antibiotic resistance.  An excellent 
source of such opinion can be found in the review by Zucca and Savio (2010). They 
suggest the following list of scientific developments which may possibly solve this 
problem: antimicrobial peptides, antivirulence factors, inhibitors of pathogen adhesion, 
inhibitors of pathogen colonization, inhibitors of toxin production and secretion, the 
development of antibodies, and finally phage therapy. It is noticeable that no mention is 
made of the use of maggot or honey therapies, despite the fact that these approaches are 
currently being successfully used in the treatment of antibiotic resistant infections.  
There therefore exists a clear mismatch between the dedication of large amounts of 
research time and effort into the study of the theoretical applications of sophisticated 
approaches and the actual currently successful application of honey and maggots in the 
“field” so to speak. It would be obviously desirable to move away from these 
“primitive”, albeit successful methods like apitherapy and maggot therapy, especially 
since these cannot be used in the treatment of systemic infections (intravenous maggot 
therapy is clearly impossible as presumably is intravenous honey therapy (note 
however, that a honey extract called M2 Woelem was developed in the 1950s in 
Germany for use in gynaecology and obstetrics, (De Buman, 1953)). Nevertheless, in 
the absence of effective, more scientific, approaches these two historical approaches 
clearly have their use in practical medicine.  
     In conclusion, the results presented here suggest that there is considerable scope for 
the testing of new approaches to the control of infection caused by bacteria and fungi. 
Alternative approaches such as maggot and honey therapies are already in wide use 
throughout the world and other treatments such as the use of tamarind could be 
introduced almost immediately. In addition, other approaches such as mycotherapy are 
ripe for re-investigation and application in modern medicine. There also remain a range 
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of other potential treatments, such as the use of chlorophyll and clays which have yet to 
be investigated using modern scientific approaches. While these alternatives to 
antibiotics are currently seen as stop gaps for use until newer antibiotics, or other 
approaches to disease control arrive, it may be that they will remain with us for a long 
time yet and may even form the centre-point of antimicrobial therapy for decades to 
come. 
7.2 SUGGESTIONS FOR FUTURE WORK 
 
1) It would obviously be desirable to conduct clinical trials to determine the 
effectiveness of tamarind paste in the treatment of indolent infections and wounds. Such 
work would require some form of collaboration with medical practitioners who have 
access to patients having these wounds.  Interestingly, the case of Fleming following his 
discovery of penicillin comes to mind once again, since his ability to demonstrate the 
effectiveness of un-purified penicillin filtrates was hindered by him not having access to 
a sufficient number of patients.  
 
2) It is desirable that the active ingredient present in maggot gasses and volatiles be 
determined to see if this could be used in wound therapy. Again collaboration, this time 
with an organic chemist, would be desirable. 
 
3) An investigation could be made of other larvae to determine if these exhibit 
potentially useful antibacterial properties examples of larvae currently studied in this 
laboratory include those of the black soldier fly and larvae of the Waxworm moth. 
 
4) Finally, it would be of interest to conduct studies on the potential antibacterial agents 
mentioned above, namely chlorophyll, silicon compounds (including clays) and olive 
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oil, as well as other materials which have been used in history and/ or folklore to treat 
wounds infected with bacteria. 
5) There are a number of other examples in the literature of biotherapy which may be 
worth re-examining. One approach which has not been emphasised here is the use of so-
called bacteriotherapy, i.e. the use of living bacteria to treat wounds infected with 
bacteria or fungi; for example, living cultures of Lactobacillus have been used to 
control bacterial infections in wounds (Peral et al., 2009). 
151 
 
8 References    
 
Abd-El Aal, A., El-Hadidy, M., El-Mashad, N. and El-Sebaie, A. (2007). 
Antimicrobial effect of bee honey in comparison to antibiotics on organisms 
isolated from infected burns. Annals of Burns and Fire Disasters 20: 83-88. 
Abubakar, M., Yerima, M., Zahriya, A. and Ukwuani, A. (2010). Acute toxicity and 
antifungal studies of ethanolic leaves, stem and pulp extract of Tamarindus 
indica. Research Journal of Pharmaceutical, Biological and Chemical Sciences 
1: 104-111. 
Adams, C. J., Manley-Harris, M. and Molan, P. C. (2009). The origin of 
methylglyoxal in New Zealand manuka (Leptospermum scoparium) honey. 
Carbohydrate Research 344: 1050-1053. 
Adebolu, T. (2005). Effect of natural honey on local isolates of diarrhea-causing 
bacteria in southwestern Nigeria. African Journal of Biotechnology 4: 1172-
1174. 
Akujobi, C. And Njoku, H. (2010). Bioassay for the determination of microbial 
sensitivity to Nigerian Honey. Global Journal of Pharmacology 4: 36-40. 
Al-Jabri, A., Nzeako, B., Al Mahrooqi, Z., Al Naqdy, A. and Nsanze, H. (2003). In 
vitro antibacterial activity of Omani and African honey. British Journal of 
Biomedical Science 60: 1-4. 
Al-Waili, N., Akmal, M., Al-waili, F., Salomm, K. and Ali, A. (2005). The 
antimicrobial potential of honey from United Arab Emirates on some microbial 
isolates. Medical Science Monitor 11.433-438. 
Al-Waili, N. and Saloom, K. (1999). Effects of topical honey on post-operative wound 
infections due to gram positive and gram negative bacteria following caesarean 
sections and hysterectomies. European Journal of Medical Research 4: 126-130. 
152 
 
Al-Waili, N. S. (2004). Topical honey application vs. acyclovir for the treatment of 
recurrent herpes simplex lesions. Medical Science Monitor: International 
Medical Journal of Experimental and Clinical Research 10: 94-98. 
Al Somal, N., Coley, K., Molan, P. and Hancock, B. (1994). Susceptibility of 
Helicobacter pylori to the antibacterial activity of manuka honey. Journal of the 
Royal Society of Medicine 87: 9-12. 
Alanis, A. (2005). Resistance to antibiotics: are we in the post-antibiotic era? Archives 
of Medical Research 36: 697-705. 
Allen, K. L., Molan, P. C. and Reid, G. M. (1991). A survey of the antibacterial 
activity of some New Zealand honeys. Journal of Pharmacy and Pharmacology 
43: 817-822. 
Aloush, V., Navon-Venezia, S., Seigman-Igra, Y., Cabili, S. and Carmeli, Y. (2006). 
Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. 
Antimicrobial Agents and Chemotherapy 50: 43-48. 
Andersen, A. S., Sandvang, D., Schnorr, K. M., Kruse, T., Neve, S., Joergensen, B., 
Karlsmark, T. and Krogfelt, K. A. (2010). A novel approach to the 
antimicrobial activity of maggot debridement therapy. Journal of Antimicrobial 
Chemotherapy 65: 1646-1655. 
Andrews, J. M. (2001). Determination of minimum inhibitory concentrations. Journal 
of Antimicrobial Chemotherapy 48 (suppl 1) : 5-16. 
Angelotti, R., Hall, H. E., Foter, M. J. and Lewis, K. H. (1962). Quantitation of 
Clostridium perfringens in foods. Applied Microbiology 10: 193-199. 
Arasu, M. V., Duraipandiyan, V., Agastian, P. and Ignacimuthu, S. (2008). 
Antimicrobial activity of Streptomyces spp. ERI-26 recovered from Western 
Ghats of Tamil Nadu. Journal de Mycologie Médicale / Journal of Medical 
Mycology 18: 147-153. 
153 
 
Arora, S. and Baptista, C. (2010). Antibacterial activity of Lucilia cuprina maggot 
aaaaaaaaextracts and its extraction techniques. International Journal of Integrative 
aaaaa   Biology 9:43-48. 
Asadi-Pooya, A., Pnjehshahin, M. and Beheshti, S.(2003) The antimycobacterial 
effect of honey: an in vitro study. Rivista di biologia 96: 491-496. 
Atrott, J. and Henle, T. (2009). Methylglyoxal in Manuka Honey- Correlation with 
Antibacterial Properties. Czech Journal of Food Science 27: 163-166. 
Aunpad, R. and Na-Bangchang, K. (2007). Pumilicin 4, A novel bacteriocin with 
anti-MRSA and anti-VRE activity produced by newly isolated bacteria Bacillus 
pumilus strain WAPB4. Current Microbiology 55: 308-313. 
Baltrusaityte, V. V., P. R. Ceksteryte, V (2007). Antibacterial activity of honey and 
beebread of different origin against S. aureus and S. epidermidis. Food 
Technology and Biotechnology 45: 201-208. 
Banerjee, S., Devaraja, T., Shariff, M. and Yusoff, F. (2007). Comparison of four 
antibiotics with indigenous marine Bacillus spp. in controlling pathogenic 
bacteria from shrimp and artemia. Journal of Fish Diseases 30: 383-389. 
Barlow, A. (1963). Nalidixic acid in infections of urinary tract. British Medical Journal 
2: 1308-1310. 
Basson, N. J. and Grobler, S. R. (2008). Antimicrobial activity of two South African 
honeys produced from indigenous Leucospermum cordifolium and Erica species 
on selected micro-organisms. BMC Complementary and Alternative Medicine 8: 
41-45. 
Bataineh, H. (2006). Resistance of Staphylococcus aureus to vancomycin in Zarqa, 
Jordan. Pakistan Journal of Medical Sciences  22: 144-148. 
154 
 
Bauer, A. W., Kirby, W. M., Sherris, J. C. and Turck, M. (1966). Antibiotic 
susceptibility testing by a standardized single disk method. American Journal of 
Clinical Pathology  45: 493-496. 
Becker, W., Cioffi Jr, W., McManus, A., Kim, S., McManus, W., Mason, A. and 
Pruitt Jr, B. (1991). Fungal burn wound infection. A 10-year experience. 
Archives of Surgery  126: 44. 
Begg, E. J. and Barclay, M. L. (1995). Aminoglycosides--50 years on. British Journal 
of Clinical Pharmacology 39: 597-603. 
Bell, S. G. (2007). The therapeutic use of honey. Neonatal Network: The Journal of 
11111111Neonatal Nursing 26: 247-251. 
Beretta, B., Gaiaschi, A., Galli, C. L. and Restani, P. (2000). Patulin in apple-based 
foods: occurrence and safety evaluation. Food Additives and Contaminants: 
Part A 17: 399-406. 
Bexfield, A., Nigam, Y., Thomas, S. and Ratcliffe, N. A. (2004). Detection and partial 
characterisation of two antibacterial factors from the excretions/secretions of the 
medicinal maggot Lucilia sericata and their activity against methicillin-resistant 
Staphylococcus aureus (MRSA). Microbes Infection 6: 1297-1304. 
Bianco, M. I., Lúquez, C., de Jong, L. I. T. and Fernández, R. A. (2008). Presence of 
Clostridium botulinum spores in Matricaria chamomilla (chamomile) and its 
relationship with infant botulism. International Journal of Food Microbiology 
121: 357-360. 
Biao, P. (1994). A  Study The  Nutrient  Composition Of The Tamarind Pulp. Journal 
Of  Sichuan ICHUAN Agricultural University 4:110-115. 
Blake, F. A. S., Abromeit, N., Bubenheim, M., Li, L. and Schmelzle, R. (2007). The 
biosurgical wound debridement: Experimental investigation of efficiency and 
practicability. Wound Repair and Regeneration 15: 756-761. 
155 
 
Boehm, S. and Kruis, W. (2006). Probiotics. Annals of the New York Academy of 
Sciences 1072: 339-350. 
Bokhari, F. M. (2009). Antifungal activity of some medicinal plants used in Jeddah, 
Saudi Arabia. Mycopath 7: 51-57. 
Borak, T. (2008). Maggot debridement. Surgical Technologist  5:553-555 
Bottone, E. J. and Peluso, R. W. (2003). Production by Bacillus pumilus (MSH) of an 
antifungal compound that is active against Mucoraceae and Aspergillus species: 
preliminary report. Journal  Medical Microbiolgy 52: 69-74. 
Bowler, P., Duerden, B. and Armstrong, D. (2001). Wound microbiology and 
associated approaches to wound management. Clinical Microbiology Reviews 
14: 244-249. 
Bowler, P. G. (2002). Wound pathophysiology, infection and therapeutic options. 
Annals of Medicine 34: 419-427. 
Boyce, J. M., Cookson, B., Christiansen, K., Hori, S., Vuopio-Varkila, J., Kocagöz, 
................S., Öztop, A. Y., Vandenbroucke-Grauls, C. M. J. E., Harbarth, S. and 
................Pittet, D. (2005). Meticillin-resistant Staphylococcus aureus. The Lancet 
...............Infectious Diseases 5(10): 653-663. 
Brasch, J. and Graser, Y. (2005). Trichophyton eboreum sp. nov. isolated from human 
skin. Journal of Clinical Microbiology 43: 5230-5237. 
Brown, A. (1987). Discovery and development of new 3-lactam antibiotics. Pure 
Applied Chemistry 59: 475-484.  
Brumfitt, W. and Hamilton-Miller, J. (1988). The changing face of chemotherapy. 
Postgraduate Medical Journal 64: 552-558. 
Bunkis, J., Gherini, S. and Walton, R. L. (1985). Maggot therapy revisited. Western 
Journal of Medicine 142: 554. 
156 
 
Carr, A. C. (1998). Therapeutic Properties of New Zealand and Australian Tea Trees. 
New Zealand Pharmacy 18. Published online in December 1998.  
Cetinkaya, Y., Falk, P. and Mayhall, C. (2000). Vancomycin-resistant enterococci. 
Clinical Microbiology Reviews 13: 686-707. 
Chan, D. C., Fong, D. H., Leung, J. Y., Patil, N. G. and Leung, G. K. (2007). 
Maggot debridement therapy in chronic wound care. Hong Kong Medical  
Journal 13: 382-386. 
Chernysh, S., Kim, S., Bekker, G., Pleskach, V., Filatova, N., Anikin, V., Platonov, 
V. and Bulet, P. (2002). Antiviral and antitumor peptides from insects. 
Proceedings of the National Academy of Sciences of the United States of 
America 99: 12628-12632. 
Chopra, I. and Roberts, M. (2001). Tetracycline antibiotics: mode of action, 
applications, molecular biology, and epidemiology of bacterial resistance. 
Microbiology and Molecular Biology Reviews 65: 232-260. 
Church, J. C. (2005). Re: Bleeding complications in patients treated with maggot 
debridement therapy, Steenvoorde P and Oskam J,  2005; 4:57-58. International  
Journal  Low Extrem Wounds 4: 57-58. 
Cohen, M. L. (1992). Epidemiology of drug resistance: Implications for a post-
antimicrobial era. Science 257: 1050-1055. 
Cooper, B. S., Stone, S. P., Kibbler, C. C., Cookson, B. D., Roberts, J. A., Medley, 
G. F., Duckworth, G. J., Lai, R. and Ebrahim, S. (2003). Systematic review 
of isolation policies in the hospital management of methicillin-resistant 
Staphylococcus aureus: a review of the literature with epidemiological and 
economic modelling. Health Technology Assessment 7: 1-194. 
157 
 
Cooper, R. (2004). A review of the evidence for the use of topical antimicrobial agents 
in wound care. World Wide Wounds. Published onlime on Febreuary 2004. 
ONLINE REF 
Cooper, R. (2007). Honey in wound care: antibacterial properties. GMS 
Krankenhaushygiene Interdisziplinar 2. Published online on December  2007. 
ONLINE REF 
Cooper, R.(2008). Using honey to inhibit wound pathogens. Nursing Times 104: 46-48. 
Cooper, R., Halas, E. and Molan, P. (2002). The efficacy of honey in inhibiting 
strains of Pseudomonas aeruginosa from infected burns. The Journal of Burn 
Care and Rehabilitation 23: 366-370. 
Cooper, R., Molan, P. and Harding, K. (1999). Antibacterial activity of honey against 
aaaaaaaastrains of Staphylococcus aureus from infected wounds. Journal of the Royal 
aaaaaaaSociety of Medicine 92: 283-285. 
Cooper, R., Molan, P. and Harding, K. (2002). The sensitivity to honey of gram 
positive cocci of clinical significance isolated from wounds. Journal of Applied 
Microbiology 93: 857-863. 
Croft, A., D'antoni, A. and Terzulli, S. (2007). Update on the antibacterial resistance 
crisis. Medical Science Monitor 13: 103-118. 
D'Arcy, C. J. and Nault, L. R. (1982). Insect transmission of plant viruses and 
mycoplasma-like and rickettsia-like organisms. Plant Disease 66: 99-171. 
Davis, C. (2005). The use of Australian honey in moist wound management. A report 
for the Rural Industries Research and Development Corporation. Kingston, 
Australia. Published online in October 2005 . 
De Buman, M. (1953). M-2 WOELM, a honey extract, in gynecology and obstetrics. 
Praxis 42: 282-288. 
158 
 
De Centorbi, O., Satorres, S., Alcaraz, L., Centorbi, H. and Fernandez, R. (1997). 
Detection of Clostridium botulinum spores in honey. Revista Argentina de 
Microbiología 29: 147-151. 
Delmas, C., Vidon, D. J. M. and Sebald, M. (1994). Survey of honey for Clostridium 
botulinum spores in eastern France. Food microbiology 11: 515-518. 
Dembry, L., Farrington, J. and Andriole, V. (1999). Fluoroquinolone antibiotics: 
adverse effects and safety profiles. Infectious Diseases in Clinical Practice 8: 
421-428. 
Deshmukh, S. (2004). Isolation of dermatophytes and other keratinophilic fungi from 
the vicinity of salt pan soils of Mumbai, India. Mycopathologia 157: 265-267. 
Deurenberg, R. H. and Stobberingh, E. E. (2008). The evolution of Staphylococcus 
aureus. Infection, Genetics and Evolution 8: 747-763. 
Devauchelle, G., Vago, C., Giannotti, J. and Quiot, J. (1970). Mycoplasma-like 
organisms in Coleóptera. Entomophaga 1: 457-461. 
Dodds, K. L. (1993). Clostridium botulinum in foods. Clostridium botulinum: Ecology 
and Control in Foods: 53–68. 
Domagk, G. (1957). Twenty-five years of sulfonamide therapy Annals of the New York 
Academy of Sciences 69: 380-384. 
Doughari, J. (2006). Antimicrobial activity of Tamarindus indica Linn. Tropical 
Journal of Pharmaceutical Research  5: 597-603. 
Douglas, M. H., van Klink, J. W., Smallfield, B. M., Perry, N. B., Anderson, R. E., 
Johnstone, P. and Weavers, R. T. (2004). Essential oils from New Zealand 
manuka: triketone and other chemotypes of Leptospermum scoparium. 
Phytochemistry 65: 1255-1264. 
Edris, A. E. (2007). Pharmaceutical and therapeutic potentials of essential oils and their 
individual volatile constituents: a review. Phytotherapy Research 21: 308-323. 
159 
 
El-Sukhon, S., Abu-Harfeil, N. andSallal, A. (1994). Effect of honey on bacterial 
growth and spore germination. Journal of Food Protection  57: 918-920. 
Ertel, A., Eng, R. and Smith, S. M. (1991). The differential effect of cigarette smoke 
on the growth of bacteria found in humans. Chest 100: 628-630. 
Feder, J. (1986). Chloramphenicol: what we have learned in the last decade. Southern 
............Medical Journal 79: 1129. 
Feng, P., Weagant, S. and Grant, M. (2002). Enumeration of Escherichia coli and the 
coliform bacteria. Ch. 4. Bacteriological analytical manual. Available at www. 
cfsan. fda. gov/~ ebam/bam-4. html (verified 1 Aug. 2006). US Food and Drug 
Admin., Washington, DC. 
Finch, R. (2003). Antibiotic and chemotherapy: anti-infective agents and their use in 
therapy. Churchill Livingstone. 
Fleischmann, W., Grassberger, M. and Sherman, R. (2004). Maggot Therapy: a 
Handbook of Maggot-assisted Wound Healing. George Thieme Verlag. 
Forlenza, S. W., Newman, M. G., Horikoshi, A. L. and Blachman, U. (1981). 
Antimicrobial susceptibility of Capnocytophaga. Antimicrob Agents Chemother 
19: 144-146. 
Fuller, R. (1992). History and development of probiotics. Probiotics: The scientific 
............basis 1992: 1-8. 
Garg, A. and Miiller, J. (1992). Inhibition of growth of dermatophytes by Indian hair 
oils. Mycoses 35: 363-369. 
Gethin, G. and Cowman, S. (2005). Case series of use of Manuka honey in leg 
ulceration. International Wound Journal 2: 10-15. 
Gilmore, D., Link, L. and Fell, R. (2010). Analysis of bacterial pathogens in Virginia 
honeys. Science Of Bee Culture 2: 11-14 
160 
 
Gimeno, A. and Martins, M. L. (1983). Rapid thin layer chromatographic 
determination of patulin, citrinin, and aflatoxin in apples and pears, and their 
juices and jams.  Journal of the Association of Official Analytical Chemists 66: 
85-91. 
Gionchetti, P., Rizzello, F., Lammers, K. M., Morselli, C., Sollazzi, L., Davies, S., 
Tambasco, R., Calabrese, C. and Campieri, M. (2006). Antibiotics and 
probiotics in treatment of inflammatory bowel. World Journal Gastroenterol 12: 
3306-3313. 
Globale, P. (2010). Effect Of  Tamarindus indica Linn. Against Isolated Goat  Tracheal  
And Guinea Pig Ilium Preperation. Pharmacie Globale 2:1-3.  
Gold, H. and Moellering, R. (1996). Antimicrobial-drug resistance. New England 
Journal of Medicine 335: 1445-1453. 
Goldway, M., Teff, D., Schmidt, R., Oppenheim, A. and Koltin, Y. (1995). 
Multidrug resistance in Candida albicans: disruption of the BENr gene. 
Antimicrobial Agents and Chemotherapy 39: 422-426. 
Goulet, M., Dular, R., Tully, J. G., Billowes, G. and Kasatiya, S. (1995). Isolation of 
Mycoplasma pneumoniae from the human urogenital tract. Journal of Clinical 
Microbiology 33: 2823-2825. 
Graninger, M., Grassberger, M., Galehr, E., Huemer, F., Gruschina, E., Minar, E. 
and Graninger, W. (2002). Biosurgical debridement facilitates healing of 
chronic skin ulcers. Archives of Internal Medicine 162: 1906-1907. 
Gräser, Y., Scott, J. and Summerbell, R. (2008). The new species concept in 
dermatophytes—a polyphasic approach. Mycopathologia 166: 239-256. 
Greenwood, D. (1997). Medical Microbiology. Churchill Livingstone/Elsevier. 
161 
 
Guyot, A., Barrett, S., Threlfall, E., Hampton, M. and Cheasty, T. (1999). 
Molecular epidemiology of multi-resistant Escherichia coli. Journal of Hospital 
Infection 43: 39-48. 
Hammond, S. and Lambert, P. (1978). Antibiotics and Antimicrobial Action. Edward 
Arnold. 
Hawkey, P. (1998). The origins and molecular basis of antibiotic resistance. BMJ: 
British Medical Journal 317: 657-660. 
Henriques, A., Burton, N. and Cooper, R. (2005). Antibacterial activity of selected 
Portuguese honeys. Journal of Apicultural Research 44: 119-123. 
Hiramatsu, K. (2001). Vancomycin-resistant Staphylococcus aureus: a new model of 
antibiotic resistance. Lancet Infectious Diseases 1: 147-155. 
Holden, M. T. G., Feil, E. J., Lindsay, J. A., Peacock, S. J., Day, N. P. J., Enright, 
M. C., Foster, T. J., Moore, C. E., Hurst, L. and Atkin, R. (2004). Complete 
genomes of two clinical Staphylococcus aureus strains: evidence for the rapid 
evolution of virulence and drug resistance. Proceedings of the National 
Academy of Sciences of the United States of America 101: 9786-9791. 
Horvath, E. E., Murray, C. K., Vaughan, G. M., Chung, K. K., Hospenthal, D. R., 
Wade, C. E., Holcomb, J. B., Wolf, S. E., Mason Jr, A. D. and Cancio, L. C. 
(2007). Fungal wound infection (not colonization) is independently associated 
with mortality in burn patients. Annals of Surgery 245: 978-785. 
Huberman, L., Gollop, N., Mumcuoglu, K., Block, C. and Galun, R. (2007). 
Antibacterial properties of whole body extracts and haemolymph of Lucilia 
sericata maggots. Journal Wound Care 16: 123-127. 
Irish, J., Carter, D. A., Shokohi, T. and Blair, S. E. (2006). Honey has an antifungal 
effect against Candida species. Medical Mycology 44: 289-291. 
162 
 
Jagusztyn-Krynicka, E. K. and Wyszynska, A. (2008). The decline of antibiotic era- 
New approaches for antibacterial drug discovery. Polish Journal of 
Microbiology 57: 91-99. 
Jaklic, D., Lapanje, A., Zupancic, K., Smrke, D. and Gunde-Cimerman, N. (2008). 
Selective antimicrobial activity of maggots against pathogenic bacteria. Journal 
Medical Microbiology 57: 617-625. 
Jarczyk, G., Jackowski, M., Szpila, K., Boszek, G., Kapelaty, S., Skwarek, E. and 
Michalak, M. (2008). Biosurgical Treatment Results in Patients with Chronic 
Crural and Foot Ulcerations. Polish Journal of Surgery 80: 190-201. 
Joerger, R. (2003). Alternatives to antibiotics: bacteriocins, antimicrobial peptides and 
bacteriophages. Poultry Science 82: 640-647. 
Jones, R. (2001). Honey and healing through the ages. Honey and Healing 1: 1–4. 
Jukema, G. N., Wai, S. W., Lagendijk, E. L., Van Dissel, J. T., Bloemberg, G. V. 
and Nibbering, P. H. (2008). Maggot excretions/secretions are differentially 
effective against biofilms of Staphylococcus aureus and Pseudomonas 
aeruginosa. Journal of Antimicrobial Chemotherapy 61: 117–122. 
Julio, E. A., Renato, P. R., Imilci, U. L., Miladis, C. P., Jesús, R. A. and Irina, L. J. 
(2010). Antimicrobial activity of extracts from Tamarindus indica L. leaves. 
Pharmacognosy Magazine 6: 242-247. 
Karaca, N. and Nedret Ko , A. (2004). In vitro susceptibility testing of dermatophytes: 
comparison of disk diffusion and reference broth dilution methods. Diagnostic 
Microbiology and Infectious Disease 48: 259-264. 
Kerridge, A., Lappin-Scott, H. and Stevens, J. (2005). Antibacterial properties of 
larval secretions of the blowfly, Lucilia sericata. Medical and Veterinary 
Entomology 19: 333-337. 
163 
 
Khanzada, S. K., Shaikh, W., Sofia, S., Kazi, T., Usmanghani, K. and  Amina, A. 
(2008). Chemical constituents of Tamarindus indica L. Medicinal plant in 
Sindh. Pakistan Journal of Botany 40: 2553-2559. 
Klein, E., Smith, D. and Laxminarayan, R. (2007). Hospitalizations and deaths 
caused by methicillin-resistant Staphylococcus aureus, United States, 1999–
2005. Emerging Infectious Diseases 13: 1840-1846. 
Koc, A. N., Silici, S., Ercal, B. D., Kasap, F., Hörmet-Öz, H. T. and Mavus-Buldu, 
H. (2008). Antifungal Activity of Turkish Honey against Candida spp. and 
Trichosporon spp: an in vitro evaluation. Medical Mycology 47: 707-712. 
Koroishi, A. M., Foss, S. R., Cortez, D. A. G., Ueda-Nakamura, T., Nakamura, C. 
V. and Dias Filho, B. P. (2008). In vitro antifungal activity of extracts and 
neolignans from Piper regnellii against dermatophytes. Journal of 
Ethnopharmacology 117: 270-277. 
Küçük, M., KolaylI, S., Karaoglu, S., Ulusoy, E., BaltacI, C. and Candan, F. 
(2007). Biological activities and chemical composition of three honeys of 
different types from Anatolia. Food Chemistry 100: 526-534. 
Kumar, C. (2002). Purification and characterization of a thermostable alkaline protease 
from alkalophilic Bacillus pumilus. Letters in Applied Microbiology 34: 13-17. 
Kuplulu, O., Goncuoglu, M., Ozdemir, H. and Koluman, A. (2006). Incidence of 
Clostridium botulinum spores in honey in Turkey. Food Control 17: 222-224. 
Lakshmipathy, D. T. and Kannabiran, K. (2010). Review on dermatomycosis: 
pathogenesis and treatment.Natural Science 2: 726-731 
Lambert, P. (2005). Bacterial resistance to antibiotics: modified target sites. Advanced 
Drug Delivery Reviews 57: 1471-1485. 
164 
 
Lee, H., Churey, J. J. and Worobo, R. W. (2008). Antimicrobial activity of bacterial 
isolates from different floral sources of honey. International Journal of Food 
Microbiology 126: 240-244. 
Lerch, K., Linde, H. J., Lehn, N. and Grifka, J. (2000). Bacteria ingestion by blowfly 
larvae: an in vitro study. Dermatology 207: 362-366. 
Levy, S. (1997). Antibiotic resistance: an ecological imbalance. Antibiotic resistance: 
origins, evolution, selection and spread 207: Published Online on September 
2007.ONLINE REF 
Levy, S. and Marshall, B. (2004). Antibacterial resistance worldwide: causes, 
challenges and responses. Nature Medicine 10: 122-129. 
Lis Balchin, M., Hart, S. and Deans, S. (2000). Pharmacological and antimicrobial 
studies on different tea tree oils (Melaleuca alternifolia, Leptospermum 
scoparium or Manuka and Kunzea ericoides or Kanuka), originating in Australia 
and New Zealand. Phytotherapy Research 14: 623-629. 
Livermore, D. M. (2000). Antibiotic resistance in staphylococci. International Journal 
of Antimicrobial Agents 16: 3-10. 
Lowy, F. D. (2003). Antimicrobial resistance: the example of Staphylococcus aureus. 
Journal of Clinical Investigation 111: 1265-1273. 
Lyon, B. and Skurray, R. (1987). Antimicrobial resistance of Staphylococcus aureus: 
genetic basis. Microbiology and Molecular Biology Reviews 51: 88-134. 
Maeda, Y., Loughrey, A., Earle, J., Millar, B. C., Rao, J. R., Kearns, A., 
McConville, O., Goldsmith, C. E., Rooney, P. J. and Dooley, J. S. G. (2008). 
Antibacterial activity of honey against community-associated methicillin-
resistant Staphylococcus aureus (CA-MRSA). Complementary Therapies in 
Clinical Practice 14: 77-82. 
 
165 
 
Mavric, E., Wittmann, S., Barth, G. and Henle, T. (2008). Identification and 
..............quantification of methylglyoxal as the dominant antibacterial constituent of 
..............Manuka (Leptospermum scoparium) honeys from New Zealand. Molecular 
..............Nutrition Food Research 52: 483-489. 
Marahier, M., Nakano, M. and Zuber, P. (1993). Regulation of peptide antibiotic 
production in Bacillus. Molecular Microbiology 7: 631-636. 
Margolin, L. and Gialanella, P. (2010). Assessment of the antimicrobial properties of 
maggots. International Wound Journal 7: 202-204. 
Mathews, K. A. and Binnington, A. G. (2002). Wound Management Using Honey. 
Compendium 24: Published online on January 2002.   
Mathur, M., Vidhani, S. and Mehndiratta, P. (2003). Bacteriophage therapy: an 
alternative to conventional antibiotics. Journal of the Association of Physicians 
of India 51: 593-596. 
Mathur, S. and Singh, R. (2005). Antibiotic resistance in food lactic acid bacteria--a 
review. International Journal of Food Microbiology 105: 281-295. 
Mazel, D. and Davies, J. (1999). Antibiotic resistance in microbes. Cellular and 
Molecular Life Sciences 56: 742-754. 
McGowan Jr, J. E. (2001). Economic impact of antimicrobial resistance. Emerging 
Infectious Diseases 7: 286-292. 
McKenna, J. (1998). Natural alternatives to antibiotics. Avery Pub. Group. 
Molan, P. (1997). Honey as an antimicrobial agent. Bee Products: properties, 
Applications, and Apitherapy 1: 27-37. 
Molan, P. and Allen, K. (1996). The effect of gamma-irradiation on the antibacterial 
activity of honey.Journal of Pharmacy and Pharmacology 48: 1206-1211. 
Molan, P. C. (1992a). The antibacterial activity of honey: 1. The nature of the 
antibacterial activity Bee World 73:5-28. 
166 
 
Molan, P. C. (1992b). The antibacterial activity of honey: 2. Variation in the potency of 
the antibacterial activity. Bee World 73: 59-76. 
Molan, P. C. (1999a). The role of honey in the management of wounds. Journal Wound 
Care 8: 423-426. 
Molan, P. C. (1999b). Why honey is effective as a medicine.2. The scientific 
explanation of its effects. New Zealand BeeKeeper 82: 22-40. 
Molan, P. C. (2001). Potential of honey in the treatment of wounds and burns. 
American Journal of Clinical Dermatology 2: 13-19. 
Molan, P. C. (2004). Clinical usage of honey as a wound dressing: an update. Journal 
Wound Care 13: 353-356. 
Molan, P. C. (2006). Using honey in wound care. International Journal of Clinical 
Aromatherapy France 3: 21-24. 
Morikawa, M., Ito, M. and Imanaka, T. (1992). Isolation of a new surfactin producer 
Bacillus pumilus A-1, and cloning and nucleotide sequence of the regulator 
gene, psf-1. Journal of Fermentation and Bioengineering 74: 255-261. 
Msadek, T. (1999). When the going gets tough: survival strategies and environmental 
signaling networks in Bacillus subtilis. Trends in Microbiology 7: 201-207. 
Mulvey, M. and Simor, A. (2009). Antimicrobial resistance in hospitals: How 
concerned should we be? Canadian Medical Association Journal 180: 408-415. 
Munimbazi, C. and Bullerman, L. (1998). Isolation and partial characterization of 
antifungal metabolites of Bacillus pumilus. Journal of Applied Microbiology 84: 
959-968. 
Murray, B. (1990). The life and times of the Enterococcus. Clinical Microbiology 
Reviews 3: 46-65. 
Murray, C. K., Loo, F. L., Hospenthal, D. R., Cancio, L. C., Jones, J. A., Kim, S. 
H., Holcomb, J. B., Wade, C. E. and Wolf, S. E. (2008). Incidence of systemic 
167 
 
fungal infection and related mortality following severe burns. Burns 34: 1108-
1112. 
Museux, K., Boretti, F. S., Willi, B., Riond, B., Hoelzle, K., Hoelzle, L. E., 
Wittenbrink, M. M., Tasker, S., Wengi, N. and Reusch, C. E. (2009). In vivo 
transmission studies of ‘Candidatus Mycoplasma turicensis’ in the domestic cat. 
Veterinary Research 40:45-59. 
Nadkarni, K. (1908). Indian Materia Medica, Vol. 2. Popular Prakashan, Bombay, 
India. 
Namias, N., Varela, E. J., Varas, R. P., Quintana, O. and Ward, G. C. (2000). 
Biodebridement: a case report of maggot therapy for limb salvage after fourth-
degree burns. Journal of Burn Care and Research 21: 254-257. 
Nations, J. and Walsh, T. (2006). Drug-resistant tuberculosis. Disease A Month 52: 
435-440. 
Nicolle, L. (2006). Beyond Antibiotics? The Canadian Journal of Infectious Diseases 
and Medical Microbiology 17: 265-266. 
Niederman, M. S. (2001). Impact of antibiotic resistance on clinical outcomes and the 
cost of care. Critical Care Medicine 29: N114-120. 
Nwodo, U., Ngene, A., Iroegbu, C. and GC, O. (2010). Effects of fractionation on 
antibacterial activity of crude extracts of Tamarindus indica. African Journal of 
Biotechnology 9: 7108-7113. 
Oduori, M. A., Lipa, J. J. and Gasparich, G. E. (2005). Spiroplasma leucomae sp. 
nov., isolated in Poland from white satin moth (Leucoma salicis L.) larvae. 
International Journal of Systematic and Evolutionary Microbiology 55: 2447-
2450. 
168 
 
Olaitan, P. B., Adeleke, O. E. and Ola, I. O. (2007). Honey: a reservoir for 
microorganisms and an inhibitory agent for microbes. African Health Sciences 
7: 159-165. 
Ouwehand, A. C., Salminen, S. and Isolauri, E. (2002). Probiotics: an overview of 
beneficial effects. Antonie Van Leeuwenhoek 82: 279-289. 
 
Panbangred, W., Shinmyo, A., Kinoshita, S. &Okada, H. (1983). Purification and 
.............properties of endoxylanase produced by Bacillus pumilus. Agricultural and 
.............Biological Chemistry 47: 957-963. 
Paramasivan, C. (1998). An overview on drug resistant tuberculosis in India. Indian 
Journal of Tuberculosis 45: 73-82. 
Peral, M. C., Huaman Martinez, M. A. and Valdez, J. C. (2009). Bacteriotherapy 
with Lactobacillus plantarum in burns. International Wound Journal 6: 73-81. 
Pereira, P. T., Arrabaça, J. D. andAmaral-Collaço, M. T. (1996). Isolation, selection 
and characterization of a cyanide-degrading fungus from an industrial effluent. 
International Biodeterioration & Biodegradation 37: 45-52. 
Postmes, T. (2001). The treatment of burns and other wounds with honey. Honey and 
Healing, ed. P. Munn and R Jones. International Bee Research Association, 
Cardiff, UK. 
Postmes, T., Bosch, M., Dutrieux, R., Van Baare, J. and Hoekstra, M. (1996). 
Speeding up the healing of burns with honey. Mizrahi and Lensky, Plenum 
Press, New York: 57-65. 
Postmes, T., Van Den Bogaard, A. and Hazen, M. (1995). The sterilization of honey 
with cobalt 60 gamma radiation: a study of honey spiked with spores of 
Clostridium botulinum and Bacillus subtilis. Experientia 51: 986-989. 
169 
 
Prabuseenivasan, S., Jayakumar, M. and Ignacimuthu, S. (2006). In vitro 
antibacterial activity of some plant essential oils. BMC Complementary and 
Alternative Medicine 6: 39-47. 
Projan, S. J. and Shlaes, D. M. (2004). Antibacterial drug discovery: is it all downhill 
from here? Clinical Microbiology and Infection 10: 18-22. 
Pugh, W. S. (1942). War Medicine: A Symposium. Taylor and Francis. 
Ray, G. and Box, E. (1950). Adsorption of gases on activated charcoal. Industrial & 
Engineering Chemistry 42: 1315-1318. 
Rode, H., Vale, I. D. and Millar, A. J. W. (2008). Burn wound infection. Continuing 
Medical Education 26: 440-444. 
Sahalan, A. Z., Omar, B. and Yusirah, A. (2007). Antibacterial activity of extracted 
hemolymph from larvae and pupae of local fly species, Musca domestica and 
Chrysomya megacephala. Journal Sains Kesihatan Malaysia 4: 1-11. 
Salyers, A. and Amabile-Cuevas, C. (1997). Why are antibiotic resistance genes so 
resistant to elimination? Antimicrobial Agents and Chemotherapy 41: 2321-
2325. 
Schocken Iturrino, R. P., Carneiro, M. C., Kato, E., Sorbara, J. O. B., Rossi, O. D. 
and Gerbasi, L. E. R. (1999). Study of the presence of the spores of 
Clostridium botulinum in honey in Brazil. FEMS Immunology & Medical 
Microbiology 24: 379-382. 
Schwarz, S. and Chaslus-Dancla, E. (2001). Use of antimicrobials in veterinary 
medicine and mechanisms of resistance. Veterinary Research 32: 201-225. 
Scott, P. M., Lawrence, J. W. and van Walbeek, W. (1970). Detection of mycotoxins 
by thin-layer chromatography: application to screening of fungal extracts. 
Applied Microbiology 20: 839-842. 
170 
 
Scott, P. M. and Somers, E. (1968). Stability of patulin and penicillic acid in fruit 
juices and flour. Journal of Agricultural and Food Chemistry 16: 483-485. 
Sealby, N. (2004). The use of maggot therapy in the treatment of a malignant foot 
wound. British Journal of Community Nursing 9: S16-19. 
Senses-Ergul, S. and Ozbas, Z. Y. (2006). Characterization of the yeast flora present 
in some Turkish high-sugar products.The Journal of General and 
Applied Microbiology 52: 99-106. 
Shah, N., Wright, A., Bai, G., Barrera, L., Boulahbal, F., Martín-Casabona, N., 
Drobniewski, F., Gilpin, C., Havelková, M. and Lepe, R. (2007). Worldwide 
emergence of extensively drug-resistant tuberculosis. Emerging Infectious 
Diseases 13: 380-387. 
Shelburne, C. E., An, F. Y., Dholpe, V., Ramamoorthy, A., Lopatin, D. E. and 
Lantz, M. S. (2007). The spectrum of antimicrobial activity of the bacteriocin 
subtilosin A. Journal of Antimicrobial Chemotherapy 59: 297-300. 
Sherlock, O., Dolan, A., Athman, R., Power, A., Gethin, G., Cowman, S. and 
Humphreys, H. (2010). Comparison of the antimicrobial activity of Ulmo 
honey from Chile and Manuka honey against methicillin-resistant 
Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. BMC 
Complementary and Alternative Medicine 10: 47-55. 
Sherman, R. A. (2003). Maggot therapy for treating diabetic foot ulcers unresponsive 
to conventional therapy. Diabetes Care 26: 446-451. 
Sherman, R. A. (2009). Maggot therapy takes us back to the future of wound care: new 
and improved maggot therapy for the 21st century. Journal of Diabetes Science 
and Technology 3: 336-344. 
171 
 
Sherman, R. A., Hall, M. J. and Thomas, S. (2000). Medicinal maggots: an ancient 
remedy for some contemporary afflictions.Annual Review of Entomology 45: 55-
81. 
Shin, H. (2005). Carbohydrate composition of honey from different floral sources and 
their influence on growth of selected intestinal bacteria: An in vitro comparison. 
Food Research International 38: 721-728. 
Simon, A., Traynor, K., Santos, K., Blaser, G., Bode, U. and Molan, P. (2009). 
Medical Honey for Wound Care--Still the'Latest Resort'? Evidence-based 
Complementary and Alternative Medicine 6: 165-173. 
Sipahi, O. R. (2008). Economics of antibiotic resistance. Expert review of Anti-infective 
Therapy 6: 523-539. 
Smith, J. K., Burns, S., Cunningham, S., Freeman, J., McLellan, A. and 
McWilliam, K. (2010). The hazards of honey: infantile botulism. British 
Medical Journal Case Reports . Published online in May 2010. 
Snow, M. and Manley-Harris, M. (2004). On the nature of non-peroxide antibacterial 
activity in New Zealand manuka honey. Food Chemistry 84: 145-147. 
Snowdon, J. A. and Cliver, D. O. (1996). Microorganisms in honey. International  
Journal of  Food Microbiology 31: 1-26. 
Spellberg, B., Guidos, R., Gilbert, D., Bradley, J., Boucher, H., Scheld, W., 
Bartlett, J. and Edwards Jr, J. (2008). The epidemic of antibiotic-resistant 
infections: a call to action for the medical community from the Infectious 
Diseases Society of America. Clinical Infectious Diseases 46: 155-164. 
Steenvoorde, P., Jacobi, C. E. and Oskam, J. (2005). Maggot debridement therapy: 
free-range or contained? An in-vivo study. Advanced Skin Wound Care 18: 430-
335. 
172 
 
Steenvoorde, P. and Oskam, J. (2005). Use of larval therapy to combat infection after 
breast-conserving surgery. Journal of  Wound Care 14: 212-213. 
Stein, T., Dusterhus, S., Stroh, A. and Entian, K. D. (2004). Subtilosin production by 
two Bacillus subtilis subspecies and variance of the sbo-alb cluster. Applied and 
Environmental Microbiology 70: 2349-2353. 
Stephens, J. M., Schlothauer, R. C., Morris, B. D., Yang, D., Fearnley, L., 
...........Greenwood, D. R. and Loomes, K. M. (2010). Phenolic compounds and 
............methylglyoxal in some New Zealand manuka and kanuka honeys. Food 
..........Chemistry 120: 78-86. 
Subrahmanyam, M. (1994). Honey-impregnated gauze versus amniotic membrane in 
the treatment of burns. Burns 20: 331-333. 
Sulakvelidze, A., Alavidze, Z. and Morris Jr, J. G. (2001). Bacteriophage therapy. 
Antimicrobial Agents and Chemotherapy 45: 649-659. 
Summers, J. and Kaminski, J. (2003). Maggot debridement therapy (MDT) for burn 
wounds. Burns: Journal of the International Society for Burn Injuries 29: 501-
502.  
Summers, W. C. (2001). Bacteriophage therapy. Annual Reviews in Microbiology 55: 
437-451. 
Tadesse, A. and Alem, M. (2006).Medical Bacteriology. University of Gondar. 
............ONLINE REF. 
Takarada, K., Kimizuka, R., Takahashi, N., Honma, K., Okuda, K. and Kato, T. 
(2004). A comparison of the antibacterial efficacies of essential oils against oral 
pathogens. Oral Microbiology and Immunology 19: 61-64. 
Tayade, P., Ghaisas, M., Jagtap, S. andDongre, S. (2009). Anti-asthmatic activity of 
methanolic extract of leaves of Tamarindus Indica Linn. Journal of Pharmacy 
Research 2: 944-947. 
173 
 
Tenover, F. (2006). Mechanisms of antimicrobial resistance in bacteria. American 
Journal of Infection Control 34: S3-S10. 
Theunissen, F., Grobler, S. and Gedalia, I. (2001). The antifungal action of three 
South African honeys on Candida albicans. Apidologie 32: 371-379. 
Thomas, S., Andrews, A., Hay, N. and Bourgoise, S. (1999). The anti-microbial 
activity of maggot secretions: results of a preliminary study. Journal of Tissue 
Viability 9: 127-132. 
Tiwari, H. andSen, M. (2006). Emergence of vancomycin resistant Staphylococcus 
aureus(VRSA) from a tertiary care hospital from northern part of India. BMC 
Infectious Diseases 6(1): 156-162. 
Tolba, O., Earle, J. A. P., Millar, B. C., Rooney, P. J. and Moore, J. E. (2007). 
Speciation of Bacillus spp. in honey produced in Northern Ireland by 
employment of 16S rDNA PCR and automated DNA sequencing techniques. 
World Journal of Microbiology and Biotechnology 23: 1805-1808. 
van Klink, J. W., Larsen, L., Perry, N. B., Weavers, R. T., Cook, G. M., Bremer, P. 
J., MacKenzie, A. D. and Kirikae, T. (2005). Triketones active against 
antibiotic-resistant bacteria: Synthesis, structure-activity relationships, and mode 
of action. Bioorganic and Medicinal Chemistry 13: 6651-6662. 
Vardi, A., Barzilay, Z., Linder, N., Cohen, H., Paret, G. and Barzilai, A. (1998). 
Local application of honey for treatment of neonatal postoperative wound 
infection. Acta Paediatrica 87: 429-432. 
Visavadia, B. G., Honeysett, J. and Danford, M. H. (2008). Manuka honey dressing: 
An effective treatment for chronic wound infections. British Journal of Oral and 
Maxillofacial Surgery 46: 55-56. 
Von Blucher, H. and De Ruiter, E. (1991).Activated charcoal filter layer for gas 
masks. Google patent number 4992084. 
174 
 
Wahdan, H. A. L. (1998). Causes of the antimicrobial activity of honey. Infection 26: 
26-31. 
Wainwright, M. (1987). The history of the therapeutic use of crude penicillin. Medical 
History 31: 41-50. 
 
Wainwright, M. (1988). Maggot therapy--a backwater in the fight against bacterial 
infection. Pharmacy in History 30: 19-26. 
 
Wainwright, M. (1989). Moulds in ancient and more recent medicine. Mycologist 3: 
21-23. 
Wainwright, M. (1990). Miracle Cure: The Story of Antibiotics. Cambridge, 
Blackwell.. 
Wainwright, M. (1998). Living alternatives to antibiotics. SGM Quanterly 25: 128-
129. 
Wainwright, M. (2007). When maggot fumes cured tuberculosis. Microbiologist 8: 33-
35. 
Wainwright, M. (2008). Some highlights in the history of fungi in medicine-A personal 
journey. Fungal Biology Reviews 22: 97-102. 
Wainwright, M., Rally, L. and Ali, T. A. (1992). The scientific basis of mould 
therapy. Mycologist 6: 108-110. 
Waites, K. B. and Talkington, D. F. (2004). Mycoplasma pneumoniae and its role as a 
human pathogen. Clinical Microbiology Reviews 17: 697-728. 
Weber, J. (2005). Community-associated methicillin-resistant Staphylococcus aureus. 
Clinical Infectious Diseases 4: 269-272. 
Weitzman, I. and Summerbell, R. C. (1995). The dermatophytes. Clinical 
Microbiology Reviews 8: 240-259. 
175 
 
Weston, R. J. (2000). The contribution of catalase and other natural products to the 
antibacterial activity of honey: a review. Food Chemistry 71: 235-239. 
Whitaker, I. S., Twine, C., Whitaker, M. J., Welck, M., Brown, C. S. and Shandall, 
A. (2007). Larval therapy from antiquity to the present day: mechanisms of 
action, clinical applications and future potential. Postgraduate  Medical Journal 
83: 409-413. 
White Jr, J. W., Subers, M. H. and Schepartz, A. I. (1963). The identification of 
inhibine, the antibacterial factor in honey, as hydrogen peroxide and its origin in 
a honey glucose-oxidase system. Biochimica et Biophysica Acta 73: 57-70. 
White, T., Holleman, S., Dy, F., Mirels, L. and Stevens, D. (2002). Resistance 
mechanisms in clinical isolates of Candida albicans. Antimicrobial Agents and 
Chemotherapy 46: 1704-1713. 
Wiegand, I., Hilpert, K. and Hancock, R. E. W. (2008). Agar and broth dilution 
methods to determine the minimal inhibitory concentration (MIC) of 
antimicrobial substances. Nature Protocols 3: 163-175. 
Willcox, P. (2000). Drug-resistant tuberculosis. Current Opinion in Pulmonary 
Medicine 6: 198-202. 
Willix, D., Molan, P. and Harfoot, C. (1992). A comparison of the sensitivity of 
wound infecting species of bacteria to the antibacterial activity of manuka honey 
and other honey. Journal of Applied Microbiology 73(5): 388-394. 
Yagi, B. H. and Zurenko, G. E. (2003). An in vitro time-kill assessment of linezolid 
and anaerobic bacteria. Anaerobe 9: 1-3. 
Yan, L., Boyd, K. G., Adams, D. R. and Burgess, J. G. (2003). Biofilm-specific 
cross-species induction of antimicrobial compounds in bacilli. Applied and 
Environmental Microbiology 69: 3719-3727. 
176 
 
Zacur, H. and Kirsner, R. S. (2002). Debridement: rationale and therapeutic options. 
Wounds 14 . Published online in September  2008. ONLINE REF. 
Zeina, B., Othman, O. and Al-Assad, S. (1996). Effect of honey versus thyme on 
rubella virus survival in vitro. Journal of Alternative and Complementary 
Medicine 2: 345-348. 
Zinner, S. H. (2007). Antibiotic use: present and future. New Microbiolology 30: 321-
325. 
Zucca, M., Savoia, D., Cabadés, A., Valencia, J., Rueda, J., Echánove, I., Sanjuán, 
R., Cebrián, J., González-Hernández, E. And Cardona, J. (2010). The post-
antibiotic era: Promising developments in the therapy of infectious diseases. 
International Journal 6:77-86. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
177 
 
9 APPENDIX 
9.1 Appendix A  (  SNAP Beta-Lactam test Kit)  
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9.2 16S rRNA partial sequences of isolated strains  
 
MB2 
gb|JF836884.1|  Bacillus pumilus strain M4 16S ribosomal RNA gene, 
partial sequence Length=1445 
 
 Score =  802 bits (434),  Expect = 0.0 
 Identities = 434/434 (100%), Gaps = 0/434 (0%) 
 Strand=Plus/Minus 
 
Query  1     TGGCTCCATAAAGGTTACCTCACCGACTTCGGGTGTTGCAAACTCTCGTGGTGTGACGGG  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1428  TGGCTCCATAAAGGTTACCTCACCGACTTCGGGTGTTGCAAACTCTCGTGGTGTGACGGG  
1369 
 
Query  61    CGGTGTGTACAAGGCCCGGGAACGTATTCACCGCGGCATGCTGATCCGCGATTACTAGCG  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1368  CGGTGTGTACAAGGCCCGGGAACGTATTCACCGCGGCATGCTGATCCGCGATTACTAGCG  
1309 
 
Query  121   ATTCCAGCTTCACGCAGTCGAGTTGCAGACTGCGATCCGAACTGAGAACAGATTTATGGG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1308  ATTCCAGCTTCACGCAGTCGAGTTGCAGACTGCGATCCGAACTGAGAACAGATTTATGGG  
1249 
 
Query  181   ATTGGCTAAACCTTGCGGTCTCGCAGCCCTTTGTTCTGTCCATTGTAGCACGTGTGTAGC  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1248  ATTGGCTAAACCTTGCGGTCTCGCAGCCCTTTGTTCTGTCCATTGTAGCACGTGTGTAGC  
1189 
 
Query  241   CCAGGTCATAAGGGGCATGATGATTTGACGTCATCCCCACCTTCCTCCGGTTTGTCACCG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1188  CCAGGTCATAAGGGGCATGATGATTTGACGTCATCCCCACCTTCCTCCGGTTTGTCACCG  
1129 
 
Query  301   GCAGTCACCTTAGAGTGCCCAACTAAATGCTGGCAACTAAGATCAAGGGTTGCGCTCGTT  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1128  GCAGTCACCTTAGAGTGCCCAACTAAATGCTGGCAACTAAGATCAAGGGTTGCGCTCGTT  
1069 
 
Query  361   GCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAACCATGCACCACCTGTCAC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1068  GCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAACCATGCACCACCTGTCAC  
1009 
 
Query  421   TCTGTCCCCGAAGG  434 
             |||||||||||||| 
Sbjct  1008  TCTGTCCCCGAAGG  995 
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MB4 
 
gb|JF505384.1|  Bacillus atrophaeus strain C552 16S ribosomal RNA, 
partial sequence Length=1014 
 
 Score =  717 bits (388),  Expect = 0.0 
 Identities = 388/388 (100%), Gaps = 0/388 (0%) 
 Strand=Plus/Minus 
 
Query  1    ACTCTCGTGGTGTGACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCGGCATGC  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  932  ACTCTCGTGGTGTGACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCGGCATGC  873 
 
Query  61   TGATCCGCGATTACTAGCGATTCCAGCTTCACGCAGTCGAGTTGCAGACTGCGATCCGAA  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  872  TGATCCGCGATTACTAGCGATTCCAGCTTCACGCAGTCGAGTTGCAGACTGCGATCCGAA  813 
 
Query  121  CTGAGAACAGATTTGTGGGATTGGCTTAACCTCGCGGTCTCGCTGCCCTTTGTTCTGTCC  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  812  CTGAGAACAGATTTGTGGGATTGGCTTAACCTCGCGGTCTCGCTGCCCTTTGTTCTGTCC  753 
 
Query  181  ATTGTAGCACGTGTGTAGCCCAGGTCATAAGGGGCATGATGATTTGACGTCATCCCCACC  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  752  ATTGTAGCACGTGTGTAGCCCAGGTCATAAGGGGCATGATGATTTGACGTCATCCCCACC  693 
 
Query  241  TTCCTCCGGTTTGTCACCGGCAGTCACCTTAGAGTGCCCAACTGAATGCTGGCAACTAAG  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  692  TTCCTCCGGTTTGTCACCGGCAGTCACCTTAGAGTGCCCAACTGAATGCTGGCAACTAAG  633 
 
Query  301  ATCAAGGGTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACA  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  632  ATCAAGGGTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACA  573 
 
Query  361  ACCATGCACCACCTGTCACTCTGCCCCC  388 
            |||||||||||||||||||||||||||| 
Sbjct  572  ACCATGCACCACCTGTCACTCTGCCCCC  545 
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gb|GU339392.1|  Bacillus licheniformis strain RUAUMTB001 16S ribosomal 
RNA gene,  partial sequence Length=850 
 
 Score = 1085 bits (587),  Expect = 0.0 
 Identities = 589/591 (99%), Gaps = 0/591 (0%) 
 Strand=Plus/Plus 
 
Query  1    TGCCTAATACATGCAGTCGAGCGGACCGACGGGAGCTTGCTCCCTTAGGTCAGCGGCGGA  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2    TGCCTAATACATGCAGTCGAGCGGACCGACGGGAGCTTGCTCCCTTAGGTCAGCGGCGGA  61 
 
Query  61   NGGGTGAGTAACACGTGGGTAACCTGCCTGTAAGACTGGGATAACTCCGGGAAACCGGGG  120 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  62   CGGGTGAGTAACACGTGGGTAACCTGCCTGTAAGACTGGGATAACTCCGGGAAACCGGGG  121 
 
Query  121  CTAATACCGGATGCTTGATTGAACCGCATGGTTCAATCATAAAAGGTGGCTTTTAGCTAC  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  122  CTAATACCGGATGCTTGATTGAACCGCATGGTTCAATCATAAAAGGTGGCTTTTAGCTAC  181 
 
Query  181  CACTTACAGATGGACCCGCGGCGCATTAGCTAGTTGGTGAGGTAACGGCTCACCAAGGCG  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  182  CACTTACAGATGGACCCGCGGCGCATTAGCTAGTTGGTGAGGTAACGGCTCACCAAGGCG  241 
 
Query  241  ACGATGCGTAGCCGACCTGAGAGGGTGATCGGCCACACTGGGACTGAGACACGGCCCAGA  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  242  ACGATGCGTAGCCGACCTGAGAGGGTGATCGGCCACACTGGGACTGAGACACGGCCCAGA  301 
 
Query  301  CTCCTACGGGAGGCAGCAGTAGGGAATCTTCCGCAATGGACGAAAGTCTGACGGAGCAAC  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  302  CTCCTACGGGAGGCAGCAGTAGGGAATCTTCCGCAATGGACGAAAGTCTGACGGAGCAAC  361 
 
Query  361  GCCGCGTGAGTGATGAAGGTTTTCGGATCGTAAAACTCTGTTGTTAGGGAAGAACAAGTA  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  362  GCCGCGTGAGTGATGAAGGTTTTCGGATCGTAAAACTCTGTTGTTAGGGAAGAACAAGTA  421 
 
Query  421  CCGTTCGAATAGGGCGGTACCTTGACGGTACCTAACCAGAAAGCCACGGCTAACTACGTG  480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  422  CCGTTCGAATAGGGCGGTACCTTGACGGTACCTAACCAGAAAGCCACGGCTAACTACGTG  481 
 
Query  481  CCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGCG  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  482  CCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGCG  541 
 
Query  541  CGCGCAGGCGNTTTCTTAAGTCTGATGTGAAAGCCCCCGGCTCAACCGGGG  591 
            |||||||||| |||||||||||||||||||||||||||||||||||||||| 
Sbjct  542  CGCGCAGGCGGTTTCTTAAGTCTGATGTGAAAGCCCCCGGCTCAACCGGGG  592 
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9.3 Appendix B: Third year student poster (Studies on the antibacterial activity 
of a high grade Leptospermum scoparium honey  
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